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The proximal tubule (PT) cells of the kidney reabsorbs a large amount of ions and solutes including 
low-molecular weight proteins, glucose, phosphate, water and vitamins, which would be otherwise 
lost in the urine. This function is based on a very efficient transport system constituted by apical 
endocytic receptors, which enable the binding and internalization of the urinary solutes inside the 
PT cells, and a well-developed endolysosomal system, which carry out the recycling of receptors at 
the apical plasma membrane and the processing of the incoming substrates. The endolysosomal 
compartment is also pivotal for the removal of damaged organelles and intracellular materials 
through autophagy, a highly conserved quality control system that sustains cellular homeostasis. 
Inherited endolysosomal disorders affecting the endocytic receptors (e.g. Donnai–Barrow and 
Imerslund-Gräsbeck syndrome) or the endolysosomal pathway (e.g. Dent disease 1 and 2, Lowe 
syndrome and cystinosis) cause PT dysfunctions leading to a massive urinary loss of solutes (renal 
Fanconi syndrome) and severe metabolic complications that may be associated with chronic kidney 
disease (CKD). Studies of rare, congenital endolysosomal disorders of the PT have contributed to 
identify fundamental biological processes that operate in kidney epithelial cells. Furthermore, com-
mon genetic variants in the components of the endolysosomal machinery have been associated with 
the risk of CKD in the general population. Despite progresses in understanding the biological rules 
governing the cross-talk between endolysosomes and function of PT cells, the mechanisms linking 
defective endolysosomal proteins with disease of the kidney PT remain unclear. In this thesis, I 
investigated cystinosis and Dent disease, two paradigmatic endolysosomal disorders causing PT 
dysfunction. By using pharmacologic and genetic approaches in cellular and animal models, I 
identified novel pathogenic cascades linking endocytosis, vesicular trafficking, lysosomal function, 
autophagy, and differentiation/function of PT cells. Based on these findings, I tested drug-
repurposing therapeutic interventions, which successfully rescued the tubular functions in vitro and 
in vivo. These studies improve our understanding of the regulatory mechanisms maintaining PT cell 
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I.1 PROXIMAL TUBULE OF THE KIDNEY 
One of the main functions of the kidney is to maintain fluids and electrolyte homeostasis in the 
body by controlling the reabsorption of solutes and water. The functional unit of the kidney is 
called nephron and consists of epithelial cells originating from different embryological lineages 
(1). The nephrons are constituted by a filtrating element, the glomerulus, and a segmented tubular 
compartment (Fig.1). The glomerular filtration barrier selectively filters blood components, 
generating a dilute primary urinary filtrate containing water, small solutes and low-molecular-
weight (LMW) proteins. Subsequently, the urinary filtrate passes through a connected series of 
epithelial tubules, starting from the proximal tubules, the loop of Henle, the distal tubules, and a 
final collecting duct, which modify its compositions. The renal tubules of the nephrons express ion 
and water channels, as well as receptors and transporters that help to concentrate and adjust the 
composition of the urinary filtrate by reabsorption and secretion (2). This step is very important for 
fluid homeostasis and maintenance of electrolyte balance. The cells lining the proximal tubule (PT) 
segment of the kidney play an essential role in this process, as they are able to reabsorb 65% -70% 




Figure 1: Structure of the nephron, functional unit of the kidney.  
Adapted from McCance K, Huether. Pathophysiology: the basis for disease in adults and children. Ed 6. 2010. 
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 I.1.1 Structure 
The proximal tubule cells are highly differentiated and present numerous morphological 
adaptations, which aid to carry out their massive transport activity. The presence of tight junctions 
(TJs) provides a barrier to the paracellular movement and serves as a fence to intramembrane 
diffusion of components between the apical and basolateral poles (4). The establishment of apico-
basal polarity allows an efficient directional transport of molecules from the urine to the blood 
circulation. Based on differences in cell ultrastructure and function, the PT is classically divided 
into three segments (S1-S2-S3). Compared to the cells lining the straight segment S3, the cells 
located in the proximal convoluted segments S1 and S2 are characterized by a more developed 
apical brush border, which increases the luminal surface and facilitates the reabsorption (3, 5). 
Compared to S2, S1 presents a higher apical expression of specific cotransporters/receptors, which, 
along with a prominent endolysosomal system, sustain the uptake and recovery of essential 
molecules from the urine (Fig.2a) (6). The cytosolic region close to the basolateral plasma 
membrane of PT cells is densely packed with mitochondria (Fig.2b). The high quantity of 
mitochondria is needed to supply energy for the activity of Na+-K+-ATPase, which is necessary to 
generate the electrochemical gradient triggering both the transcellular and paracellular transport 
(Fig.2c) (7). In summary, the structural characteristics of the PT predispose this kidney segment to 
perform a highly efficient activity of transport, which is central for maintaining nutrient 




Figure 2: Structure and function of PT. 
Adapted from (a) Claus D. Schuh et al. J. Am. Soc. Nephrol. 2018. (b-c) J. Larry Jameson et al., Harrison’s principles of internal medicine. 19th 
Edition. 2017. 
 
 I.1.2 Function 
The proximal tubule controls the body fluid composition and regulates the blood pressure, the 
intracellular pH and the electrolyte equilibrium by reabsorbing approximately two third of the 
filtered water and NaCl, a greater proportion of the filtered HCO3
-
 and nearly all the nutrients 
contained in the ultrafiltrate. The primary energy driving the process of PT reabsorption is 




-ATPase, which creates an inward negative plasma membrane 




 transport (8). In PT water is 
passively following the osmolality gradient through transcellular and paracellular pathways. 
Various cotransporters use the energy of this gradient to promote the transport of solutes (ions, 
amino acids, and glucose) and the reclamation of HCO3
−
, key player of the renal acidification (9). 
The PT is also the site for the massive reabsorption of LMW (Low-Molecular-Weight) proteins. 
This function is carried out by multiligand endocytic receptors, which bind and allow the 
intracellular internalization of a variety of filtered ligands such as albumin, hormones, carrier 
proteins, enzymes, antigen components and immunoglobulin κ light chains. Once internalized, 
these substances are metabolized and recovered into the blood circulation; indeed the human 
urine is virtually devoid of plasma proteins under physiological conditions (6). In addition to the 
reabsorption of proteins and solutes, the PT is also a metabolic organ. For example, PT cells are the 
major site of synthesis of the active vitamin D (1,25-dihydroxy-vitamin D), an hormone that 
increases blood Ca
2+
 levels, contributing to bone mineralization and skeletal health (10). In 
summary, PT cells have an important role in metabolic clearance, hormones homoeostasis and 
activation of essential vitamins and provides a protein-free luminal environment for the 
downstream tubular segments of the nephron (11).  
 
I.2 ENDOCYTOSIS, RECYCLING AND DEGRADATION IN PROXIMAL TUBULE  
The uptake of albumin and LMW proteins by PT cells is carried out by a process known as 
receptor-mediated endocytosis (RME). This process is mediated by the apical expression of 
multiligand endocytic receptors, which bind the urinary ligands at the apical surface of the cells and 
allow their intracellular internalization in clathrin-coated vesicles (CCV) (12). Of note, a 
programmed series of phosphoinositide conversions is required to enable the maturation of these 
vesicles and their detachment from the plasma membrane (13). Many different cargoes can be 
packaged through the RME, which is therefore considered a versatile pathway. Once cargoes have 
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been internalized in clathrin vesicles, they are sorted in the early endosomes (EEs) and either 
recycled to the apical surface or targeted to the late endosomes (LEs) and finally to the lysosomes 
for degradation (14). Several genetic and acquired (acute and chronic) kidney diseases are 
characterized by the impairment of the endocytosis and/or defective processing of the urinary 
ligands within the PT, suggesting that these processes are fundamental for the global renal health. A 
better understanding of the molecular mechanisms governing these events is needed to identify new 
therapeutic targets and prevent or limit kidney diseases.  
 
 I.2.1 Clathrin-dependent receptor-mediated endocytosis  
I.2.1.a Multiligand endocytic receptors 
The multiligand endocytic receptors megalin and cubilin mediate the uptake of the majority of 
proteins and many other molecules, which are filtered daily through the glomerulus. In the kidney, 
megalin (also known as LRP2 or gp330) is expressed predominantly at the apical surface and in the 
endocytic compartment of PT epithelial cells. Megalin is a member of the family of low-density 
lipoprotein receptor (LDLR) and shares many features with the other members of this group of 
archetypal endocytic receptors (15). The structural elements composing the megalin ectodomain 
are: (i) four clusters of cysteine rich complement-type repeat motifs, which constitute the ligand-
binding regions; (ii) seventeen epidermal growth factor (EGF)-like repeats and (iii) eight beta 
propeller spacers, characterized by YWTD motifs involved in the release of ligands in the acidified 
endocytic compartments (15). The cytoplasmic tail of megalin contains two NPXY motifs that 
mediate the clustering of the cargo/receptor complex in the endocytic vesicles, and an additional 
NPXY-like motif, known as VENQNY, that may be involved in the targeting of the receptor to the 
apical surface (Fig.3a) (16). It has been shown that the transmembrane domain of megalin 
undergoes to regulated proteolytic cleavage; however, the physiological significance of this event is 
unclear (17). Folding and trafficking of megalin from the endoplasmic reticulum (ER) to the plasma 
membrane is facilitated by the interaction with the chaperone receptor-associated protein (RAP), 
which prevents the premature binding of the newly synthesized receptor with ligands, thus avoiding 
megalin aggregation and its retention in the ER (18). The essential role of megalin in the 
reabsorption of filtered ligands has been substantiated by the striking LMW proteinuria observed in 
mice lacking this receptor (19, 20). An additional role of megalin in sustaining the proteolytic 
function of PT cells is mediated via the uptake of lysosomal enzymes from the tubular lumen (21). 
Megalin can bind ligands independently or in cooperation with cubilin, also known as the intrinsic 
factor cobalamin receptor. The structure of this receptor is characterized by (i) an initial amino-
terminal stretch of 110 amino acids, followed by (ii) eight EGF-like repeats and (iii) 27 tandem 
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CUB domains, which occupy the majority of the protein sequence and act as binding-sites for a 
variety of ligands (Fig.3a) (22). Cubilin does not exhibit transmembrane domains, therefore it 
interacts with megalin to stabilize itself at the plasma membrane and participate in the RME (23). 
The apical sorting of cubilin relies critically on its interaction with Amnionless (AMN). This is a 
38–50 kDa transmembrane protein, which plays a key role in ensuring the membrane anchorage of 
cubilin, its trafficking along the biosynthetic pathway and its recycling to the plasma membrane 
(24). Cubilin shares many ligands with megalin, however, protein such as transferrin, intrinsic 
factor-vitamin B12 complex, and apoA1 are bound exclusively by cubilin. Up to now, no animal 
models harboring targeted deletion of cubilin gene have been published. Previous studies showed 
that cubilin expression plays a key role during embryogenesis, thus its absence could affect the 
survival (25). Human mutations in megalin and cubilin result in rare genetic conditions clinically 
described as Donnai–Barrow (# MIM 222448) and Imerslund-Gräsbeck (# MIM 261100) 
syndromes, respectively. Previous studies of these genetic disorders demonstrated that loss of 
function of one or the other protein leads to a reduction of the apical endocytic activity, which 
results in a dramatic tubular proteinuria. These observations substantiate the essential role of these 
receptors in the human kidney physiology (6).  
I.2.1.b Clathrin-dependent endocytosis 
The binding of urinary ligands with megalin and cubilin induces a formation of a ligand-receptor 
complex, which is internalized in CCV). This process allows to select and gather many different 
proteins in one vesicle and to coordinate cellular responses to the external environment. In the 
initial phase of the endocytosis, the heterotrimeric adaptor protein complex AP2 is recruited at the 
plasma membrane through its binding with phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) and 
with other adaptor proteins, which interact with megalin and cubilin/amnionless complex to ensure 
their internalization (26, 27). This event creates a platform for the assembly of hexagonal lattices of 
clathrin triskelia, which are necessary for enhancing membrane tension at the plasma membrane and 
facilitate vesicles budding (12). The scission of the vesicles rely on the capacity of the BAR 
domain-containing protein sorting nexin 9 (SNX9) to coordinate membrane dynamics at the neck of 
the nascent vesicles. Indeed, SNX9 interacts with N-WASP to trigger actin nucleation and increase 
membrane bedding and with the GTPase dynamin to mediate fission (Fig.3b) (28, 29). Once the 
vesicles detach from the plasma membrane, the clathrin coat is disassembled by the combined 
action of the ATPase heat shock cognate 70 (HSC70) protein and its cofactor Auxilin (30,31). Of 
note, changes in the phosphoinositides composition mediated by the inositol polyphosphate 5-
phosphatase OCRL (Oculocerebrorenal protein) and other enzymes are also required for the process 
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of uncoating. This event is fundamental as it allows the vesicles to progress their travel and fuse 
with the target endosomes. 
 
Figure 3: Multiligand endocytic receptors and clathrin-dependent endocytosis.  
Adapted from (a) Nielsen R, Christensen EI. Pediatr.Nephrol. 2010. (b) Sean D. Conner & Sandra L.Schmid. Nature. 2003. 
I.2.1.c Endocytic players: adaptor proteins, phosphoinositides & cytoskeleton dynamics  
Many steps of the endocytic process require directed interactions among membrane lipids, 
structural elements and regulatory proteins. CCV formation, for instance, is mostly coordinated by 
AP2, which is attracted at the plasma membrane by high concentrations of PI(4,5)P2 and, in turn, 
promotes clathrin assembly and budding of the vesicles. Also other components necessary for the 
maturation of CCV (including dynamin) are recruited at the plasma membrane via the binding with 
these lipids (32). Because of their ability to modulate the cytoskeleton dynamics, phosphoinositides 
are also involved in the excision step of the CCV. Indeed, it has been recently shown that the 
coincidence of PI(4,5)P2 and PI(3)P at the membrane of the budding vesicles catalyzes the 
activation of the SNX-9 dependent signaling pathway (involving N-WASP, and ARP2/3 complex) 
driving actin polymerization (33). Actin filaments create a tension around the neck of the vesicles, 
which help them to detach from the plasma membrane. In the subsequent trafficking steps a 
phosphoinositide conversion from high (plasma membrane) to low (early endosomes) levels of 
PI(4,5)P2  is required for uncoating of CCV and actin disassembly. Of note, the 4,5-bisphosphate 5-
phosphatase OCRL plays a critical role in this process. Indeed, the loss of OCRL function leads to 
inefficient clathrin uncoating and impaired release of the actin nucleating machinery resulting in 
endocytic trafficking defects (34). Although the role of this phosphatase has been described to be 
particularly relevant in maintaining endocytosis in PT cells, mutations in OCRL result not only in 
kidney dysfunctions but also in brain, muscle and ocular defects (34). Further investigations are 




 I.2.2 Trafficking of ligands and receptors along the endocytic pathway  
I.2.2.a Recycling of receptors  
The trafficking of ligands and receptors along the endocytic route is coordinated by a complex 
molecular machinery functioning at different stations of the endolysosomal pathway. Key players of 
this machinery are the members of the Rab proteins family that, by recruiting specific effectors, 
orchestrate the sorting of the receptor/cargo complex as well as the motility and tethering of the 
endocytic vesicles. A specific set of Rab GTPases establishes an identity code for each 
compartment of the endocytic route (35). Rab5, is associated with EEs (pH ∼6.9), which are the 
first membrane-bound organelles to fuse and receive material from the endocytic vesicles. In these 
slightly acidified organelles, occurs the pH-dependent dissociation of the ligands from the receptors. 
Receptors are recycled back to the surface in tubular structures originating from the EEs while the 
ligands are released into the LEs. Receptors can undergo slow or fast recycling. In non-epithelial 
cells “Fast” recycling is regulated by Rab4 and occurs through the apical sorting endosomes (ASEs) 
(36) while “slow” recycling is driven by Rab11 or Rab8 and is mediated by the recycling 
endosomes (REs) localized close to the nucleus (Fig.4, left) (14). Studies in polarized epithelial 
cells demonstrate the involvement of Rab11- and Rab8-positive compartments also in the “fast 
apical recycling” of megalin. In this case, megalin traffics through the Rab4-ASEs and 
subsequently crosses the Transferrin receptor (TfR) pathways at Rab8-common-recycling 
endosomes (CREs). Whereas TfR recycles to the basolateral membrane from CREs, megalin 
reaches the apical membrane via the Rab11-apical recycling endosomes (AREs) (Fig.4, right). 
These recycling cycles last about 15 minutes. The fast recycling of megalin receptor is consistent 
with its very efficient role in protein reabsorption. In conclusion, it is essential to study endocytic 
recycling in epithelial polarized cells as non-epithelial cells fail to distinguish the different recycling 
routes and recycle TfR and megalin through the same compartments, thus providing an artificial 










Figure 4: Recycling of endocytic receptors in epithelial and non-epithelial cells.  
Adapted from Andres E. Perez Bay et al. Nat. Commun. 2016. 
I.2.2.b Endosome maturation and cargo sorting 
As cargos enter the endosomal network, they are sorted in the EEs towards their final destination. 
Dissociation of the cargos from the receptors in the EEs and their delivery and degradation into the 
LEs and lysosomes is dependent on the correct acidification of each of these organelles by the 
vacuolar H
+
-ATPase (V-ATPase). V-ATPase actively transports protons from the cytosol into the 
endosomal and lysosomal lumen with the energy obtained from the hydrolysis of ATP to ADP. 
Previous studies show that chloride channels (ClCs) conduct passive Cl− ion current, which 
counteracts the proton accumulation produced by the V-ATPase. These ClCs stimulate V-ATPase 
activity at the endolysosomal compartment, thereby facilitating the acidification (38). The crucial 
role of these channels in maintaining the activity of the endolysosomal network is evidenced by the 
fact that loss of function of ClCs and pharmacological inhibition of V-ATPase are associated with 
pathologic conditions characterized by major defects of the endocytic uptake and/or lysosomal 
impairment (39). The EEs act as major sorting stations, allowing the receptors to recycle back to the 
cell surface and the ligands to be transported to LEs and finally to lysosomes for degradation 
(Fig.5). The maturation of EEs into LEs is characterized by the formation of multivesicular bodies 
(MVBs). During this process the endosomal sorting complexes required for transport (ESCRT), 
drives the sorting of ubiquitinated cargos from the endosomal limiting membrane into luminal 
vesicles. Subsequent fusion of the mature LEs/MVBs with the lysosomes, results in the degradation 
of the cargos in the lysosomal lumen (40). This maturation step is accompanied by the exchange of 
Rab5 to Rab7, which regulates the late endocytic trafficking downstream the biogenesis of MVBs 
and cargo sequestration (41). Finally, LEs are also involved in the activation of quiescent 
lysosomes. LEs replenish the lysosomes with acid hydrolases that, upon activation in the lysosomal 
lumen, enable the digestion of the molecules reabsorbed by endocytosis (42). The tight regulation of 
the various stages of endosomal maturation, including the sorting of receptors, cargos and 
hydrolytic enzymes, is essential in PT cells, where a functional processing of endocytic substrates is 




Figure 5: Endocytosis and ligands processing in PT cells.  
Adapted from Devuyst O.and Pirson Y., Kidney Int. 2007. 
 
 I.2.3 Lysosomal degradation of endocytic/autophagy cargo 
I.2.3.a Lysosomal dynamics and function 
 
The lysosome, described for the first time by Christian de Duve, is a single-membrane organelle, 
which is able to degrade a large array of both extracellular and intracellular substrates (43). The 
majority of extracellular substrates are transported to the lysosomes via the endocytic route 
(endosomes-lysosomes fusion) while intracellular substrates reach the lysosomes via the autophagic 
pathway (autophagosomes-lysosomes fusion). By mediating the catabolism of endocytic and 
autophagy cargos, lysosomes maintain the metabolic balance and cellular homeostasis (44). 
Lysosomal degradation is critical also for other physiological events, including downregulation of 
signaling receptors, killing pathogenic organisms and presenting antigens. In addition to LEs and 
autophagosomes, lysosomes are also able to fuse with the plasma membrane (Fig.6) (45). This 
event allows to repair plasma membrane ruptures and to secrete the lysosomal content in the 
extracellular space. The latter process mediates important biological functions, such as bone 
resorption by osteoclasts and cytotoxicity of killer T lymphocytes (44). Lysosomal fusion with other 
cellular membranes is carried out by a molecular machinery involving Rab7, HOPS complex, and 
SNARES while the degradative function is executed by luminal hydrolases. Normally, these 
enzymes are recognized by mannose 6-phosphate receptors (M6PR) at the trans Golgi network 
(TGN), packed into vesicles and delivered to endosomes and later on to lysosomes for completing 
lysosomal maturation (46). Most hydrolases are functioning only in acidic pH; therefore a proper 
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lysosomal ionic flux is necessary to ensure their proteolytic activity (47). By driving the proton 
transport across the lysosomal membrane, the V-ATPase is responsible to generate the acidic pH of 
the lysosomal lumen (~4.5–5.0). Of note, inhibition of V-ATPase blocks lysosomal acidification 
and results in impaired lysosomal degradative function (48). Lysosomal degradation of complex 
molecules is important for energy production and recycling of fundamental units that will be used 
as building blocks during the biosynthetic process (49). Lysosomal degradation is also necessary for 
the removal of damaged organelles (e.g., mitochondria), whose intracellular accumulation could be 
harmful for the cells (50).  
Lysosomes are dynamic structures, which undergo to fission and fusion events. Fusion of 
lysosomes with endocytic or autophagic vesicles generates hybrid organelles from which new 
primary lysosomes are reformed. Phosphoinositides associated to the lysosomal membrane are 
involved in this reformation process (51). Indeed, deficiency of either PI(3)P or PI(3,5)P2 leads to 
lysosomal swelling and inhibition (52) while defective conversion of PI(4)P to PI(4,5)P2 is 
responsible for constitutive lysosomal tubulation (53). Interestingly, the mammalian target of 
rapamycin (mTOR) covers an important role in controlling the phosphoinositides balance during 
lysosomal reformation (52). Despite the notable advances during the last decades, much remains to 
be discovered about the molecular regulation of these complex fusion, fission, and reformation 
reactions in the late autophagic and endocytic pathway. The investigation of the molecular events 
underlying the lysosomal homeostatic cycle will be essential for understanding whether these 
processes are perturbed in the diseases and how to target them.  
 The transport of substances from the lysosomes back into the cytosol is enabled by 
specific channels and transporters through mechanisms, which are still not completely understood. 
Mutations affecting proteins involved in the transport, in lysosomal acidification or linked to the 
lysosomal function are often associated to a group of about 50 diseases named lysosomal storage 
disorders. These pathologic conditions are characterized by an accumulation of waste products in 
the lysosomes, resulting in the formation of large intracellular vacuoles. Most of the patients with a 
lysosomal storage disorder are born apparently healthy and the symptoms develop progressively. 
The lysosomal storage diseases have a broad spectrum of clinical phenotypes and may affect a 
variety of organs including the kidneys (54). Two inherited lysosomal diseases manifesting with 
kidney dysfunctions are Fabry disease and cystinosis. Previous studies elucidated the key role of the 
lysosomes for the kidney function; however, further work is needed to characterize the specific 




Figure 6: Lysosomes at the crossroad between endocytosis & autophagy pathway.  
Adapted from Carmine Settembre and Andrea Ballabio. Cold Spring Harb. Perspect. Biol. 2014. 
I.2.3.b Autophagy & organelles homeostasis 
Autophagy is an evolutionarily conserved degradative pathway, which occurs at a basal rate in most 
cell types. This process is needed to eliminate protein aggregates and damaged organelles in order 
to maintain cytoplasmic homeostasis. This event includes the degradation of dysfunctional 
mitochondria via mitophagy, a cytoprotective process that limits both the production of reactive 
oxygen species (ROS) and the release of toxic mitochondrial proteins (56). As functional and 
numerous mitochondria are essential to carry out the high transport activity of kidney PTs, the 
homeostatic role of autophagy to regulate the mitochondria life cycle is key to safeguard the 
function of this kidney segment (57). Autophagy is activated by cellular stresses such as starvation, 
hypoxia or chemotherapeutic drugs. In these conditions of energy depletion, autophagy degradation 
of proteins, lipids and carbohydrates is essential to produce energy and to fuel the metabolic needs 
of the cells (58). Upon induction of autophagy, a protein complex consisting of ULK1/2, ATG13, 
FIP200 and ATG101 assembles on the pre-autophagosomal structure, called phagophore, and 
triggers the initiation of autophagosomes formation. In mammals, the origin of the autophagosomes 
membranes is debated. Many studies have identified the site of formation of the isolation membrane 
at ER in regions called omegasomes. Other potential platforms for the autophagosomes formation 
include mitochondria, ER-Golgi and ER-mitochondria contact sites, REs and plasma membrane 
(59). The second step of autophagy is called nucleation. At this stage the class III 
phosphatidylinositol 3-kinase (PI3K) complex consisting of Beclin-1, VPS34, VPS15 and ATG14 
is gathered on the phagophore and promotes the local production of PI(3)P, which, in turn, recruit 
other effector proteins like WIPI1/2 (60). The final expansion and closure steps are carried out by 
two ubiquitin-like conjugation systems. The first system, comprising E1-like Atg7 and E2-like 
Atg10 proteins, catalyzes the formation of the Atg12-Atg5-Atg16L1 complex, which is needed for 
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the efficient closure of autophagosomes (61). The second ubiquitin-like conjugation system, 
coordinated by Atg7 and the E2-like Atg3 enzymes, enables the lipidation of LC3/Atg8 on the 
autophagosomal membrane (Fig.7).  LC3/Atg8 proteins have multiple functions in autophagy. In 
addition to promote the expansion and closure of phagophore membranes, they bind adaptor 
proteins (such as ubiquitin-binding protein sequestosome1 SQSTM1/p62), which mediate the 
recruitment of different cellular structures and protein aggregates within the autophagosomes (62). 
To date, LC3-II is the only well-characterized protein that is specifically localized on the 
autophagic structures, thus its detection directly correlates with the amount of autophagosomes in 
the cells. When initiation, elongation, and expansion have been completed, the autophagosomes 
close and fuse with lysosomes to form the autophagolysosomes. In these organelles, the final 
degradation of intracellular substances takes place (63).  
Autophagy is not only acting as a quality control machinery for maintaining cellular 
homeostasis but it is also involved in many other biological processes including cytoprotective 
mechanisms, development and differentiation. Furthermore, the induction of autophagy has been 
shown to promote longevity in many species, suggesting that autophagy may be a player in the 
ageing process (64). Given its key role in many physiological functions, it is not surprising that 
defects in autophagy are associated to various human disorders including cancer, 
neurodegeneration, inflammatory diseases and chronic kidney diseases (65). Considering these 
observations, pharmacological approaches to modulate this pathway are currently receiving 




Figure 7: Schematic steps of autophagy in mammals.  
Adapted from Hacer Ezgi Karakaş, Devrim Gözüaçik. Turkish J. Biol. 2014. 
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I.2.3.c mTORC1: lysosomal sensing & regulation of autophagy 
Autophagy is regulated by upstream signaling including growth factors, amino acids, glucose and 
energy status. Many of these signals are integrated by the kinase activity of mTOR, which is the 
target of a molecule named rapamycin -a macrolide produced by Streptomyces Hygroscopius 
bacteria (66, 67). mTOR is an atypical serine/threonine protein kinase that cooperates with several 
proteins to form two different complexes called mTOR complex 1 (mTORC1) and 2 (mTORC2). 
mTORC1, the better characterized of the two complexes, is composed by the scaffolding proteins 
RAPTOR (regulatory-associated protein of mTOR), mLST8 (mammalian lethal with SEC13 
protein), and DEPTOR (DEP domain-containing mTOR-interacting protein). mTORC1 is recruited 
on the lysosomal surface through physical interactions with the Rag GTPases (RagA or RagB and 
RagC or RagD). These interactions are enabled by the guanine-exchanging factor (GEF) activity of 
Ragulator complex, which induces the activation and docking of the Rag GTPases to the lysosomal 
membrane (68). Once at the lysosome, mTORC1 is activated by the small GTPase Rheb (RAS 
homolog enriched in brain), which powerfully stimulates its kinase function (69). mTORC1 activity 
is dependent on the luminal lysosomal content of amino acids. In presence of amino acids, 
mTORC1 is recruited on the lysosomal membrane and activated through a mysterious mechanism 
involving conformational changes of the V-ATPase and the Ragulator complex. In contrast, amino 
acids withdrawal causes the release of mTORC1 from the lysosome and its inactivation (Fig.8) 
(69). By inhibiting Rheb activity, the trimeric tuberous sclerosis complex (TSC) is a powerful 
negative regulator of mTORC1 function. The activity of TSC complex is under the control of 
numerous extracellular and intracellular inputs including mitogen and growth factor signaling, 
energy levels, oxygen availability and genotoxic stress (70).  
mTORC1 controls the cellular homeostasis through the downstream regulation of various 
metabolic pathways: on one side, its activation increases cell growth and biosynthetic processes; on 
the other side, active mTORC1 represses catabolism through the inhibition of autophagy. 
Conversely, inhibition of mTORC1 induces down-regulation of biosynthetic pathways and 
activation of the catabolic-autophagy process through the induction of the transcriptional factor EB 
(TFEB) (71). This double-way regulation of catabolic and anabolic processes is needed to avoid 
wasting of energy in uncoordinated cycles of synthesis and degradation (70). Given its central role 
as signaling hub, mTORC1 emerged as a key metabolic rheostat regulating the physiologic function 
of many organs and tissues in the body, including kidney epithelial cells. Indeed, mTORC1 
deregulation has been observed in many kidney diseases. Aberrant activation of the mTOR pathway 
was detected in patients and animal models of renal transplant rejection, autosomal dominant 
polycystic kidney disease, renal cell carcinoma, diabetic nephropathy, lupus nephritis and 
angiomyolipoma. The frequent hyper-activation of mTOR signaling makes it an attractive target for 
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therapeutic interventions and has driven the development of numerous mTOR inhibitors, which 
could be potentially used for the treatment of many human disorders (72).  
 
 
Figure 8: Amino acid signaling to mTORC1.  
Adapted from Kim, S.G., Buel, G. R. & Blenis. J. Mol. Cells. 2013. 
 
I.3 TIGHT JUNCTIONS AND REGULATION OF CELL DIFFERENTIATION 
Epithelia are composed by continuous cellular sheet consisting of polarized cells adhering to each 
other. The intercellular adhesions of epithelial cells are constituted by the apical junctional 
complex, which comprises tight and adherent junctions (AJs) as well as desmosomes. The epithelial 
TJs have three major functions: (i) as constituents of semipermeable barriers controlling 
paracellular diffusion of solutes and fluids, (ii) as fences maintaining the apical-basal polarity of 
cells of a confluent epithelium and (iii) as signaling platforms regulating epithelial biogenesis and 
function (73). The renal tubular epithelium is characterized by the expression of TJs, which play a 
pivotal role in sustaining the kidney function. Indeed, numerous kidney pathologic conditions, such 
as ischemia/reperfusion injuries and autosomal dominant polycystic kidney disease present 
alterations of the TJ complex. The epithelial TJs are composed by proteins belonging to three main 
families: (i) integral membrane proteins such as claudins, occludins and junctional adhesion 
molecules, (ii) scaffolding proteins such as zona occludens-1 (ZO-1) and 2 (ZO-2) and (iii) 
signaling proteins comprising G proteins, kinases and phosphatases (Fig.9). Here we focused on the 
scaffolding protein ZO-1, which not only exerts functions related to preserve the structural barrier 
of TJ but also participates in signal transduction pathways regulating the transition of renal 




Figure 9: Simplified scheme of major tight junction proteins.  
Adapted from Bradley M. Denker and Ernesto Sabath. J. Am. Soc. Nephrol. 2011. 
 I.3.1 Tight junction protein ZO-1 
I.3.1.a ZO-1 and plasma membrane barriers  
ZO-1 is belonging to the family of membrane-associated guanylate kinase (MAGUK) homologue 
proteins, which are scaffolding molecules able to stabilize multi-molecular complexes at the 
cytoplasmic surface of the plasma membrane (75). This function is carried out by the expression of 
multiple protein-protein interaction domains. ZO-1 interacts with cell adhesion molecules, ion 
channels and signaling molecules through its PSD-95/discs large/zonula occludens-1 (PDZ) 
domains. The Src-homology3 (SH3) domains of ZO-1 mediate the interaction with proteins 
involved in signaling pathways or modulating the cytoskeleton dynamics – such as Ras protein and 
Src kinase. Finally, the region homologous to mammalian and yeast cytosolic guanylate kinase 
(GK) is necessary for the assembly of apical surface components, including those guiding the 
organization of cortical F-actin (Fig.10) (76). ZO-1 is a key component of the TJ and plays a central 
role in the formation of plasma membrane barrier. TJs form two types of barriers: (i) the 
paracellular ones, which regulate the passive transport of solutes across the tissues and (ii) the 
intramembrane barriers, which limit the exchange of membrane components between the apical and 
basolateral pole of the cells. The two barriers overlap for physical location and are structurally 
related (77). Multiple signaling pathways regulate the integrity of the TJs barriers. One example is 
represented by Gα12, whose activation leads to tyrosine phosphorylation of ZO-1 proteins resulting 
in TJ disruption and increased paracellular permeability. Oxidative stress and calcium levels have 
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also been described to govern TJs assembly, however, many other signaling coordinating this 
process remain to be further explored (78, 79). 
 
Figure 10: Structural and functional properties of ZO-1.  
Adapted from H. Bauer et al. J. Biomed. Biotechnol.2010. 
I.3.1.b ZO-1 crosstalk with ZONAB signaling pathway 
Beyond their role of permeability barriers, TJs are also important signaling platforms. TJs 
transduce signals to the intracellular environment to regulate various physiologic processes. 
Recent studies indicate the crucial involvement of the TJ protein ZO-1 in epithelial cell 
proliferation and differentiation (77). In kidney epithelial cells ZO-1 interacts with the Y-box 
transcription factor ZONAB (ZO-1 associated nucleic acid binding protein). ZONAB 
transcriptional activity is inversely correlated with the TJs levels of ZO-1. In confluent polarized 
kidney cells, the high expression of ZO-1 blocks ZONAB to the TJs. In contrast, the low level of 
ZO-1 in non-confluent kidney cells results in enhanced translocation of ZONAB in the nucleus 
(Fig.11). Nuclear ZONAB promotes the expression of genes involved in proliferation while 
repressing the genes driving apical differentiation (80). Thus, the ZO-1 trapping of ZONAB at 
the TJs is essential for maintaining the differentiated non-proliferative state of polarized 
epithelial kidney cells (81).  
 
Figure 11: ZO-1/ZONAB axis regulates epithelial proliferation and differentiation.  




 I.3.2 Transcription factor ZONAB  
I.3.2.a Proliferation 
Y-box transcription factors are multifunctional regulators of gene expression and have been 
described as major players in cell proliferation. The Y-box transcription factor ZONAB also 
known as DbpA/Msy3 (DNA binding protein A/Mouse Y box protein3), is particularly relevant 
for the kidneys, where it contributes to modulate epithelial growth during development.  Previous 
works demonstrated that active nuclear ZONAB is abundant in the peripheral regions of growing 
kidney cells, which are characterized by low cell density, low TJ expression of ZO-1 and increased 
proliferation. Conversely, the ZONAB nuclear activation decrease in central regions, where the cell 
density is high, ZO-1 expression is high and the proliferative rate is low (Fig.12) (81). These studies 
highlighted a direct correlation between nuclear ZONAB and proliferation during kidney ontogeny. 
Further studies demonstrated that ZONAB regulates the G1/S-phase transition of the epithelial cell 
cycle by two mechanisms: (i) the transcriptional regulation of cell cycle factors, such as 
proliferating cell nuclear antigen A (PCNA) and cyclin D1 and (ii) the modulation of the nuclear 
shuttling of cyclin D/cyclin-dependent kinases 4 (CDK4) (82). Extensive transcriptional and 
biochemical analyses demonstrated that PCNA and cyclin D1 are direct target genes of ZONAB. 
However, ZONAB can regulate epithelial cell cycle also through physical interaction with CDK4. 
When ZONAB is trapped at the TJs, the entering of CDK4 in the nucleus is prevented. Conversely, 
the nuclear translocation of ZONAB results in increased nuclear shuttling of CDK4 and progression 
of cell cycle (Fig.11) (81). Taken together, these data suggest that ZONAB is an important player of 
the mechanisms that sense epithelial density (in this case through ZO-1) and drive the 
transcriptional program regulating cell proliferation. 
 
Figure 12: ZONAB overexpression promotes proliferation and represses differentiation.  
Adapted from Wânia R. Lima et al. J. Am. Soc. Nephrol.2010. 
I.3.2.b Differentiation  
Previous investigations in vivo and in vitro showed that ZONAB expression and localization 
determine the state of proliferation and differentiation of proximal renal tubular cells. At the early 
stage of kidney development, nuclear ZONAB-expressing cells are highly proliferative (high 
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PCNA) and scarcely differentiated (low megalin). In the subsequent stage, the decrease of nuclear 
ZONAB expression is mirrored by a parallel increase of non-proliferating, megalin-expressing 
cellular population. Further studies confirmed the inverse relation between nuclear ZONAB and 
apical differentiation (Fig.12) (80). In silico and chromatin immunoprecipitation analyses 
demonstrated the presence of ZONAB binding sites in the promoter regions of megalin and cubilin. 
Functional data indicate that ZONAB is a direct repressor of genes required for apical endocytosis 
including megalin and cubilin (83). This is important as it suggests that dysregulation of ZONAB 
activity might be involved in numerous genetic kidney diseases characterized by defective tubular 
reabsorption.  
 
I.4 DISEASES OF THE PROXIMAL TUBULE OF THE KIDNEY 
The epithelial cells that line the kidney PT play a pivotal role in the reabsorption of water, 
electrolytes and processing of filtered proteins. This function relies on a well-differentiated apical 
compartment and a particularly well-developed and efficient endolysosomal network. Dysfunction 
of endosomal and/or lysosomal compartment caused by congenital or acquired disorders often leads 
to generalized dysfunction of the PT, causing massive urinary loss of solutes (renal Fanconi 
syndrome) and severe metabolic complications, which can result in the development of CKD (34). 
The section below provides an overview of our current understanding of the molecular mechanisms 
underlying Fanconi syndrome in congenital endolysosomal disorders affecting the kidney PT. 
 
I.4.1 Renal Fanconi Syndrome 
Renal Fanconi syndrome (RFS) is described as a generalized dysfunction of the PT resulting in 
polyuria, phosphaturia, glycosuria, calciuria, proteinuria, aminoaciduria and proximal tubular renal 
acidosis. These urinary metabolic changes are reflected by multiple clinical complications, which 
include dehydration and electrolyte imbalances, rickets, osteomalacia, growth retardation, failure to 
thrive, kidney stones and CKD culminating in ESRD (84). RFS is associated with congenital 
disorders disrupting the function of endolysosomal pathway of PT cells such as Dent disease, Lowe 
syndrome and cystinosis -the first cause of RFS in pediatric patients. RFS can also be observed in 
inherited disorders primarily affecting other cellular compartments, whose function is directly 
related to the activity of the endolysosomal network, such as mitochondriopathies and metabolic 
diseases. Although an increasing number of genetic causes have been identified, RFS can also occur 
as an acquired disorder during adulthood, for instance upon exposure to toxins, drugs and 
immunoglobulin free κ light chains, which accumulate and damage the endolysosomes (84). The 
primary therapy for RFS is to replace the substances lost in the urine. For instance, in order to 
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prevent dehydration resulting from polyuria, patients are administered with fluids and electrolytes 
while metabolic acidosis is treated by small boluses of intravenous sodium bicarbonate. Bone 
defects, also reported in patients with Fanconi syndrome, can be improved by supplementation with 
active Vitamin D (85). The multimodality of RFS makes difficult the diagnosis and prevents the 
setup of causal therapies. Genetic forms represent a major concern as they are difficult to manage 
being associated with disruption in growth and affecting other organs beyond the kidney. 
Symptomatic management is still the therapy of choice, thus, further investigations regarding 
etiologies and therapies are required. 
 
I.4.2 Endosomal disorders: Dent disease and Lowe Syndrome 
Dent disease is a heterotypic X-linked proximal tubulopathy. The majority of the cases (~60%) are 




 exchanger ClC-5 
(Dent disease 1, MIM #300009) (86). However, a subgroup of Dent disease patients (~15–20%) 
harbors mutations in OCRL, the gene encoding the type II phosphatidylinositol (PI) bisphosphate 5-
phosphatase OCRL (Dent disease 2, MIM #300555). The clinical profile of Dent disease 1 and 2 is 
similar: they both present with LMW proteinuria and frequently develop hypercalciuria and 
progressive renal failure. Mutations in OCRL are also associated with the oculocerebrorenal 
syndrome of Lowe (MIM #309000), which includes systemic manifestations such as congenital 
cataract, cognitive disability and hypotonia (87). The current therapeutic options for these disorders 
are only supportive. There is no treatment that targets the causes of these diseases, thus, avoiding 
the burden associated to the disorders and preventing early death. In this respect, the understanding 
of how loss-of-function mutations in OCRL or CLCN5 give rise to common clinical entities 
represents an opportunity to identify molecular pathways that could be targeted for treating both 
conditions.  
Studies in Clcn5-KO mouse models reveal that the functional loss of ClC-5 generates a 
trafficking defects involving megalin and cubilin, which underlies the defective endocytosis and PT 
dysfunction observed in patients with Dent disease 1 (Fig.13) (88). These defects could be 
explained by the role of ClC-5 at the apical-endosomal compartment of the PT epithelial cells. ClC-
5 is mainly expressed at the subapical endosomes of the S1 segment of the PT, where it contributes 
to the endosomal acidification, and partially at the plasma membrane, where it interacts with 
megalin and other scaffolding proteins. Initially, the disruption of the endosomal acidification was 
supposed to be the cause of the endocytic defects resulting from the loss of ClC-5 function. 
However, not all the disease-causing mutations in ClC-5 result in perturbation of the endosomal pH, 
suggesting that the defective acidification is, at best, only partially responsible for the endocytic 
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dysfunction (89). Alternatively, the endocytic defect could be explained by the disruption of ClC-5 
function at the plasma membrane. Indeed, at the apical surface, ClC-5 interacts with megalin and 
Cofilin and enables the invagination of endocytic vesicles by coordinating the process of actin 
depolymerization (90). More insights into the function of ClC-5 in apical endocytosis may be 
extrapolated by investigating its cross-talk with OCRL. The loss of function of this enzyme leads to 
a renal phenotype very similar to those observed in absence of ClC-5, thus OCRL could cooperate 
with ClC-5 to coordinate the endocytic process (5). 
OCRL is a 97 kDa cytosolic protein ubiquitously expressed, with highest levels in the brain, 
liver and kidney. OCRL is predominantly located at the trans-Golgi network but it is also expressed 
at the clathrin-coated pits, early and recycling endosomes, cilia, TJs and during cytokinesis. OCRL 
is able to hydrolyze the phosphate group in position 5 of the inositol rings of PI(4,5)P2 and 
PI(3,4,5)P3 to generate PI4P and PI(3,4)P2, respectively, with a slight preference for the former. 
PI(4,5)P2 are abundantly expressed at the plasma membrane, where they regulate fundamental steps 
of clathrin-mediated endocytosis (34). Studies on immortalized cells revealed that during 
endocytosis OCRL regulates the transition from a stage with high PI(4,5)P2 levels, which drive the 
recruitment of actin and clathrin machinery at the plasma membrane, to a stage with low PI(4,5)P2 
levels, which allows clathrin uncoating and actin disassembly at the endocytic vesicles enabling 
their maturation in early endosomes. Recent studies in human cells showed that the loss of OCRL 
function results in the accumulation of PI(4,5)P2  at the EEs triggering a local hyper-polymerization 
of actin, which impairs the endocytic trafficking of multiple cellular receptors, including megalin 
(Fig.13).  
 
Figure 13: The role of ClC-5 and OCRL in the pathogenesis of Dent disease.  
Adapted from O.Devuyst, A.Luciani. J. Physiol. 2015. 
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This event could contribute to the endocytic defect and PT dysfunction observed in Lowe 
syndrome/Dent disease 2 patients (91). The lack of a reliable in vivo model is a significant 
limitation in demonstrating the involvement of this mechanism in the LMW proteinuria 
characterizing the kidney disease. The recent availability of a mouse model and primary PT cell 
systems that mimics the Lowe syndrome/Dent Disease 2 kidney phenotype is predicted to be of 
significant benefit in this regard (92).  
 
I.4.3 Lysosomal storage disorders: nephropathic cystinosis 
Cystinosis is a rare autosomal recessive disorder -general incidence of 1:100,000–1:200,000 live 
birth -which belongs to the family of lysosomal storage diseases. Cystinosis is caused by mutations 
or deletions in CTNS gene encoding cystinosin- a lysosome proton-symporter, which enables the 
excretion of cystine from the lysosome to the cytosol (93). Loss of cystinosin function results in 
accumulation of cystine inside the lysosomes and formation of lysosome cystine crystals within 
multiple organs including the kidney PT (94, 95). Patients presenting with infantile cystinosis 
(#MIM 219800), the most frequent and severe form of cystinosis, appear normal at birth but exhibit 
failure to thrive, rickets and PT dysfunction (RFS) by 6–18 months of age. Continual loss of kidney 
function in absence of treatment eventually leads towards ESRD. Other systemic complications, 
appearing later on in the life of cystinosis patients, involve photophobia, painful cornea erosions, 
hypothyroidism, hypogonadism, diabetes, myopathy and deterioration of the central nervous 
system. Juvenile (#MIM 219900) and ocular (#MIM 219750) cystinosis are milder and rarer than 
infantile cystinosis (96). The only available strategy to counteract cystine storage is oral 
administration of cysteamine, which allows cystine to exit lysosomes. However, cysteamine 
treatment is hampered by side effects and poor tolerance, and it does not treat nor prevent PT 
dysfunction. Thus, there is an urgent need to identify novel therapeutic strategies for this 
devastating disorder (97). 
Previous studies show that Ctns ko mice are able to recapitulate multiple features of 
cystinosis, including the renal pathology. Although RFS in mice is delayed compared to patients, 
Ctns ko mice reproduce ESRD, thus mimicking the progression of the human disease. Another 
human feature recapitulated in Ctns ko mice is the accumulation of cystine crystals within PT 
cells (98). However, these crystals appear at a later stage compared to the PT dysfunction, thus 
these crystals cannot be the primary trigger for the renal defect. Previous studies in cellular 
models of cystinosis lead to the identification of several organelles aberrations and trafficking 
defects, which could contribute to the pathogenic cascade underlying the disease. Studies on 
immortalized cells derived from Ctns ko mice or cystinosis patients have demonstrated that loss 
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of cystinosin is associated to mitochondrial impairment. This event could be explained by the 
decreased levels of cytosolic cysteine, which is normally used for the synthesis of glutathione 
(GSH) -a cellular anti-oxidant with a major role in preventing mitochondrial damage. Decrease 
in cellular ATP and increased levels of oxidative stress could be also explained by the aberrant 
mitochondrial function (99, 100). Further studies showed that cystinotic lysosomes are 
dysfunctional and appear enlarged and clustered to the perinuclear region of the cells (101). 
Impairment of the lysosomal proteolysis results in the accumulation of luminal undigested 
material, which could potentially affect lysosomal amino acid sensors, such as mTORC1. Of 
note, co-immunoprecipitation and mass spectrometry studies demonstrate that cystinosin itself 
interacts with almost all the regulatory subunits of mTORC1 and that cystinosin depletion leads 
to defective activation and recruitment of mTORC1 on the lysosomal membranes (102, 103). In 
line with those data, immortalized patient-derived cells show a persistent nuclear translocation of 
the master regulator of lysosomal biogenesis and autophagy TFEB, whose activity is negatively 
controlled by mTORC1 phosphorylation (104). Moreover, defects in chaperone-mediated 
autophagy have been detected in cystinosis models (Fig.14). Despite the huge progresses in 
understanding the molecular mechanisms underlying cystinosis, many questions regarding the 
cross-talk between mitochondria, lysosomal function, autophagy, mTORC1 signaling and epithelial 
differentiation remain unsolved.  
 
Figure 14: Cell biological alterations in cystinotic cells.  
Adapted from Stephanie Cherqui & Pierre J. Courtoy. Nat. Rev. Nephrol. 2017. 
 
Of note, the use of immortalized cellular systems as the major tool of investigation could lead to 
artificial results. Indeed, many methods used for immortalizing the cells affect the activation of 
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autophagy and mTORC1 (105, 106), which are relevant pathways for cystinosis. Thus, studies on in 
vivo models closer to human such as Ctns ko rat model and in vitro systems mimicking the kidney 
transport activity like mouse primary culture of PT cells, are required to elucidate the molecular 





II. AIMS OF THE THESIS  
 
The reabsorptive function of the PT cells of the kidney relies on the responsiveness of the 
endolysosomal compartment to the stimuli provided by the external environment (107). By 
internalizing and degrading urinary substrates and recycling receptors and transporters at the apical 
surface, the endolysosomal system of PT cells governs the recovery of fundamental nutrients that 
would otherwise be lost in the urine. Impairment of the endolysosomal compartment in PT cells 
leads to a massive loss of solutes in the urine (renal Fanconi Syndrome) often followed by a 
deterioration of the global kidney function culminating in renal failure (1). The mechanisms of PT 
dysfunction associated with these endolysosomal disorders remain largely obscure due to limited 
availability of faithful animal models and cellular systems with conserved PT transport activity.  
The first aim of this thesis was to substantiate the molecular mechanisms underlying kidney PT 
disorders caused by primary dysfunctions of the early endosomal compartment such as Dent disease 
and Lowe syndrome. These two clinical entities are caused by loss-of-function mutations in very 
distinct proteins (a chloride-proton exchanger and a phosphatase, respectively) but they present by 
overlapping renal phenotypes. We performed a comprehensive phenotyping of kidney function in 
mouse models lacking the expression of the endosomal exchanger ClC-5 (Dent disease 1) or the 5-
phospahatase OCRL (Dent disease 2/ Lowe syndrome) in order to validate these models of human 
diseases and to identify potentially common dysfunctional pathways underlying these 
disorders. We next derived differentiated primary proximal tubular cells from the kidneys of these 
mouse models to explore the role of ClC-5 and OCRL in the reabsorptive function of the PT 
and their involvement in endocytic trafficking.  
The second aim of the thesis was to analyze the mechanisms linking lysosomal disease and kidney 
epithelial dysfunction in nephropathic cystinosis - a paradigmatic lysosomal storage disorder caused 
by mutations in the lysosomal amino acid transporter cystinosin. We used cutting-edge cell biology 
approaches on Ctns ko zebrafish, mouse and cellular models to investigate the consequences of 
disrupted lysosomal transport on the autophagy pathway and to explore how these changes 
affect differentiation and function of PT cells. Based on these insights we set up a drug-
repurposing approach aiming to improve the kidney function of cystinotic mice.  
In the last section, we used Ctns knockout mouse and rat models to decipher the evolutionary 
conserved disease-mechanisms linking loss of cystinosin function with disrupted lysosomal 
identity in PT cells. We specifically focused on mTORC1 pathway, given its central role in 
bridging amino acids sensing with lysosomal signalling and function.  
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These studies have the final aim to expand our understanding of the regulatory mechanisms 
maintaining the homeostasis of highly specialized epithelial cells which provide essential transport 
functions in the PT of the kidney. Obtaining insights into the molecular machinery leading to 
dysfunction of these cells in rare genetic disorders is a prerequisite for the identification of new 
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Mutations in OCRL encoding the inositol polyphosphate 5-phosphatase OCRL (Lowe 
oculocerebrorenal syndrome protein) disrupt phosphoinositide homeostasis along the 
endolysosomal pathway causing dysfunction of the cells lining the kidney proximal tubule. The 
dysfunction can be isolated (Dent disease 2) or associated with congenital cataracts, central 
hypotonia and intellectual disability (Lowe syndrome). The mechanistic understanding of Dent 
disease 2/Lowe syndrome remains scarce, due to limitations of animal models of OCRL deficiency. 
Here, we investigate the role of OCRL in Dent disease 2/Lowe syndrome by using Ocrl
Y/-
 mice, 
where the lethal deletion of the paralogue Inpp5b was rescued by human INPP5B insertion, and 





mice show muscular defects with dysfunctional locomotricity and present
 
massive 
urinary losses of low-molecular-weight proteins and albumin, caused by selective impairment of 
receptor-mediated endocytosis in proximal tubule cells. The latter was due to accumulation of 
phosphatidylinositol 4,5–bisphosphate PI(4,5)P2 in endolysosomes, driving local hyper-
polymerization of F-actin and impairing trafficking of the endocytic LRP2 receptor, as evidenced in 
Ocrl
Y/- 
mPTCs. The OCRL deficiency was also associated with a disruption of the lysosomal 







 mice suggest shared mechanisms in Dent disease 1 and 2. 
These studies substantiate the first mouse model of Lowe syndrome and give insights into the role 
of OCRL in cellular trafficking of multiligand receptors. These insights open new avenues for 






The maintenance of body fluid and electrolyte homeostasis critically depends on the appropriate 
handling of solutes and water by the epithelial cells lining the proximal tubule (PT) of the kidney(1, 
2). These cells are characterized by an efficient endolysosomal pathway involving the apical 
multiligand receptors megalin (LRP2) and cubilin (3). By processing internalized cargoes and 
recycling of receptors and transporters at the apical surface, the endolysosomal system of the PT 
cells recover essential substances that are filtered through the glomerulus, including a large variety 
of low-molecular-weight (LMW) proteins that would otherwise be lost in the urine (2). Congenital 
and acquired disorders of the endolysosomal pathway cause PT dysfunction (renal Fanconi 
syndrome) with massive urinary loss of solutes, dehydration, electrolyte imbalance, rickets, growth 
retardation, and the development of chronic kidney disease (CKD). Such PT dysfunctions are 
typically encountered in Dent disease, a rare, X-linked disorder characterized by LMW proteinuria, 
renal Fanconi syndrome, kidney stones, nephrocalcinosis and progressive renal failure (4, 5). 
 Dent disease is genetically heterogeneous. The majority of cases (approx. 60%) is due to 




 exchanger ClC-5 (Dent disease 
1, MIM # 300009) (6). In a subset of patients (~15-20%), the disease is caused by mutations in 
OCRL, the gene encoding the type II phosphatidylinositol (PI) bisphosphate 5-phosphatase OCRL 
(Dent disease 2, MIM #300555). Mutations in OCRL are also associated with the oculocerebrorenal 
syndrome of Lowe (MIM # 309000), which includes systemic manifestations such as congenital 
cataracts, cognitive disability and hypotonia (4, 7). OCRL is a protein of 110 kDa which, in addition 
to the 5-phosphatase catalytic domain, comprises: (i) a pleckstrin homology (PH) domain 
containing a clathrin-binding site (8); (ii) an ASPM, SPD-2, Hydin (ASH) domain, characteristic of 
protein that localizes to centrosome and primary cilia (9); and (iii) a RhoGAP-like domain, which 
mediates interactions involved in cytoskeleton dynamics and progression of cell cycle (10). Almost 
all the mutations associated with Lowe syndrome occur in exons 8-23 which include the 5-
phosphatase catalytic domain, the ASH domain and the RhoGAP-like domain. Conversely, the 
majority of mutations that cause Dent disease 2 are positioned in exons 1-7 which comprise the PH 
domain (11). Although mutations in the catalytic domain of OCRL have been described in both 
clinical profiles, the mutations in Dent disease 2 are always missense - compatible with a residual 
biological activity that could explain a less severe cellular phenotype (7). 
 The convergence of clinical phenotypes among patients with mutations in OCRL and 
CLCN5 raises the questions whether these genes products are part of the same pathways and how 
they cause dysfunction of endolysosomes in PT cells. ClC-5 is predominantly expressed in the EEs 
of PT cells of the kidney, potentially involved in their maturation towards the degradative 
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compartments or the recycling route (6). Studies in mouse models showed that the functional loss of 
ClC-5 generates a trafficking defect involving megalin and cubilin, reflected by defective 
endocytosis and manifestations of PT dysfunction (6, 12). OCRL is located at different stations of 
the endo-lysosomal pathway where it maintains the cellular metabolism of phosphatidylinositol 4, 
5-bisphosphate PI(4,5)P2 , an essential regulator of membrane trafficking. Increased PI(4,5)P2 levels 
and marked vesicular trafficking defects affecting the endocytic network have been observed in 
cells lacking OCRL, resulting in defective receptor-mediated endocytosis (13).  
 The direct impact of OCRL on transport events leading to renal Fanconi syndrome cannot be 
reliably assessed on dedifferentiated cell systems including non-kidney or non-epithelial cell types, 
or clonal cells isolated from urine (14). Renal biopsy material, usually obtained at an advanced 
disease stage, is of limited value. Furthermore, limitations of animal models of OCRL deficiency 
impede the development of translational studies. The first Ocrl KO mouse showed no kidney, eye 
or brain defects (15), due to a compensation by INPP5B, the closest paralogue of OCRL in mice 
and humans (16). Accordingly, a generalized endocytic defect (affecting both receptor-mediated 
and fluid-phase endocytosis) was detected in a conditional tubular deletion of Ocrl and Inpp5b 
mouse model (17). However, studies performed in this strain do not allow to discriminate the 
individual role of OCRL and INPP5B in the pathophysiology of Dent disease. 





generated (18). The replacement of mouse Inpp5b with human INPP5B in the whole body of Ocrl
Y/-
 
mouse provides a humanized background, which therefore allows to investigate the consequences 
related to the specific loss of OCRL activity. Preliminary studies revealed PT dysfunction in this 
line (18), with no investigation of the time-course, multi-systemic aspect, and cellular basis of this 





INPP5B mouse model; compared the kidney dysfunction to that of Clcn5 KO mice; and 







 mice show early manifestations of proximal tubule dysfunction 
A humanized mouse model for Lowe syndrome/Dent disease 2 was generated by targeted 
disruption of both Ocrl and Inpp5b and oocyte injection of a bacterial artificial chromosome (BAC) 
containing the human gene INPP5B to avoid embryonic lethality (18). The mouse littermates 













INPP5B) mice, respectively. All mice were born at mendelian ratio and were viable and fertile. The 
genotype of Ocrl mice was demonstrated by genomic DNA analyses of Ocrl, Inpp5b and BAC-





 mice. We first used the Ocrl mice to characterize the kidney 
phenotype over time. Growth retardation was observed in Ocrl
Y/-
 mice starting from 16 weeks of 
age onwards (Fig. 1A), whereas manifestations of PT dysfunction appeared in Ocrl
Y/-
 mice from 8 
weeks of age, with albuminuria (Figs. 1B and 1C) and LMW proteinuria (Figs. 1D and 1E). The 
inappropriate loss of the LMW clara cell secretory protein 16 (CC16) in the urine of Ocrl
Y/-
 mice 
was observed at all time points analyzed (Fig. 1D). Western blotting of the urine confirmed the 
major loss of transferrin (TFR) and vitamin D binding protein (VDBP) along CC16 in the urine of 
Ocrl
Y/-
 mice (Fig. 1E). The Ocrl
Y/-
 mice did not show manifestations of renal failure, and no 
polyuria, calciuria, glycosuria and phosphaturia during the timeframe of investigation, suggesting a 
partial renal Fanconi syndrome (Table 1). The expression levels of BAC-INPP5B were not 
associated with variable levels of PT dysfunction in Ocrl
Y/-
 mice (Suppl. Figs. 1C-F). Since 
mutations in CLCN5 and OCRL produce similar kidney defects in human patients, we compared the 




 mouse models. The Ocrl
Y/-
 mice display a 
milder LMW proteinuria (CC16) than that observed in Clcn5
Y/-
 mice (Fig. 1F). This difference is 




 mice show a specific defect in receptor-mediated endocytosis 
To determine the mechanism of LMW proteinuria, we followed the in vivo uptake of the LMW 
protein Cy5-labelled β-lactoglobulin in the kidneys of OcrlY- mice compared to their control 
littermates. Fifteen minutes after injection, a substantial accumulation of fluorescent vesicles was 
observed in the brush border of PT cells of the Ocrl
Y/+ 
mice, contrasting with a considerable 
reduction of the signal in PT cells from Ocrl
Y/-
 mice (Fig. 2A). A similar defective uptake in Cy5-
labelled β-lactoglobulin was observed in Clcn5Y/- tubules (Fig. 2B). By contrast, the internalization 
of Alexa 647-dextran, a marker of fluid phase endocytosis, was unaltered in Ocrl
Y/-
 mice (Fig. 
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2C), suggesting that loss of OCRL function impacts specifically on receptor-mediated 
endocytosis. To substantiate this observation, we investigated the LRP2 receptor and found its 
expression dramatically decreased in PT cells of the Ocrl
Y/-
 kidneys whereas its mRNA level was 
unchanged (Figs. 2D-F). In line with absent phosphaturia and glycosuria, no modifications in the 
sodium- phosphate cotransporter IIa (NaPi-IIa), the sodium-glucose cotransporter 2 (SGLT2) or 
other PT components were observed in Ocrl
Y/-
 kidneys (Figs. 2E and 2F). These data reveal that a 
defective receptor-mediated endocytosis, caused by a decreased protein level of LRP2, 
characterizes Ocrl
Y/-
 mice, similar to Clcn5
Y/-
 mice. The renal Fanconi syndrome is restricted to 
LMW proteinuria in Ocrl
Y/-
 mice, contrasting with a more severe PT dysfunction in Clcn5
Y/-
 
mice. At age 8 weeks, the latter showed a decreased expression of SGLT2 and NaPi-IIa (Suppl. 
Fig. 2A), explaining glycosuria and phosphaturia along polyuria and calciuria (Table 1; Suppl. 
Figs. 2C-D), and a defective uptake of fluid-phase endocytosis (dextran) markers (Suppl. Fig. 
2B).  
 
Loss of OCRL increases PI(4,5)P2 and disrupts receptor-mediated endocytosis in vitro 
In order to further analyse the endocytic defect observed in vivo, we developed primary cultures of 
PT cells (mPTC) from micro-dissected PT segments of Ocrl
Y/- 
mice aged 8 weeks. This cell culture 
system preserves the differentiation and polarized transport processes and therefore represents a 
relevant in vitro model to investigate mechanisms underlying PT disorders (19). To validate the 
Ocrl cellular system, we evaluated whether the loss of OCRL in mPTC reproduced the typical 
endosomal accumulation of PI(4,5)P2 observed in Lowe syndrome/Dent disease 2 (20). Compared 
to control, Ocrl
Y/-
 mPTCs exhibited a remarkable increase of PI(4,5)P2  in early endosomal 
structures, as shown by colocalization with the early endosome marker EEA1 (Figs. 3A-B). The 
unchanged PI3P levels, the PI hallmark of the endosomal system, demonstrated that OCRL 
disruption in mPTCs exclusively targets the homeostasis of PI(4,5)P2 (Suppl. Fig. 3A). These 
results, which are consistent with PI(4,5)P2 accumulation observed in a transgenic zebrafish model 
of Lowe syndrome or in OCRL-depleted immortalized cells, substantiate the reliability of Ocrl 
mPTCs system (13, 21). Given that the tight regulation of PI(4,5)P2 homeostasis is fundamental for 
a proper endocytic trafficking, we asked whether its increase at the EEs might impair the endocytic 
function of mPTCs. Functional studies demonstrated that albumin uptake was markedly reduced in 
Ocrl
Y/- 
(-84%) when compared to control mPTCs (Fig. 3C). A similar disruption of the endocytic 
capacity was observed in Clc5
Y/-
 mPTCs (Fig. 3D). Confirming the observations made in vivo, fluid 
phase endocytosis was unaltered in Ocrl
Y/-
 mPTCs (Fig. 3E), highlighting the specificity of the 




OCRL deficiency perturbs expression of LRP2 through aberrant F-actin polymerization  
We next examined whether the defective uptake capacity of Ocrl
Y/-
 mPTCs was reflected by 
alterations of the endogenous LRP2 expression. LRP2 protein level was reduced in the total lysates 
of mPTCs lacking OCRL (Fig. 4A), similarly to Clcn5
Y/-
 mPTCs (Suppl. Fig. 4A). This reduction 
was confirmed by the analysis of the confocal Z-stack images, evidencing a decreased LRP2 
fluorescent signal in each focal plane throughout the entire volume of Ocrl
Y/-
 mPTCs (Fig. 4B and 
Suppl. Fig. 4B). The latter analysis showed a shift of LRP2 signal from the apical plasma 
membrane towards a more intracellular compartment in Ocrl
Y/-
 mPTCs, whose polarization is 





markers (Fig. 4C and Suppl. Fig. 4C). This result was corroborated by a striking decrease of LRP2 
level in the plasma membrane fraction of Ocrl
Y/-
 mPTCs (Fig. 4D). These changes were not 
associated with LRP2 transcriptional modifications or alterations of other PT receptors or 
transporters (Suppl. Fig. 3B). The intracellular localization of LRP2 in Ocrl
Y/-
 mPTCs prompted us 
to examine its organelles compartmentalization. OCRL is known to modulate the trafficking of 
endocytic receptors by orchestrating the recycling of endosomal vesicles to the surface (13). Thus, 
lack of OCRL function might disrupt the return of the endocytic receptors to the apical membrane, 
leading to their accumulation in endosomal structures. Imaging studies confirmed LRP2 increase 
within EEA1
+
 early endosomes in Ocrl
Y/-
 mPTCs, suggesting that loss of OCRL function impacts 
on both expression and distribution of this endocytic scavenger (Fig. 4E). As PI(4,5)P2 promote the 
recruitment of the actin nucleating machinery, we asked whether their endosomal accumulation, 
observed in Ocrl
Y/- 
mPTCs, might locally induce an aberrant actin polymerization and, in turn, 
affect the trafficking of endocytic receptors (22).We observed that, in Ocrl
Y/- 
mPTCs, the levels of 
actin stress fibres decreased and foci of filamentous actin (F-actin) accumulated on internal 
membranes ruffles (Suppl. Fig. 4D). Compared to controls, an increase of F-actin structures, 
colocalizing with EEA1, was observed in Ocrl
Y/- 
mPTCs (Suppl. Fig. 4E). This uncontrolled actin 
dynamics might impede the entrance of the endosomes in the recycling route and coerce LRP2 to 
stick inside them. Supporting this hypothesis, a considerable amount of LRP2 vesicles were 
coalescent with F-actin membranes (Fig. 4F). Furthermore, by high magnification confocal 
microscopy, it was possible to visualize the formation of F-actin basket-like structure surrounding 
LRP2 (Suppl. Fig. 4F). These data indicate that the increased association of F-actin with early 
endosomes may affect the endocytic trafficking and prevent the recycling of LRP2 to the apical 
surface. In order to substantiate the role of OCRL in maintaining the recycling activity, we 
investigated the localization of the canonical recycling marker transferrin receptor (TfR), which 
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crosses the same endocytic stations traveled by LRP2 (plasma membrane - early 
endosomes/recycling endosomes) (23). Our data showing the redistribution of TfR from the plasma 
membrane to enlarged cytoplasmic structures, which also trap LRP2, provide another evidence of 
defective endocytic recycling in Ocrl
Y/-
 mPTCs (Suppl. Fig. 5A and Fig. 4G). We also tested 
whether the lack of OCRL might affect the trafficking of the cation-independent mannose 6-
phosphate receptor (CI-MPR), which is required for the transport of lysosomal enzymes and travels 
through intracellular itineraries diverging from those exploited by LRP2 (TGN-LEs- plasma 
membrane) (24). An increase in the CI-MPR associated with peripheral structures and a decrease in 
the perinuclear pool was observed in the kidneys and mPTCs from Ocrl
Y/–
 mice compared to 
controls (Suppl. Figs. 5B-C), indicating a defective retrograde transport of CI-MPR from the 
endosomes to the Golgi. All together, these data suggest that the actin-trapping mechanism 
impairing the recycling of LRP2 extends to other receptors traveling through the endosomal 
structures of Ocrl
Y/- 
mice, highly relevant for the molecular basis of Lowe syndrome.  
 
OCRL depletion alters lysosomal dynamics and function 
It has been recently shown that, under lysosomal overload conditions, OCRL translocates on the 
lysosomal membrane, where it ensures adequate levels of PI(4,5)P2 necessary for fusion and 
subsequent degradation of  cargo vesicles (25). We thus explored whether loss of OCRL function 
might generate a rearrangement of PI(4,5)P2 at the lysosomal membrane and, consequently, affect 
lysosomal morphology. Confocal microscopy analysis showed that Ocrl deletion increased the 
number of PI(4,5)P2 positive structures colocalized with LAMP1-labeled lysosomes (Fig. 5A). 
These changes were associated with dramatic modifications in the dynamics of lysosomes as 
evidenced by their abnormal increase in number and size (Fig. 5B). As changes in lysosomal 
dynamics could affect their proteolytic activity, we examined whether OCRL disruption impairs the 
lysosomal cargo degradation in Ocrl
Y/- 
mPTCs. To this end we used dequenched BSA (BSA-DQ) 
reagent, which is readily incorporated by cells via fluid-phase endocytosis. Upon fusion with endo-
lysosomes, BSA-DQ is digested into smaller fragments, thereby relieving its self-quenching 
properties and causing a fluorescent signal that reflects lysosomal degradative capacity (26). Ocrl
Y/- 
mPTCs showed a remarkable decrease in BSA-DQ fluorescent puncta colocalized with LAMP1 
(Fig. 5C), indicating a specific impairment of lysosomal proteolysis as fluid phase endocytosis was 
not affected by the loss of OCRL. To substantiate the defective lysosomal activity, we tested the 
processing of the EGFR, an endogenous protein which, upon EGF induced internalisation, is 
normally sorted to endo-lysosomal proteolytic pathway for degradation (27). Control mPTCs, 90 
min after EGF stimulation, showed an efficient degradation of EGFR. On the contrary, at the same 
time frame, the levels of EGFR remained high in Ocrl
Y/- 
mPTCs, suggesting a delayed lysosomal 
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processing of the receptor (Fig. 5D). One mechanism by which cargo clearance might be impeded is 
a defective maturation of lysosomal cathepsins. Western blot analyses of cathepsin D (Cts-D) 
showed a decreased generation of the 32kDa mature Cts-D in Ocrl
Y/- 
mPTCs compared to control 
(Fig. 5E). We next tested the lysosomal Cts-D activity by incubating the cell with Bodipy-FL-
PepstatinA (PepA), a fluorescence-tagged PepA that binds to the active site of Cts-D in acidic 
lysosomes. Although the majority of lysosomes were co-stained with PepA in control mPTCs, the 
number of PepA-labeled vesicles colocalizing with LAMP1 were substantially lower in Ocrl
Y/- 
mPTCs (Fig. 5F). Similarly, the lysosome-based processing of the LMW -lactoglobulin, which is 
normally internalized and degraded by endolysosomes, was dramatically reduced in Ocrl
Y/- 
proximal tubules compared to wild-type (Fig. 5G). To investigate whether mis-sorting of lysosomal 
hydrolases in the extracellular space might contribute to the aberrant lysosomal proteolysis 
observed in Ocrl
Y /–
 mice, we tested for and detected significantly increased levels of the lysosomal 
protease Cts-D (immature form) in the plasma of these mice (Suppl. Fig. 6A). This result was in 
line with the mis-trafficking of CI-MPR at the cell periphery and with previous studies performed in 
patients with Lowe syndrome (13). Collectively these data indicate that OCRL is important to 
maintain lysosome homeostasis, itself crucial for PT function. Of note, impaired lysosomal 
proteolysis and insufficient degradation of β-lactoglobulin was also observed in Clcn5Y/- proximal 




mice show dysfunctional locomotricity associated with muscular defects 
In order to test whether the deletion of OCRL in this model was reflected by extra-renal 
manifestations, we performed comprehensive behavioral tests of Ocrl
 
mice to examine basic motor 
activity, learning and memory skills, social behaviour and vision. To identify disturbances in 
locomotor activity, we evaluated the general mobility of the mice by challenging them with the 
open field large arena test, which has been extensively used for analyzing the locomotor defects 
exhibited by Parkinson and Huntington mouse models (28, 29). While velocity was comparable 
between genotypes (data not shown), Ocrl
Y/-
 mice exhibited an overall decreased locomotor activity, 
as scored by the measurement of their trajectories (Figs. 6A and 6B). The Ocrl
Y/-
 mice presented 
more resting episodes than controls, as well as fewer lingering and walking events during the test 
(Fig. 6C). Of note, center-field avoidance was robust and equal in both genotypes (data not shown), 
suggesting that the impaired motor activity in Ocrl
Y/-
 mice was more likely driven by a muscular 
defect rather than an abnormal anxiety-related response. To test the latter hypothesis, we pursued 
mice analyses in IntelliCage, an automated system, which allowed the evaluation of the 
spontaneous behaviour of the animals (30). During free adaptation phase, Ocrl
Y/-
 mice made fewer 
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corner visits compared to controls, confirming the reduced locomotor and exploratory activity 
shown in the test above (data not shown). However, Ocrl
Y/-
 mice showed an incompetent licking 
pattern, which became more evident during the drinking restriction protocol and was associated 
with slower progress of water intake during drinking sessions (Fig. 6D).We excluded an influence 
of the kidney defect on the licking pattern as similar water intake was detected between genotypes 
(Suppl. Fig. 7A). Thus, the impaired licking of Ocrl
Y/-
 mice was most likely caused by a global 
muscular dysfunction, which affected also the oro-lingual motor apparatus. To explore whether the 
defective locomotricity evidenced in Ocrl
Y/-
 mice was driven by muscular defects, we performed 
whole body composition analysis (EchoMRI), which evidenced a striking decrease in lean 
mass/body weight ratio in Ocrl
Y/-
 mice compared to controls (Fig. 6E), with a global reduction of 
the mass of several hind limb (gastrocnemius, triceps surae, plantaris, tibialis posterior/anterior and 
quadriceps) muscles relative to body weight (Fig. 6F) demonstrating skeletal muscle atrophy. These 
changes were paralleled by a strong increase in plasma creatine kinase (CK) activity, suggesting 
membrane fragility of striated muscles. (Fig. 6G). These events, which are in line with the muscle 
hypotonia observed in Lowe Syndrome patients (7), support the motor defect detected in Ocrl
Y/-
 
mice. To assess the cognitive function of Ocrl mice we applied IntelliCage standard protocol which 
investigated the hippocampus-dependent spatial learning ability of the animals. No sign of 
dysfunctional learning was observed in OCRL deficient mice, even during the most challenging 
chaining task (data not shown). Aggressive behavior reported in patients with Lowe syndrome was 
also not reflected in Ocrl
Y/- 
mice, which showed intact sociability (Suppl. Fig. 7B). Given that 
congenital cataract and glaucoma are hallmarks of Lowe syndrome, we also examined the 
visuospatial and visuoperceptual ability of Ocrl mice. During water maze cue navigation, Ocrl
Y/-
 
mice exhibited a robust learning without evidences for an inadequate vision (Suppl. Fig. 7C). In 
addition no noticeable differences were observed in lens epithelium and in retinal morphology 
between control and Ocrl
Y/-
 mice. Irrespective of the Ocrl genotype, an impairment of retinal 
photoreceptor layer was observed in mice harboring rd8 (retinal degeneration 8) mutation in Crb1 
gene, a spontaneous mutation associated with C57BL/6N genetic background, leading to 






In these studies, we present the first OCRL-deficient mouse model that associates renal and extra-
renal manifestations encountered in patients with Lowe syndrome. The absence of OCRL in kidney 
proximal tubule triggers endolysosomal defects and epithelial dysfunction, with a consistent LMW 
proteinuria reflecting defective receptor-mediated endocytosis due to decreased expression of LRP2 
endocytic receptor, in absence of renal failure. We also evidence a partial convergence of disease-
mechanism and kidney tubular phenotype between mouse models deficient in ClC-5 (Dent disease 
1) and OCRL (Lowe syndrome/Dent disease 2). These results provide insights into the mechanisms 
of endocytosis and the pathophysiology of Dent disease/Lowe syndrome. 
 In contrast with a previous kidney tubular conditional Ocrl and Inpp5b KO mouse model, 
where the phenotype reflects the combined loss of OCRL and INPP5B (17), the genetic architecture 
of the mouse line investigated here allows to directly address dysfunctions related to the single loss 





irrespective of its level of expression, was fundamental for survival but it was not compensating for 
the renal defect. This observation is in line with studies on cells derived from patients with Lowe 
syndrome, which exhibit INPP5B-independent phenotypic variability (32). Although the renal 
defect was observed in all the Ocrl
Y/- 
mice analysed, a noticeable spread was observed comparing 
individual animals. This individual variability was not due to different levels of INPP5B expression. 
The possibility that compensatory changes in kinases or phosphatases crossing the same metabolic 
pathway than OCRL may contribute to such variability should be further investigated. 
The differences between the conditional double Ocrl and Inpp5b KO and the humanized 
transgenic Ocrl
Y/- 
mice studied here are evident when comparing the defective tubular endocytic 
phenotypes. The conditional deletion of OCRL and INPP5B resulted in an unspecific impairment of 
the clathrin-dependent and clathrin-independent endocytosis. By contrast, the single lack of OCRL 
in Ocrl
Y/-
 transgenic mice resulted in a selective dysfunction of the clathrin receptor-mediated 
endocytosis, as evidenced by the defective uptake of β-lactoglobulin and the unaffected 
internalization of the fluid-phase marker dextran. These differences are in line with the function of 
OCRL in regulating the membrane trafficking of clathrin-coated vesicles (33). 
Defective receptor-mediated endocytosis was reflected in Ocrl
Y/-
 mice by a consistent LMW 
proteinuria, occurring early, in absence of renal failure. In contrast, the Ocrl
Y/-
 mice did not show 
glycosuria, phosphaturia and calciuria, even at old age, mimicking the partial renal Fanconi 
syndrome typically present in the majority of patients carrying mutations in OCRL (7, 34) . The 
Clcn5
Y/-
 mice showed a similar defect in receptor-mediated endocytosis, causing a severe LMW 
proteinuria. The Clcn5
Y/-
 mice also showed a defective uptake of fluid phase endocytosis markers, 
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in line with previous data from mouse models and patient-derived cells (35-37) but not with others 
(12). The presence of a more complete form of renal Fanconi syndrome in the Clcn5
Y/- 
mouse model 
was evidenced by the hypercalciuria, phosphaturia and glucosuria detected at 8 weeks, paralleled by 
a decreased expression of SGLT2 and NaPi-IIa in addition to LRP2.  
Filtered LMW proteins are reabsorbed through megalin /LRP2 and cubilin endocytic 
receptors expressed at the apical membrane of PT cells. This reabsorptive function is maintained by 
the degradative and recycling activity of the endolysosomal system, as evidenced by severe defects 
in tubular homeostasis associated with endolysosomal disorders (1, 2). Our investigations 
characterize the involvement of LRP2 in the pathogenesis of Lowe syndrome, and demonstrate 
analogies with the endocytic defect associated with the loss of ClC-5 in Dent disease1/Clcn5
Y/-
 
mouse model (12). Previous studies, relying on OCRL-deficient immortalized cells expressing 
LRP2 mini‐receptor, showed a redistribution of LRP2 from the apical membrane to the intracellular 
compartments rather than a defective expression (13). Here, analyses on kidney tissues reveal a 
remarkable decrease of LRP2 protein in the proximal tubule from Ocrl
Y/-
 mice, similar to that 
observed in Clcn5
Y/-
 mice. These findings are in line with observations made in zebrafish 
pronephros, demonstrating the evolutionary conservation of the role of OCRL in endocytosis (21). 
The identification of converging kidney phenotypes in mouse models for Lowe syndrome and Dent 
disease supports the view that the endosomal exchanger ClC-5 and the 5-phosphatase OCRL impact 
on common pathways operating in kidney tubular cells. In absence of transcriptional changes, the 
mechanism by which the loss of ClC-5 or OCRL might affect LRP2 protein levels remains to be 
clarified. First, the decrease of apical LRP2 may reflect an increased shedding of the receptor in the 
urine in response to the endolysosomal engorgement observed in Ocrl
Y/-
 mice. Previous studies 
showed that LRP2 is a substrate for metalloproteases and is constitutively subjected to ectodomain 
shedding (38). This event produces LRP2 membrane-associated fragments, which in turn form the 
substrate for - secretase, the main player of regulated intramembrane proteolysis. Preliminary data 
showing a higher abundance of LRP2 fragments in Ocrl
Y/-
 urine, together with a transcriptional 
increase of all subunits composing the -secretase (39) are in line with this hypothesis (data not 
shown). Alternatively, the loss of LRP2 could be explained by an increased urinary excretion of 
(full length) LRP2-containing exosomes. A third mechanism might be an aberrant degradation of 
LRP2, mediated by the proteasome in response to altered lysosomal proteolysis (see below). Further 
studies of post-translational modifications potentially triggering LRP2 to the proteasome are 
necessary to test this hypothesis (40). 
By establishing differentiated and polarized proximal tubular cell cultures (mPTCs) directly 
derived from Ocrl
Y/-
 mouse kidneys (19), we were able to reconstitute critical aspects of the disease 
in vitro. The Ocrl
Y/-
 mPTCs recapitulate the selective impairment of receptor-mediated endocytosis 
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and the ectopic accumulation of PI(4,5)P2 in early endosomes (20). The latter is due to the loss of 5-
phospatase activity of OCRL that regulates the transition from high (plasma membrane) to low 
(early endosomes) levels of PI(4,5)P2  in clathrin coated vesicles, enabling progression of the 
cargo/receptor along the endocytic pathway (33, 41). The PI(4,5)P2 dynamic is critical for actin 
assembly at the plasma membrane ruffles and early endosomes, hence, for the regulation of 
membrane trafficking (42, 43). Accordingly, the endosomal accumulation of PI(4,5)P2  in Ocrl
Y/-
 
mPTCs triggers an aberrant F-actin polymerization, which impairs the recycling of residual LRP2, 
thus impeding the endocytic uptake. The actin-trapping mechanism impairing LRP2 recycling 
might be extended to other receptors, as evidenced by the redistribution of the canonical recycling 
marker TfR in Ocrl
Y/-
 mPTCs. These defects in receptor recycling represent an appealing druggable 
target for rescuing the epithelial dysfunction associated with the disease. 
It has been shown recently that OCRL can translocate to the lysosome under cargo overload 
conditions, where its fine regulation of PI(4,5)P2 balance is instrumental for maintaining lysosomal 
function (25). Here, we demonstrate that lack of OCRL induces an abnormal lysosomal 
accumulation of PI(4,5)P2 leading to altered lysosomal dynamics and defective lysosomal function, 
as scored by decreased expression and activity of lysosomal cathepsin D and impaired processing of 
lysosomal substrates in Ocrl
Y/-
 kidney and mPTCs. These results, which are consistent with 
previous observations on biopsies derived from Lowe patients (25), raise the issue of the 
mechanisms responsible for lysosomal dysfunction associated with loss of OCRL. The peripheral 
mislocalization of the CI-MPR, a protein regulating the transport of lysosomal hydrolases from the 
Golgi to lysosomes, along with increased levels of lysosomal protease cathepsin D (immature form) 
in the plasma, indicates that misrouting of lysosomal enzymes could be involved. This finding is in 
line with previous studies performed in Lowe syndrome patients (13). Alternatively, the lysosomal 
engulfment of PI(4,5)P2 driven by the loss of OCRL may somehow alter the V-ATPase complex, 
thereby impairing lysosome acidification and activation of cathepsins. It should be noted that 
similar defects in receptor-mediated endocytosis and lysosomal dynamic and activity are observed 
in mouse and cellular models deficient for the endosomal ClC-5 or lysosomal cystinosin (CTNS) 
transporters, highlighting the role of the endolysosome network as crucial signaling hub to ensure 
epithelial homeostasis (44). 
Studies on the locomotor, neurological and vision abnormalities detected in patients with 
Lowe syndrome have been hindered by the limitations of available mouse models. Deep 
phenotyping analyses unveiled a defective locomotricity in Ocrl
Y/-
mice, which reflects a global 
impairment of the muscular apparatus, as indicated by the increased plasma activity of protein 
creatine kinase and atrophy of several hind limb muscles. This phenotype was reminiscent of the 
muscle hypotonia associated with Lowe syndrome and therefore highly relevant (45). Whether this 
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defective muscular/motor pattern originates from a primary myopathy or is rather a consequence of 
neurological alterations and how OCRL contributes in maintaining muscular tone remains to be 
further investigated. Behavior, learning-memory function and vision were not altered in Ocrl
Y/-
mice. 
The discrepant clinical manifestations in mice and humans could be partly explained by differences 
in tissue-specific expression of enzymes with overlapping functions or by specific roles of OCRL in 
the tissues affected by the disease (46, 47).  
Collectively, these studies validate the first mouse model of Lowe syndrome and give 
insights into the role of OCRL in cellular trafficking of multiligand receptors. Partial convergence 
of disease-mechanism and renal phenotypes observed in Ocrl
Y/-
 and Clcn5 
Y/-
 mice suggest shared 
mechanisms in Dent disease 1 and 2. These insights open new avenues for therapeutic interventions 







MATERIALS AND METHODS  
Antibodies and reagents. The following antibodies were used: rabbit anti-human transferrin (A0061, Dako); rabbit anti-
human Gc-globulin (also known as VDBP, A0021, Dako); rabbit anti-uteroglobin (also known as CC16, ab40873, 
Abcam); rabbit anti-SLC1A5 (also known as SGLT2, ab84903, Abcam); rabbit NaPi-IIa (gift from C.A.Wagner, 
University of Zurich, Zurich, Switzerland); rabbit anti-human AQP1 (ab2219, Millipore); mouse anti--actin (A2228, 
Sigma-Aldrich); mouse conjugated to Fluorescein (FITC) anti-PI(4,5)P2 (Z-G045, Echelon Biosciences Inc.); mouse 
anti-EEA1 (610456, BD Bioscience); rabbit anti-RFP (600-401-379, ROCKLAND); sheep anti-LRP2 (gift from P. 
Verroust and R. Kozyraki, INSERM, Paris, France); mouse anti Flotillin-1(610821, BD Bioscience); mouse anti-α-
tubulin (T5168, Sigma-Aldrich); rabbit anti-GAPDH (2118, Cell Signaling Technology); rat anti-LAMP1 (sc-
19992, Santa Cruz Biotechnology);  goat anti-cathepsin-D (Cts-D; sc-6486, Santa Cruz Biotechnology); 
rabbit anti-EGFR (1005 sc-03, Santa Cruz Biotechnology); Alexa-488 Phalloidin (F-actin , A12379, 
Thermofisher Scientific); mouse anti-Transferrin Receptor Antibody (H68,4, ThermoFisher Scientific), 





subunit 1 (C464.6 EMD Millipore), rabbit anti -MPR and rabbit anti -OCRL (gift from A. De 
Matteis, Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, I taly).  
 









mouse littermates harboring BAC-INPP5B expression in equal copies (BAC1) (129S/SvEv * 129S6/SvEvTac * 




 mice littermates (C57BL/6 background) (48). All the 
mice used in this study were expressing similar levels of INPP5B as analyzed by RT-qPCR (see below). Mice were 
maintained under temperature-and humidity-controlled conditions with 12 h light/12 h dark cycles with free access to 
appropriate standard diet in accordance with the institutional guidelines of National Institutes of Health Guide for the 
Care and Use of Laboratory Animals.  
 
Renal function parameters. Mice were placed overnight in metabolic cages with ad libitum access to food and drinking 
water. Urines were collected over ice and body weight, water intake and diuresis were measured at the indicated time 
point (49). Blood (from sublingual vein) was obtained after anesthesia with ketamine/xylazine or isoflurane. Urine and 
blood parameters were measured using a UniCel DxC 800 pro Synchron (Beckman Coulter, Fullerton, CA, USA), 
whereas urinary Clara cell protein (CC16) concentration was measured in duplicate by enzyme-linked immunosorbent 
assay (ELISA; BIOMATIK EKU03200) (44). Albuminuria was measured by Coomassie Blue staining by using 
ProtoBlue Safe (EC-722, national diagnostics) according to manufacturer instructions.   
 








 mice as previously described (44). Briefly, one half of the kidney was fixed in 4% PFA 
and processed for immunostaining while the other half was used for protein isolation or RT-qPCR analysis. The 
contralateral kidney was taken to generate primary cultures of mouse proximal tubule cells (mPTCs) according to a 
previously established protocol (14). Confluent monolayers of mPTCs, characterized by a high endocytic uptake 
capacity, were expanded from tubular segments after 6–7 days. 
 








; BAC-INPP5B mice by using E.Z.N.A Forensic DNA Kit (OMEGA bio-tek) according to the manufacturer instruction. 
PCR was performed by using the following primers: Ocrl wild-type: the forward primer 5’-CCC TTT 
TCATCTGTTAGGAGAAATC-3’is located at the junction of intron 18 and the 5’end of exon 19. The reverse primer 
5’- GCATGG TTAAACGCACTATGTGG-3’ is located in intron 19, which is deleted in the OcrlY/- line. Ocrl knock-
out: the forward primer 5’GCCCTTTGATTCTAATCCCTTTTC ATC-3’ is located in the intron positioned just before 
the exon 19. The reverse primer 5’-TCT GAGCCCAGAAAGCGAAG-3’ is located in the PGK promoter, which is part 
of the neo-cassette gene targeting vector. Inpp5b knock-out: the forward primer 5’-TAAAGTCTGAAA 
ATCCAAGGC-3’ is located in exon 25. The reverse primer 5’-CTCATTTCTCCTTGATTC CAAT-3’ is located in 
exon 34. BAC-INPP5B: the forward primer 5’-CCACCCCACGATTGACTC-3’ is localized in exon 1. The reverse 
primer 5’-GGTGTCCCAGCCCTCAG-3’ is localized also in exon 1. PCR conditions were: 32 cycles of 94°C for 30 




Quantitative real-time PCR. Total RNA was extracted from mouse kidney tissues using Aurum Total RNA Fatty and 
Fibrous Tissue Kit according to manufacturer’s protocol (Bio-Rad, Hercules, CA). DNAse I treatment was performed to 
eliminate genomic DNA contamination. Total RNA was extracted from primary cell cultures with RNAqueous kit 
(Applied Biosystems, Life Technologies). 1 μg of RNA was used to perform the reverse transcriptase reaction with 
iScript™ cDNA Synthesis Kit (Bio-Rad). Changes in target gene mRNA levels were determined by relative RT-qPCR 
with a CFX96™ Real-Time PCR Detection System (BioRad) by using iQ™ SYBR Green Supermix (Bio-Rad). RT-
qPCR analyses were performed in duplicate. Specific primers were designed by using Primer3 (Supplementary 
Table 1). PCR conditions were 95°C for 3 min followed by 40 cycles of 15 sec at 95°C, 30 sec at 60°C. The PCR 
products were sequenced with the BigDye terminator kit (Perkin Elmer Applied Biosystems, Thermo Fischer 
Scientific). The efficiency of each set of primers was determined by dilution curves (Supplementary Table 1). The 
relative changes in targeted genes over Gapdh, Actb, Hprt1, Ppiase, 18S, 36B4 mRNAs were calculated using the 
2
−ΔΔ
Ct formula (50).  
 
Immunofluorescence and confocal microscopy. Mouse kidneys were fixed by perfusion with 50–60 ml of 4% PFA in 
PBS before being snap-frozen in cryogenic Tissue-Tek OCT compound (Electron Microscopy Sciences, Hatfield, 
USA). The embedded tissues were sectioned at 5 µm and processed for immunofluorescent staining as previously 
described (44). The slides were acquired on Leica SP5 confocal laser scanning microscope (Center for Microscopy and 
Image Analysis, University of Zurich) equipped with a Leica APO 63x NA 1.4 oil immersion objective at a definition 
of 1024 x 1024 pixels, adjusting the pinhole diameter to 1 Airy unit for each emission channel. Quantitative image 
analysis was performed by selecting random visual fields containing at least 3-5 proximal tubules (LTL-positive) each 
one and acquired with the same setting parameters. For quantification of -lactoglobulin and dextran internalization, the 
integrated density signal detected within each LTL-positive tubule was calculated. Internalization was then expressed as 
a ratio between the internal fluorescence and tubule area. Tubules at the border of the picture were excluded. ImageJ 
software was used for the analysis (17). 
The mPTCs were fixed in 4% PFA and processed for immunofluorescent staining as previously described (44).  Briefly, 
after incubation with blocking/permeabilization solution (0.1% Saponin ,0.5% BSA and 50mM NH4Cl in PBS), mPTCs 
were stained overnight with the appropriate primary antibodies and 45 minutes with the suitable fluorophore-conjugated 
Alexa secondary antibodies (Invitrogen) or with Alexa-488 Phalloidin (F-actin) or 10 minutes with wheat germ 
agglutinin (WGA) FITC Conjugate . Immunostained mPTCs were analyzed by a Leica SP5 confocal laser 
scanning microscope using the settings described above. The quantitative cell image analyses were performed by using 
ImageJ software and the open-source cell image analysis software CellProfiler
TM 
(51).  More details regarding the 
quantifications are described in Supplementary Materials. 
 
Endocytosis assays. Proximal tubules endocytic capacity of Ocrl and Clcn5 mice was examined by measuring β-
lactoglobulin and dextran uptake. β-lactoglobulin was tagged with Cy5 using TM2 Ab labeling kit (Amersham) in 
accordance with the manufacturer’s instructions. 15 minutes after tail-vein injection of Cy5 β-lactoglobulin (1mg/kg 
B.W., L3908, Sigma) or 30 minutes after injection of 10 kDa Alexa 647-dextran (6 mg/kg B.W.; D22914, Thermo 
Fisher Scientific), mice were anesthetized and their kidneys were harvested and processed for confocal microscopy. The 
endocytic capacity of Ocrl and Clcn5 mPTCs was examined by measuring albumin and dextran uptake as described 
previously (44). Briefly mPTCs were incubated at 37°C with 100g/mL Alexa488-BSA (A13100, Thermo Fisher 
Scientific) or 250g/mL Alexa 647-dextran diluted in medium without FBS supplementation, for 15 and 30 min 
respectively. After washing, the cells were fixed in 4% PFA and processed for confocal microscopy  
  
PI(4,5)P2 and PI3P staining. mPTCs were grown on 35mm dishes and PI(4,5)P2 or PI3P staining were performed 
according to previously established protocols (25). Briefly, mPTCs were fixed for 15 min in 2% PFA and permeabilized 
for 5 min with 20µM digitonin in buffer A (20mM PIPES pH 6.8, 137mM NaCl, 2.7mM KCl) for PI(4,5)P2 or buffer 
A
1
 (150 mM NaCl, 20 mM Hepes, pH 7.4, and 2 mM EDTA) for PI3P. Next, mPTCs were incubated  for 45 minutes 
with buffer A containing 10% fetal bovine serum and anti-PI(4,5)P2 antibody or in buffer A
1
 supplemented with 5% 
goat serum and mCherry-2×FYVE  PI3P-binding domain (gift from J.Gallop, Gurdon Institute, University of 
Cambridge). Anti –RFP was used for amplifying m-cherry staining. Studies of colocalization with early endosomes or 
lysosomes were performed by 1h incubation at room temperature with anti-EEA1 or anti-LAMP1 antibodies 
respectively. After washing and subsequent incubation with appropriate secondary antibodies, mPTCs were post-fixed 




Lysosomal activity and degradation assays. The detection of lysosomal activity and degradative capacity in mPTCs 
was performed by using Bodipy-FL-PepstatinA (P12271, Thermo Fischer Scientific) and DQ-RED BSA (D12051, 
Thermo Fischer Scientific), respectively. Briefly, mPTCs were pulsed with 1μM Bodipy-FL-Pepstatin A or with 
10μg/mL DQ-RED BSA in pre-warmed media at 37°C for 1h. After washing, cells were fixed, immunostained with 
anti-LAMP1 and suitable secondary antibody and subsequently analyzed by confocal microscopy (14, 26).  Lysosomal 
processing in Ocrl and Clcn5 mice was measured by confocal analysis of kidney proximal tubules after 120 minutes 
from tail-vein injection of Cy5 β-lactoglobulin.  
 
Western blotting. Proteins were extracted from mouse kidney tissues or primary cultured cells and lysed as previously 
described (44). Samples were normalized for protein or urinary creatinine levels before loading (20 μg/lane or 4μg/lane, 
respectively), diluted in Laemmli buffer and separated by SDS–PAGE in reducing conditions. Briefly, gels were blotted 
onto PVDF membranes, blocked in 5% non-fat milk and probed with appropriate primary and peroxidase-labeled 
secondary antibody. Protein bands were visualized by chemiluminescence (WBKLS0050, Millipore, Life technologies). 
Image intensity was measured by ImageJ.  
 
Plasma membrane isolation. mPTCs were lysed in a fractionation buffer (250mM sucrose, 20mM HEPES, 10mM 
KCL, 1.5mM MgCl2, 1mM EDTA, 1mM EGTA) containing protease and phosphatase inhibitors and passed through a 
25G needle. Cell lysates were kept on ice for 20 minutes and centrifuged at 720 g (5 minutes at 4°C). The resultant 
postnuclear supernatants were centrifuged at 10,000 g (5 minutes at 4°C) to eliminate mitochondria. The 
postmitochondria supernatant were centrifuged at 100,000 g (1h at 4°C) to separate cytosolic (supernatant) and 
membrane fractions (pellet). The membrane pellets were washed in fractionation buffer by centrifugation (100,000 g for 
45min at 4°C) and suspended in lysis buffer (10% glycerol and 0.1% SDS supplemented with protease and phosphatase 
inhibitors). The cytosolic and membrane fractions were analyzed by SDS-PAGE and western blotting. 
 
Behavioral tests. Open field large arena test, water maze cue navigation and  three chambers sociability test were 








;BAC-INPP5B)  in order to investigate motor coordination, vision and  spatial learning and the social attitude of the 
mice respectively. Behavior testing procedures will be described briefly here and in more detail in the Supplementary 
Materials. Open field large arena test. Each subject was released near the wall of the arena and observed for 10 min on 
two subsequent days. Movements were tracked using Noldus EthoVision. Water-maze cue navigation. Animals were 
trained for 2 days to reach the goal platform hidden under milky-water and marked by a salient cue. The localization of 
the platform in the pool changed for every trial. All subjects were trained on the same sequence of goal positions and 
released from the same start points (52). Three-chambers sociability test. The test consisted of a 10-minutes trial where 
a test mouse was given the choice to spend time in the chamber with the novel object (the cylinder) plus the unfamiliar 
mouse (social stimulus) and the chamber containing only the empty cylinder. The time spent by the test mouse in the 
lateral chambers was noted (53). 
 









; BAC-INPP5B). More details regarding the description of 
IntelliCage apparatus and mice preparation for IntelliCage experiments are provided in the Supplementary Materials.  
Exploration and free adaptation. During the first 4-7 days in IntelliCage all doors were open providing free access to 
all 8 drinking bottles (free adaptation). Data of the first 24h of free adaptation were analyzed separately to monitor 
exploration and habituation of the mice in the new environment (IntelliCage exploration). Nosepoke adaptation. 
During 3-7 days, all doors were closed but can be opened at any time with a nosepoke for 5s once per visit. Drinking 
session adaptation. During 3-7 days the mice were adapted to a fixed drinking schedule with doors opening in response 
to nose pokes only in the following time spots: 04:00-05:00, 11:00-12:00, 16:00-17:00 and 23:00-00:00. (30). 
 
Epon embedding and retinal morphology. 36 weeks old mice were euthanized and perfused with PFA 4%. Eyes were 
enucleated and post-fixed in 4% PFA or 2.5% glutaraldehyde before being embedded in paraffin or epon plastic, 
respectively. For light microscopy, paraffin sections (including the lens, 5 µm) were stained with hematoxylin-eosin 
(HE), while plastic-embedded semi-thin cross-sections (0.5 μm) were counterstained with toluidine blue as described 








 male mice aged 24 weeks. Lean mass/body 
weight ratio was determined in 6 pairs of live mice by using the whole body composition analyzer EchoMRI™ (Zinsser 
Analytic, Frankfurt, Germany) (56) . Five pairs of mice were used for muscle and blood sampling. The mice were 
slightly sedated using isoflurane before being anesthetized with an i.p. injection of a mixture containing urethane (1.5 
g/kg) and diazepam (5 mg/kg) and killed by exsanguination. Blood and muscle tissues were collected as previously 
described (57). Selected leg muscles (triceps surae, soleus, plantaris, gastrocnemius, tibialis anterior, tibialis posterior, 
quadriceps) were carefully dissected bilaterally and weighed. Muscle mass was expressed relative to body weight. 
Creatine kinase (CK) activity in plasma was determined by spectrophotometry using a kit (C184-0B ; Catachem, 
Nuuchem, Oxford, CT, USA) according to the manufacturer’s instructions (57). 
 
Data analysis and Statistics. The quantitative data were expressed as means ± standard error of the mean (s.e.m.). 
Differences between experimental groups were evaluated using analysis of variance followed by post hoc test, when 
appropriate. When only two groups were compared, unpaired or paired two tailed Student’s t-tests were used as 
appropriate. No statistical methods were used to predetermine the sample size. The sample size (n of biological 
replicates derived from distinct mice) of each experimental group is described in figure legends. GraphPad Prism 
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Figure 1. Growth retardation and renal phenotype in a whole body OcrlY/- mouse model. (A) Dot plot representing the measurement of body weight, (B) albumin and (D) clara cell protein 16 (CC16) urinary excretion in Ocrl 
male mice at 8, 16, 24 and 48 weeks after birth (8 weeks n= 7 mice per group, 16 weeks n= 7 mice per group, 24 weeks n=7 mice per group, 48 weeks n=5 mice per group). (C) Coomassie blue-stained SDS-PAGE analysis of urine 
derived from 8 weeks old Ocrl mice and densitometry quantification of Albumin (n=3 mice per group).10 μg of bovine serum albumin (BSA) were loaded as positive control (first lane; molecular weight (MW) 66.5 kDa). (E) 
Representative western blotting and densitometry quantification of transferrin (TFR), vitamin D binding protein (VDBP) and CC16 in urine derived from 8 weeks old Ocrl mice. (TFR, VDBP and CC16 n= 5 mice per group). (F) 
Quantification of CC16 urinary excretion in 8 weeks old Clcn5 and Ocrl mice (n=5 mice per group). All the urine parameters were normalized to urinary creatinine concentration. Plotted data represent mean ± SEM. Each dot of the 






Figure 2. Defective receptor-mediated endocytosis in OcrlY/- mice. (A-B) Representative confocal micrographs showing Cy5 labeled β-lactoglobulin (red, 1mg/kg B.W.) or (C) Alexa 647–labeled dextran uptake (red, 6 mg/kg 
B.W.) after 15 and 30 minutes from tail vein injections respectively and quantifications of the corresponding fluorescent signal in LTL+ (Lotus Tetragonolobus Lectin, green) proximal tubules from Ocrl and Clcn5 mouse kidneys 
(n=90 Ocrl and n=70 Clcn5 proximal tubules for Cy5 labeled β-lactoglobulin uptake;  n = 40 Ocrl proximal tubules for Alexa 647 dextran uptake); n=2 per group, each dot representing fluorescence intensity in one proximal tubule; 
fluorescence intensity was normalized on tubule area; two-tailed unpaired Student’s t-test, ***P < 0.001 relative to OcrlY/+or Clcn5Y/+ kidneys. ns: not significant). Insets: high magnification of Cy5 labeled β-lactoglobulin+ or Alexa 
647 dextran+ structures in LTL+ proximal tubules. (D) Representative confocal micrographs showing LRP2 (red) expression in LTL+ (green) proximal tubules of Ocrl mouse kidneys. Insets: high magnification of LRP2+ structures in 
LTL+ proximal tubules. (E) Western blotting and densitometry analyses of LRP2, SGLT2, NaPi-IIa and AQP1 protein levels in whole kidney lysates from Ocrl mice. β-actin was used as loading control. Protein levels normalized on 
β-actin and relative to OcrlY/+ mice (black dotted line), (LRP2 n = 6 mice per group; SGLT2, NaPiIIa and AQP1 n=3 mice per group. Mann-Whitney U test, **P < 0.01 relative to OcrlY/+ kidneys). (F) The mRNA kidney levels of 
Lrp2, Sglt2, Slc34a1 and Aqp1 were analyzed by real-time qPCR. Gene target expression normalized to Gapdh and relative to OcrlY/+ mice (black dotted line), (n = 3 mice per group). Nuclei counterstained with DAPI (blue) in A, B, 





Figure 3. Altered PI(4, 5) P2  subcellular distribution and receptor-mediated endocytosis in Ocrl
Y/- mPTCs. (A) Representative confocal micrographs and quantification of PI(4,5)P2
+ structures (green) in Ocrl mPTCs (n  80 
cells pooled from three mouse kidneys per condition; each dot representing the number of PI(4,5) P2
+ structures in a cell). (B) Representative confocal micrographs of Ocrl mPTCs immunostained with anti- PI(4,5)P2 (green) and anti-
EEA1 (red, early endosomes) and quantification (adjacent panel) of the number of PI(4,5)P2/EEA1
+ structures by confocal microscopy (percentage of total EEA1+ vesicles; n= 3 OcrlY/+; n=4 OcrlY/-  randomly selected fields per 
condition, each containing  15-20 cells). Insets: high magnification of PI(4,5)P2/EEA1+ structures. (C-D) Ocrl and Clcn5 mPTCs were loaded with Alexa 488-BSA (green, 100 μg ml−1 for 15 min at 37 °C), fixed, and analyzed by 
confocal microscopy. Quantification of the number of Alexa 488-BSA+ structures (n 150-250 cells pooled from three mouse kidneys per condition; each point representing the number of BSA+ structures in a cell). (E) Ocrl mPTCs 
were loaded with Alexa 647-dextran 10kDa (red, 250 μg ml−1 for 30 min at 37 °C), fixed, and analyzed by confocal microscopy. Quantification of the number of Al647-dextran+ structures (n 200-250 cells pooled from three mouse 
kidneys per condition; each dot representing the number of dextran+ structures in a cell). Nuclei counterstained with DAPI (blue). Scale bars in A and B 15μm, in C, D and E 10 μm. Plotted data represent mean ± SEM. Two-tailed 






Figure 4. OcrlY/- mPTCs exhibit decreased expression of LRP2 and defective endocytic recycling . (A) Representative western blotting and quantification of LRP2 in whole Ocrl mPTCs lysates. α- tubulin was used as loading 
control (n=4 mice per group). (B) Dot plot representing distribution and average fluorescence intensity of LRP2 along Z-stacks projections in Ocrl mPTCs. Yellow rhombus represents the maximum peak of fluorescence intensity. 
Quantifications of Z-stacks were obtained from 3 randomly selected fields per condition, with each containing  15-20 cells. (C) Representative confocal micrographs and quantification of LRP2/WGA+ structures by confocal 
microscopy (in percentage of total LRP2+ vesicles, n=7 OcrlY/+; n=8 OcrlY/- randomly selected fields per condition, each containing 10-15 cells). (D) Representative western blotting and quantification of LRP2 protein levels in 
plasma membrane fraction derived from Ocrl mPTCs. Flotillin A1 and GAPDH were used as purity marker and loading control of the plasma membrane and cytosolic fractions respectively (n=3 independent experiment). (E) 
Representative confocal micrographs of Ocrl mPTCs immunostained with anti-LRP2 (red) and anti-EEA1 (green, early endosomes) and quantification (adjacent panel) of the number of LRP2/EEA1+ structures by confocal 
microscopy (percentage of total LRP2+ vesicles; n=5 OcrlY/+; n=6 OcrlY/- randomly selected fields per condition, each containing  15-20 cells). Insets: high magnification of LRP2/EEA1+ structures. (F) Representative confocal 
micrographs of Ocrl mPTCs immunostained with anti-LRP2 (red) and Alexa-Fluor-488-phalloidin (green, F-actin). Quantification (adjacent panel) of the number of F-Actin/LRP2+ structures (in percentage of total LRP2+ vesicles, 
n= 4 OcrlY/+; n=6 OcrlY/- randomly selected fields per condition, each containing 10-15 cells). Insets: high magnification of F-actin/LRP2+ structures. (G) Representative confocal micrographs of Ocrl mPTCs stained with anti-TfR 
(green) and anti-LRP2 (red) and quantification of the number of TfR/LRP2+ structures by confocal microscopy (in percentage of total LRP2+ vesicles, n=8 randomly selected fields per condition, each containing 20-25 cells). Insets: 
high magnification of TfR/LRP2+ structures. Nuclei counterstained with DAPI (blue) in C, E, F and G. Scale bars in E, F and G 15μm and in C 20μm. Plotted data represent mean ± SEM. Two-tailed unpaired Student’s t-test, *P < 





Figure 5.  Altered lysosomal dynamics and degradative capacity in OcrlY/- mPTCs. (A) Ocrl mPTCs were immunostained with anti-PI(4,5)P2 (green) and anti-LAMP1 (red, lysosomes) and the number of PI(4,5)P2 /LAMP1
+ 
structures were quantified by confocal microscopy (in percentage of total PI(4,5)P2
+ vesicles; n=3  randomly selected fields per condition, each containing  40-50 cells). (B) Representative confocal micrographs of Ocrl mPTCs 
immunostained with anti-LAMP1 (green). Quantification of the average LAMP1+ vesicles diameter (top, n= 4 OcrlY/+ ; and n=6 OcrlY/- randomly selected fields per condition, each containing  50-60 cells) and number of structures 
(bottom, n 200-220 cells pooled from 3 Ocrl kidneys per group, each point representing the number of LAMP1+ structure in a cell ). (C) Ocrl mPTCs were loaded with DQ (dequenched) Red BSA (red, 10 μg ml−1 for 1h at 37 °C), 
immunostained with anti- LAMP1 (green, lysosomes) fixed and analyzed by confocal microscopy. Quantification of number of DQ Red BSA /LAMP1+ structures (in percentage of total LAMP1+ structures, n = 8 randomly selected 
fields per condition, with each containing  10–15 cells). Insets: high magnification of DQ Red BSA / LAMP1+ vesicles. (D) Ocrl mPTCs were serum starved for 24 h and then stimulated with EGF (100 ng/ml) for the indicated 
times. EGFR protein levels were evaluated by western blotting and quantified relative to time 0 (starved cells). (n=3mice per group; two-tailed unpaired Student’s t-test, *P < 0.05, **P < 0.01 relative to OcrlY/+ or OcrlY/- starved 
mPTCs. ns: not significant). (E) Western blotting and densitometry analyses of cathepsin D (Cts-D) protein levels in Ocrl mPTCs (n= 4mice per group). (F) Ocrl mPTCs were loaded with Bodipy-FL-PepA (1 μM, for 1 h at 37 °C, 
green), immunostained with anti- LAMP1 antibody (red) and analysed by confocal microscopy. Quantification of numbers of PepA/LAMP1+ structures (in percentage of total LAMP1+ structures; n = 4 randomly selected fields per 
condition, with each containing ~ 20–25 cells). (G) Representative confocal micrographs showing Cy5 labeled β-lactoglobulin (red) after 120 minutes from tail vein injections and quantifications of the corresponding fluorescent 
signal in LTL+ proximal tubules from Ocrl mouse kidneys (n=50 Ocrl proximal tubules; each dot representing fluorescence intensity in one proximal tubule; fluorescence intensity was normalized on tubule area). Nuclei 
counterstained with DAPI (blue) in A, B, C, F and G. Scale bars in A, B and C 15 μm; in F 10 μm and in G 50 μm. Plotted data represent mean ± SEM. Two-tailed unpaired Student’s t-test.  **P < 0.01, ***P < 0.001 relative to 






Figure 6. Impaired locomotor activity and muscular defects in OcrlY/- mice. (A-C) Open field large arena test was performed during 10 minutes of two subsequent days in a circular arena with a diameter of 150 cm on a cohort of 
16 OcrlY/+and 16 OcrlY/- age matched male mice. (A) Illustrative pictures representing the trajectories traveled by Ocrl mice during the open field large arena test. (B) Dot plot representing the distance covered by Ocrl mice during 
the large open field arena test. The distance traveled by each mouse is normalized to 1 minute observation time and plotted as function of time for each bin (bin=5 minutes) (split ANOVA effects followed by post-hoc tests between 
genotype for each bin: Bin1 ’P < 0.1, Bin2 *P < 0.05, Bin3 *P < 0.05). (C) Dotted bar graph representing the frequency of resting, lingering and walking episodes exhibited by Ocrl mice during the open field large arena test (split 
ANOVA effects followed by post-hoc tests between genotype for each state: rest *P < 0.05, linger, *P < 0.05, walk *P < 0.05). (D) IntelliCage experiments were performed on a cohort of age matched male Ocrl mice (13 OcrlY/+and 
13 OcrlY/-). Dot plot representing the median licking frequency during drinking restriction protocol. Base indicates the licking frequency during the last 24h of nose poke adaptation phase (split ANOVA effects followed by post-hoc 
tests between genotype for each time point: Day1 **P < 0.01, Day 2-2last *P < 0.05, Last day **P < 0.001). (E) Lean mass/body weight ratio determined by whole body composition analysis in Ocrl mice (n=6 mice per group). (F) 
Muscle mass, relative to body weight, of selected hind limb muscles obtained by bilateral dissection of 5 pairs of Ocrl mice (n=10 values for symmetrical leg muscles). (G) Plasma creatine kinase activity (CK) in the corresponding 5 
pairs of Ocrl mice (as in B). Plotted data represent mean ± SEM. In B, C and D One-way ANOVA between subject factor genotype: *P < 0.05; **P < 0.01 (on the top of each graph); in E, F and G Mann Withney test, **P < 0.01; 







Table 1. Body weight, urine and blood parameters in Ocrl and Clcn5 mice. 
        
 U, Urine; CC16, Clara cell protein 16; BUN, Blood urea nitrogen. All the measurements were performed on OcrlY/+ and OcrlY/- male mice matched per age. 
Plotted data represent mean ± SEM. Two-tailed unpaired Student’s t-test was applied between genotypes for the indicated time point. 
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MATERIALS AND METHODS 
Cell profiler quantifications. The pipeline “Speckle counting” derived from the open source Cell Profiler image 
analysis software was used to identify dots (PI(4,5)P2 or PI3P or BSA or Dextran or LAMP1 or MPR-positive 
structures) surrounding nuclei and to perform per-nuclei aggregate measurements (eg. the number of dots/nucleus), as 
described by Carpenter et al. (2006) and De Leo et al. (2016). Briefly, the images were converted to greyscale using the 
module “ColorToGray”. The “IdentifyPrimaryObjects” module was used to identify nuclei and dots while cells were 
identified by using the module “IdentifySecondaryObjects”. “MaskObject” and “RelateObject” modules were used to 
establish a parent-child relationship between the cells and the dots, identified as masked objects, and to calculate the 
average of dots per cell. The module “MeasureObjectIntensityDistribution” was used to score the fluorescence intensity 
of MPR and TfR positive structures contained into perinuclear region (area defined by the first 10 bin) and peripheral 
region (area defined by the last 10 bin) of the cells. Briefly, the software generates 20 concentrically bin around the 
nucleus of each cell and calculates the intensity distribution for each bin. The module “MeasureObjectSizeShape” was 
used to score the vesicle size of LAMP1. The pipeline “Cell/particle counting, and scoring the percentage of stained 
objects” was used to score the percentage of EEA1+ structures colocalizing with PI(4,5)P2 or F-actin, the percentage of 
LRP2
+
 structures colocalizing with F-actin, EEA1 or TfR and the percentage of LAMP1
+
 structures colocalizing with 
PI(4,5)P2, DQ-BSA or PepA. Briefly, the images were converted to greyscale using the module “ColorToGray”. Then 
the “ObjectIdentification” module was used to identify the nuclei and the aforementioned stained structures/vesicles. 
The “RelateObject” module was used to establish a parent-child relationship between the stained objects. In this case, a 
“parent” object is one that touches, overlaps or encloses a “child” object. Objects1 that touch or overlap with an Object2 
are considered to be colocalized and will be assigned as a parent to a corresponding child. The “ClassifyObjects” and 
“FilterObjects” modules were used to categorize structures that were either colocalizing or not-colocalizing, and to 
calculate the percentage of colocalizing structures on the total amount per image. Fluorescence intensity of LRP2 was 
measured from a Z stack of 55 serial images acquired, according to Nyquist theorem, every 0.13 µm to maximize the 
spatial information. The average fluorescence intensity of LRP2 was calculated every 0.5 µm of the Z-stacks projection 
by using ImageJ software. Qualitative analysis of F-actin dynamics was performed by maximal projection of Z-stack 
images acquired throughout the entire volume of the cells. 
 
Behavioral tests. Open field large arena test. The large open-field arena is circular with a diameter of 150 cm, a 
slightly roughened white plastic floor, and 35cm high smooth sidewalls made of white polypropylene. Illumination is 
performed by indirect diffuse room light (4 40W bulbs, 12 lux). Each subject is released near the wall and observed for 
10 min on two subsequent days. Movements are tracked using Noldus EthoVision. Between subjects, the arena is 
thoroughly cleaned with water and dried. Water-maze cue navigation. The water maze is constituted by a round white 
poly-propylene pool with a diameter of 150 cm with 68 cm high walls. It is filled with water (24-26° C, depth 15 cm) 
which is rendered opaque by addition of 1l of milk (UHT whole milk 3.5% fat, Coop, Switzerland). The white quadratic 
goal platform (14x14 cm) is made of metallic wire mesh and painted white. It is hidden 0.5 cm below the water surface 
in the center of one of the 4 quadrants, approximately 30 cm from the side wall. Salient extra-maze cues made of black 
cardboard are placed on the walls of the testing room. Computer and experimenter are hidden behind a curtain. 
Illumination is performed by indirect diffuse room light (4 40W bulbs, 12 lux at the center of the pool). During the test 
animals are trained for 2 days with the goal platform marked by a salient cue and placed in a different quadrant for 
every trial. All subjects are trained on the same sequence of goal positions and released from the same start points. 
Three-chambers sociability test. The 3-chamber cage is a polycarbonate type III cage (20.5 cm high, 58 × 40 cm top, 
55 × 37.5 cm bottom, Techniplast, 2000P, Buguggiate, Italy). Two dividers provided with gates regulate the access of 
the test mouse from the middle to the lateral chambers. One unfamiliar stimulus mouse is placed inside a metallic 
cylinder in one of the two lateral chambers. The cylinder allows visual and olfactory contact between the test mouse and 
the stimulus mouse, reducing the possibility of physical contact. In the other lateral empty chamber, an empty cylinder 
is placed giving then the test mouse the choice to spend time in the chamber with the novel object (the cylinder) plus the 
unfamiliar mouse (social stimulus) and the chamber containing only the empty cylinder. This test runs for 10 minutes 
after which the stimulus mouse is considered to be familiar to the test mouse. The time spent by the test mouse in the 
lateral chambers is noted. 
IntelliCage apparatus and mice preparation. The IntelliCage apparatus (TSE Systems, Bad Homburg, Germany) is 
placed in a polycarbonate cage (20.5 cm high, 58 × 40 cm top, 55 × 37.5 cm bottom, Techniplast, 2000P, Buguggiate, 
Italy) and accommodates up to 16 mice. Its aluminum top contains a freely accessible food rack filled with standard 
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mouse chow (Standard 3430, Kliba Nafag, Kaiseraugst, Switzerland). The floor is covered with woodchip bedding and 
provides 4 central red shelters (Techniplast, Buguggiate, Italy). Four triangular conditioning chambers (15×15×21 cm) 
are fitted in the cage corners and provide room for one mouse at a time. Each chamber contains two drinking bottles, 
accessible via two round openings that can be opened and closed with motorized doors. Mice were tagged with RFID-
transponders, subcutaneously implanted under isoflurane anesthesia, which can be read by a circular RIFD antenna 
located at the entrance of each chamber. The duration of their visit is determined by both the antenna reading and a 
temperature sensor that detects the presence of the animal inside the corner. During a visit, number and duration of 
individual nosepokes at each door are recorded using IR-beam sensors. Licking episodes at each bottle are monitored 
using lickometers (duration of the episode, number of licks, total contact time). IntelliCages have individual controllers 
and are connected to a central PC running the software that permits to design and control experiments remotely, as well 
as to analyze the recorded data (IntelliCage Plus, TSE Systems, Bad Homburg, Germany). After RIFD implantation, 
mice are allowed to recover for one week in groups of 8-16 mice in standard Type III cages with water and food ad 
libitum. The same grouping is maintained when the mice are later transferred to IntelliCages. During all adaptation 
phases and tasks in IntelliCage, mice are fed ad libitum. Ambient lights are on 20:00-08:00. Room temperature is kept 
constant at 23°C. 
 
Additional References: 
Carpenter, A.E., Jones, T.R., Lamprecht, M.R., Clarke, C., Kang, I.H., Friman, O., Guertin, D.A., Chang, J.H., 
Lindquist, R.A., Moffat, J. et al. (2006) CellProfiler: image analysis software for identifying and quantifying cell 
phenotypes. Genome Biol., 7, R100. 
De Leo, M.G., Staiano, L., Vicinanza, M., Luciani, A., Carissimo, A., Mutarelli, M., Di Campli, A., Polishchuk, E., Di 
Tullio, G., Morra, V. et al. (2016) Autophagosome-lysosome fusion triggers a lysosomal response mediated by TLR9 






Supplementary Figure 1. Genotype confirmation and analyses of the kidney phenotype in OcrlY/- mice harboring different levels of human BAC-INPP5B expression. (A) Ocrl, Inpp5b and BAC-INPP5B genomic DNA 
analyses by PCR and agarose gel electrophoresis isolated from kidney biopsies derived from Ocrl mice. (B) Western blotting of OCRL protein level in whole kidney lysates from Ocrl mice. GAPDH was blotted as loading control. 
(C) BAC-INPP5B mRNA expression in kidneys derived from Ocrl mice was analyzed by quantitative RT-PCR. Gene target expression was normalized on 6 housekeeping genes and expressed as relative to OcrlY/+ BACI-INPP5B 
(n=5 mice per condition). (D) Dot plot representing the measurement of the body weight, (E) Clara cell secretory protein (CC16) and (F) albumin urinary excretion in Ocrl mice harboring different level of BAC-INPP5B expression 
as shown in C. Each dot represents one mouse (n=6 mice per group). All the analyses in D, E and F were performed on mice matched for age (24 weeks) and gender (male). All the urine parameters were normalized to urinary 




Supplementary Figure 2. Proximal tubule dysfunction in Clcn5Y/ - mice. (A) Western blotting and densitometry analysis of LRP2, NaPi-IIa and SGLT2 protein levels in whole kidney lysates from Clcn5 mice. β-actin was used as 
loading control. (n= 3 mice per group). (B) Representative confocal micrographs showing Alexa 647–labeled dextran uptake (red, 6 mg/kg B.W.) in LTL+ (Lotus Tetragonolobus Lectin, green) proximal tubules of Clcn5 mouse 
model after 30 minutes from tail vein injections. Nuclei counterstained with DAPI (blue). Scale bar 25μm. (C) Dot plot representing the measurement of glucose and (D) phosphate urinary excretion in 8 weeks old Clcn5 mice. Each 
dot represents one mouse (n=4 mice per group). All the urine parameters were normalized to urinary creatinine concentration. Plotted data represent mean ± SEM. Two-tailed unpaired Student’s t-test, *P < 0.05, ***P < 0.001 




Supplementary Figure 3. OcrlY/- mPTCs exhibit no changes in PI3P (Phosphatidylinositol 3 phosphate) levels and no transcriptional alterations of proximal tubule receptors and channels. (A) Representative confocal 
micrographs and quantification of the number of PI3P+ structures stained by 2XFYVE-mcherry domain (red) in Ocrl mPTCs (n  200-250 cells pooled from three Ocrl kidneys per group; each point representing the number of PI3P+ 
vesicles in a cell). Nuclei counterstained with DAPI (blue). Scale bar 15μm. (B) The mRNA mPTCs levels of Lrp2, Sglt2, Slc34a1 and Aqp1 were analyzed by real-time qPCR. Genes target expression normalized to Gapdh and 




Supplementary Figure 4. LRP2 dynamics in Dent disease. (A) Western blot and densitometry analysis of LRP2 in whole Clcn5 mPTCs lysates. β-actin was used as loading control (n= 4 mice per group). (B) Representative 
confocal micrographs and X–Z side view of Ocrl mPTCs immunostained with anti-LRP2 (red). (C) Representative confocal micrographs of X–Z side view of a z-stack performed on Ocrl mPTCs immunostained with WGA (green) 
and Na,K-ATPase (cyan) in the upper panels, WGA (green) and LRP2 (red) in the middle panels and Na,K-ATPase (cyan) and LRP2 (red) in the lower panels. (D) Maximum intensity projection of a confocal Z-stacks series 
representing Ocrl mPTCs immunostained with Alexa-Fluor-488-phalloidin (green, F-actin). (E) Representative confocal micrographs of Ocrl mPTCs immunostained with anti-EEA1 (red, early endosomes) and Alexa-Fluor-488-
phalloidin (green, F-actin). Quantification of F-actin/EEA1+ structures (in percentage of total EEA1+ vesicles, n=5 OcrlY/+; n=4 OcrlY/- randomly selected fields per condition, each containing   10-15 cells). Insets: high 
magnification of F-actin/EEA1+ structures. (F) High magnification confocal micrographs of Ocrl mPTCs immunostained with anti-LRP2 (red) and Alexa-Fluor-488-phalloidin (green, F-actin). Nuclei counterstained with DAPI 




Supplementary Figure 5. Impaired trafficking of MPR and TfR cellular receptors in OcrlY/- mPTCs. (A) Representative confocal micrographs and quantification of TfR+ structures distribution (green) in Ocrl mPTCs (in 
percentage of the total TfR+ vesicles, n=4 OcrlY/+; n=6 OcrlY/- randomly selected fields per condition, each containing  20 cells). Two-tailed unpaired Student’s t-test, ***P < 0.001 relative to OcrlY/+ mPTCs. (B) Representative 
confocal micrographs and quantification of distribution of MPR+ structures (green) in Ocrl mPTCs (perinuclear vs peripheral in percentage of the total MPR+ vesicles, n=3 randomly selected fields per condition, each containing  
40-50 cells). Two-tailed unpaired Student’s t-test, Peripheral/perinuclear MPR+ vesicles ***P < 0.001 relative to OcrlY/+ mPTCs. (C) Representative confocal micrographs showing MPR+ structures (red) in LTL+ (Lotus 





Supplementary Figure 6. Altered lysosomal activity in Dent disease. (A-B)Western blotting and densitometry analysis of cathepsin D (Cts-D) protein levels in (A) plasma samples from Ocrl mice (n= 4 OcrlY/+ and  n= 5 OcrlY/- 
mice) and in (B) Clcn5 mPTCs (n= 3 mice per group). β-actin was used as loading control. Plotted data represent mean ± SEM. Two-tailed unpaired Student’s t-test, *P < 0.05 relative to OcrlY/+ plasma or Clcn5Y/+ mPTCs. (C) 
Confocal micrographs showing Clcn5 mPTCs immunostained with Bodipy-FL-PepA (1 μM, for 1 h at 37 °C, green). (D) Representative confocal micrographs showing Cy5 labeled β-lactoglobulin (red, 1mg/kg B.W.) after 120 





Supplementary Figure 7. No impairment of social behavior neither defective ocular morphology is observed in OcrlY/- mice. (A) Dot plot representing the measurement of water intake, over 12 hours, in 24 weeks old Ocrl male 
mice. Each dot represents one mouse. (B) Dotted bar graph representing the number of nose contact time with the social (cage with mouse) and object (empty cage) stimulus during the 3 chambers sociability test. Plotted data 
represent mean ± SEM. Each dot of the graphs represents one mouse. (C)  Schematic representation of the water maze cue navigation test (left panel): animals are trained in the water maze to reach a platform marked by a salient cue 
and placed in a different quadrant for every trial. Dot plot (right panel) representing the swim path as function of 3 trial blocks. Each dot of the graphs represents one mouse. (D) Light microscopy representative pictures of high 
magnification hematoxylin-eosin stained lens (left panels, scale bars 50μm) and midsagittal sections of whole eyes (right panels, scale bars 500μm) derived from Ocrl mice. LC (lens capsule), LE (lens epithelium), DFL 
(differentiating lens fiber), MFL (mature lens fiber), L (lens) and R (retina). (E) Toluidine blue stained retina derived from Ocrl mice in presence or absence of the spontaneous rd8 (retinal degeneration 8) mutation in Crb1 gene 
(right panel, rd8/rd8). RPE (retinal pigment epithelium), PS (photoreceptor segments), OLM (outer limiting membrane), ONL (outer nuclear layer), INL (inner nuclear layer), IPL (inner plexiform layer), GCL (ganglion cell layer); 
















III.2 NEPHROPATHIC CYSTINOSIS 
 
III.2.1 Disruption of lysosomal identity triggers PT dysfunction 
 
 
Impaired Autophagy Bridges Lysosomal Storage Disease and 
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The endolysosomal system sustains the reabsorptive activity of specialized epithelial cells. 
Lysosomal storage diseases such as nephropathic cystinosis cause a major dysfunction of epithelial 
cells lining the kidney tubule, resulting in massive losses of vital solutes in the urine. The 
mechanisms linking lysosomal defects and epithelial dysfunction remain unknown, preventing the 
development of disease-modifying therapies. By combining genetic and pharmacologic approaches 
in vitro and in vivo, we demonstrate that the lysosomal dysfunction in cystinosis results in defective 
autophagy-mediated clearance of damaged mitochondria, generating oxidative stress that stimulates 
G12/Src-mediated phosphorylation of tight junction ZO-1 and triggers a signaling cascade 
involving the ZO-1-associated Y-box factor ZONAB, that leads to epithelial cell proliferation and 
transport defects. Correction of the primary lysosomal defect, neutralization of mitochondrial 
oxidative stress, and blockage of tight junction-associated ZONAB signaling rescue the epithelial 
dysfunction. This work unveils a link between defective lysosome-autophagy degradation pathways 


















The epithelial cells lining the proximal tubules (PT) of the kidney constitute a paradigm of effective 
communication between the environment and endomembrane compartments, allowing the 
reabsorption of essential nutrients. By processing incoming substances and recycling receptors and 
transporters at the apical plasma membrane, the endolysosomal system dictates cell differentiation, 
hence the maintenance of homeostasis (1,2). The PT uptake accounts for ~80% of the clearance of 
small proteins and peptides, which are continuously filtered and completely reabsorbed by apical 
endocytosis involving the multi-ligand receptors, megalin and cubilin (3). Alterations in these 
transport processes lead to generalized PT dysfunction (an entity named renal Fanconi syndrome, 
RFS), causing urinary loss of solutes  and low molecular weight (LMW) proteins, often complicated 
by dehydration, electrolyte imbalance, rickets, growth retardation and development of chronic 
kidney disease (CKD). Such PT dysfunctions are typically encountered in congenital disorders due 
to defective endolysosomal transporters, particularly in nephropathic Cystinosis (4). 
Cystinosis is a lysosomal storage disease (LSD) caused by recessive, inactivating mutations 
in the CTNS gene coding for the proton-driven cystine transporter cystinosin which exports cystine 
out of lysosomes (5). The loss of cystinosin causes an accumulation of cystine in tissues, leading to 
renal failure, diabetes, hypothyroidism, myopathy, and central nervous system deterioration. 
Infantile (MIM #219800) and juvenile (MIM #219900) forms of Cystinosis represent a frequent 
cause of congenital PT dysfunction and RFS, most often complicated by CKD (6). The only 
available strategy to counteract cystine storage is oral administration of cysteamine, which allows 
cystine to exit lysosomes. However, cysteamine treatment is hampered by side effects and poor 
tolerance, and it does not treat nor prevent PT dysfunction (6,7). Thus, there is an urgent need to 
identify novel therapeutic strategies for this devastating disorder. Recent studies based on a Ctns 
mouse model that recapitulates multiple features of Cystinosis (8) have demonstrated that the loss 
of cystinosin is associated with aberrations of the endolysosomal compartment, and abnormal 
proliferation and dysfunction of PT cells (9). Despite identification of cellular defects associated 
with Cystinosis in different models and cell systems (10), a unifying mechanism linking loss of 
cystinosin, lysosomal dysfunction and defective epithelial transport has not been deciphered.  
 In most mammalian cells, the endolysosomal system captures and degrades intracellular 
worn-out constituents through autophagy (11). This homeostatic process is particularly active in 
renal PT cells, whose reabsorptive and transport activities require the maintenance of mitochondria 
network (12). The autophagy-mediated turnover of damaged mitochondria is required for protecting 
the PT from acute tubular injury (13), whereas deletion of essential autophagy genes dacells 
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through defective mitochondrial clearance and increased reactive oxygen species (ROS) (14). Of 
note, accumulation of distorted mitochondria (15) and of autophagy receptor SQSTM1/p62 has 
been described in kidney biopsies and urinary cells from cystinotic patients (16), suggesting a 
possible involvement of autophagy. Also, recent evidence shows that cystinosin is a component of 
the lysosomal mammalian target of rapamycin complex-1 (mTORC1) (17), a hub that regulates 
autophagy-lysosome functions (18) and nutrient transport in epithelial cells (19). Altogether, these 
data suggest potential interactions between cystinosin function, the autophagy-lysosome 
degradation pathway and the transport properties in PT epithelial cells.  
 In the present study, we decipher a pathway linking loss-of-function of cystinosin, 
lysosome-autophagy dysfunction, mitochondrial oxidative stress, disruption of tight junction 
integrity and activation of a signaling cascade causing epithelial cell dysfunction and loss of 
transport capacity. These insights offer new therapeutic strategies for treating epithelial dysfunction 





Loss of cystinosin leads to alterations in lysosomal dynamics and autophagy  
We first investigated the consequences of Ctns deletion on the lysosomal-autophagy pathway in 
epithelial cells. The loss of cystinosin, reflected by the accumulation of cystine in mouse kidneys 
and derived PT cells (mPTCs), induced a phenotype switch associating abnormal proliferation and 
apical dedifferentiation, leading to defective receptor-mediated endocytosis and urinary loss of 
LMW proteins in vivo (Suppl. Fig. 1a-g). These changes, which confirmed the validity of the Ctns 
mouse model and derived mPTCs (8,9), were associated with a dramatic modification in lysosomal 
dynamics as evidenced by enlarged lysosomes, clustered into the perinuclear region (Fig. 1a; Suppl. 
Videos 1 and 2). Since the intracellular positioning of lysosomes coordinates autophagy in response 
to nutrient availability (20), we tested whether the perinuclear clustering of lysosomes reflects 
changes in autophagy. We used mPTCs because this well-established primary culture system 
provides a particularly suited model to explore mechanisms of endolysosome disorders in epithelial 
cells (21,22). Autophagy was assessed by quantifying the conversion of the non-lipidated form of 
LC3-I to the lipidated, autophagosome-associated form LC3-II and the numbers of LC3 vesicles 
(23) in mPTCs cultured in nutrient-rich media (hereafter referred to as “fed”) or in nutrient 
deprived-conditions (hereafter referred to as "starved"). Compared to wild-type cells,  Ctns
-/-
 cells 
showed higher numbers of punctate LC3-structures and steady-state levels of LC3-II, which did not 
further increase in starved conditions (Fig. 1b,c), as well as higher numbers of EM structures 
compatible with autophagic vacuoles (Fig.1d). Likewise, Ctns
-/-
 cells showed larger numbers of 
aggregates positive for the autophagy receptor SQSTM1(Fig.1e) and higher SQSTM1 protein 
levels, which did not further increase in starved conditions (Fig.1f). The accumulation of LC3-
marking autophagosomes and SQSTM1-positive aggregates was consistently detected in the PTs of 
Ctns
-/- 
kidneys (Fig. 2a,b). To further explore the consequences of cystinosin deletion in vivo, we 
established a novel ctns knock-out zebrafish model using the TALENs (transcription activator-like 
effector nucleases) technique (Suppl. Fig. 2a-c). One mutant zebrafish line showed a 8-bp TALEN-
driven deletion (ctns
del8/del8
), resulting in a premature stop codon within exon 3 of ctns, which would 
result in a truncated protein deprived of the transmembrane domains of cystinosin. Microinjection 
of wild-type (but not mutant) human CTNS mRNA decreased the cystine storage in ctns-deficient 
embryos to the same extent than cysteamine treatment (Suppl. Fig. 2d). The protein levels of LC3-II 
and the numbers of autophagic vesicles were remarkably increased in cystine-accumulating 
pronephric tubules in ctns-deficient zebrafish (Fig. 2c-f), demonstrating the evolutionary 
conservation of this connection. These results demonstrate that the deletion of cystinosin alters 
lysosomal dynamics and autophagy in PT cells, both in vitro and in vivo.   
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Cystinosin deficiency perturbs autophagic clearance in PT cells 
An increased number of autophagic vesicles may arise from stimulation of autophagosome 
biogenesis or from alteration of their degradation by lysosomes. To discriminate between these two 
possibilities, we treated Ctns mPTCs with Bafilomycin A1 (BfnA1), a proton pump inhibitor that 
prevents lysosome degradation and thus increases autophagic cargoes and substrates exclusively 
when autophagy is active (23). Treatment with BfnA1 increased the amounts of LC3-II and 
SQSTM1 in nutrient-deprived Ctns
+/+
 cells, whereas it did not change the already elevated levels of 
these proteins in nutrient-deprived Ctns
-/-
 cells (Fig. 3a). We next performed a pulse-chase assay to 
monitor the degradation of resting autophagosomes in Ctns
 
mPTCs. Cells were starved to form 
autophagosomes and then treated with the class III phosphoinositide 3-kinase (PI3K) vacuolar 
protein sorting 34 (Vps34) kinase inhibitor SAR-405 (24) to prevent the formation of new 
autophagosomes. We validated the selectivity of SAR-405 by determining the intracellular 
phosphatidylinositol-3-phosphate pools (PtdIns-3P, the end-product generated by Vps34 kinase 
activity) in mPTCs (Suppl. Fig. 3a). The degradation of the formed autophagosomes following 
SAR-405 treatment was tracked by time-lapse confocal microscopy: in contrast to the autophagic-
mediated degradation observed in starved Ctns
+/+
 cells, the Ctns
-/-
 cells retained almost all the 
formed autophagosomes (Suppl. Fig. 3b,c). Upstream events regulating autophagosome biogenesis, 
such as conjugation (ATG7) and phagosome formation (ATG16L+ vesicles), including Beclin-1, 
remained unchanged in control and Ctns
-/- 
PT cells (Suppl. Fig. 4a-c). Taken together, these results 
indicate that the accumulation of autophagosomes in Ctns
-/-
 cells results predominantly from a 
slower autophagosome clearance rather than augmented biogenesis.  
 
Defective lysosomal function impedes autophagic cargo clearance in Ctns
-/-
 cells 
A blockade in LC3-II degradation can occur at any step after autophagosome formation and can be 
induced by delayed trafficking of autophagosomes to lysosomes and/or reduced fusion between 
both compartments (25). We thus explored whether the delayed autophagosome clearance in Ctns
-/-
 
cells might be caused by an impaired autophagosome delivery to lysosomes. To test this hypothesis, 
we examined the subcellular distribution of LC3-labeled autophagic structures and LAMP1-labeled 
lysosomes in response to short incubations with non-saturating concentrations of BfnA1 (50nM for 
1h) (26). Confocal microscopy analysis showed that cystinosin deletion did not decrease the 
colocalization of LC3 and LAMP1- labeled lysosomes in BfnA1-treated PT cells but rather 
increased the number of large LAMP1 vesicles filled by LC3 in Ctns
-/- 
PT cells (Suppl. Fig. 5a). 
Electron tomography microscopy and three-dimensional (3-D) reconstructed tomograms confirmed 





cells (Suppl. Fig. 5b; Suppl. Video 3). Accumulation of autophagic material in 
autolysosomes of Ctns
-/- 
cells was confirmed by correlative light-electron microscopy (CLEM), 
where GFP-LC3-positive autophagosome containing intracellular components coalesced within 
enlarged, single-membrane RFP-LAMP1-positive organelles (Fig. 3b), indicating that the transport 
and/or autophagosome-lysosome fusion are not compromised. One mechanism by which the 
autophagic cargo clearance might be impeded is defective lysosomal degradation capacity (11). To 
substantiate the delayed autophagosome degradation in Ctns
-/-
cells, we analyzed trafficking, 
processing and maturation of lysosomal cathepsins. Western blot analyses of cathepsin-D showed a 





cells (Fig. 3c). We next tested the lysosomal cathepsin-D activity by incubating mPTCs with 
Bodipy-FL-PepstatinA (PepA), a fluorescence-tagged PepA that binds to the active site of 
cathepsin-D in acidic lysosomes (22). Although the majority of lysosomes were co-stained with 
PepA–labeled cathepsin-D in Ctns+/+cells, the number of PepA-labeled vesicles and the 
colocalization of active cathepsin-D with LAMP1 were substantially lower in Ctns
-/- 
cells (Fig. 3d). 
These changes in lysosome dynamics and function were observed despite normal trafficking of 
cathepsin-D between Golgi and LAMP1 compartments (Suppl. Fig. 5c,d). Similarly, the lysosomal-
based processing of the LMW -lactoglobulin, that is normally internalized and degraded by PT 
endolysosomes (2,3), was dramatically reduced in pronephric tubules of ctns
del8/del8
 compared to 
ctns
+/+
 zebrafish (Fig. 3e). The key role of cystinosin depletion in lysosomal-autophagy dysfunction 
was assessed by transducing Ctns
-/- 
cells with an adenovirus that expresses mouse hemagglutinin 
(HA)-tagged cystinosin (Ad-Ctns-HA; Fig. 4). The functional re-expression of HA-CTNS protein at 
late endosomal/lysosomal compartments in Ctns
-/- 
cells (Fig. 4a; Suppl. Fig. 6) lowered the 
intracellular cystine content (Fig. 4b), rescued the lysosomal dynamics (Fig. 4c,d), activated 
cathepsin-B within lysosomes (Fig. 4e), and augmented the lysosome-mediated degradation of 
autophagy substrates SQSTM1 and LC3-II (Fig. 4f) when compared to Ctns
-/-
 cells transduced with 
an empty vector. These features were abolished by treating the HA-CTNS expressing Ctns
-/- 
cells 
with BfnA1 (Fig.4f), indicating that cystinosin deficiency blocks autophagosome clearance by 
compromising the lysosome function.  
 
Disruption of autophagy causes mitochondrial oxidative stress and epithelial cell dysfunction 
Because autophagy mediates cellular homeostasis, we tested whether and how its disruption may 
cause epithelial dysfunction. Inactivation of basal autophagy was obtained by transducing mPTCs 
with an adenovirus-expressing a short hairpin RNA (Ad-shRNA) against Atg7 or by inhibiting the 
autophagy Beclin1/Vps-34 complex with SAR-405 or Spautin-1. We confirmed that either Atg7 
79 
 
shRNA (Fig. 5a) or autophagy inhibitors (Suppl. Fig. 7a-b) prevented the conversion of LC3-I to 
LC3-II and increased the SQSTM1 protein levels and amounts of aggregate-forming SQSTM1 and 
ubiquitin-positive inclusions (Fig. 5a-c; Suppl. Fig.7c) in mPTCs. Disruption of autophagy led to 
the accumulation of dysfunctional mitochondria, as shown by increased levels of prohibitin (an 
inner mitochondrial membrane protein; Fig. 5d) and decreased resting mitochondrial membrane 
potential (m, assessed by quantitative confocal imaging of tetramethylrhodamine methyl ester 
[TMRM] dye; Fig. 5e; Suppl. Fig 7d), and the induction of a major mitochondrial oxidative stress, 
as scored by elevated mtROS levels (MitoSOX; Fig. 5f; Suppl. Fig. 7e). Importantly, either the 
genetic or the pharmacological impairment of autophagy induced the nuclear translocation of tight-
junction ZO1-associated Y-box factor ZONAB (Fig. 5g) and its activity (as measured by the 
regulation of the Ccdn1, Pcna and Lrp2 targets (27,28) (Fig. 5h; Suppl. Fig. 7f). These changes 
were reflected by a phenotype switch that included abnormal cell proliferation, as evidenced by 
bromodeoxyuridine (BrdU) incorporation (Fig. 5i; Suppl. Fig. 7g), and dedifferentiation, as 
evidenced by reduced expression of the apical endocytic receptor megalin (Fig. 5h) and by 
decreased endocytic uptake capacity (Fig. 5j; Suppl. Fig. 7h). Collectively, these data demonstrate 
that the maintenance of mitochondrial function and homeostasis by autophagy is required for the 
terminal differentiation, hence regulating the reabsorptive capacity of PT epithelial cells.  
 
Impaired clearance of dysfunctional mitochondria drives oxidative stress in PT cells  
Having established that disruption of autophagy recapitulates the phenotype switch of proliferation-
dedifferentiation, we next investigated how defective lysosomal degradation of autophagy 
substrates might lead to epithelial dysfunction in Cystinosis. Because autophagy delivers protein 
aggregates and organelles to endolysosome for cellular degradation, we analyzed the ability of Ctns
-
/-
 mPTCs to clear polyubiquitinated aggregates and compromised mitochondria. Correlating with 
the reduced autophagy flux, we found an accumulation of ubiquitin-forming aggregates and 
abnormal mitochondria with disorganized cristae in Ctns
-/-
 compared to Ctns
+/+
 cells (Fig. 6a-c). 
The defective mitochondria in Ctns
-/-
 cells were retained within enlarged, dysfunctional lysosomes 
(Fig. 6d) and showed a major decrease in m (Fig. 6e). Seahorse metabolic flux analyses 
measuring the overall consumption rates (OCRs) confirmed markedly decreased mitochondrial 





mPTCs (Fig. 6f). These changes were paralleled by a major mitochondrial oxidative 
stress, as scored by the elevated mtROS levels (MitoSOX; Fig. 6g) and increased anti-oxidant 
response (HO1; data not shown). Overall these findings indicate that impaired lysosome-mediated 
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autophagic degradation of dysfunctional mitochondria causes a major oxidative stress in cystinosin-
deficient cells.  
 
Abnormal tight junction signaling leads to epithelial dysfunction   
Oxidative stress has been shown to induce the phosphorylation of the zona occludens1 (ZO-1) 
adaptor protein, disrupting the integrity of the tight junction complex (29). Because ZO-1 traps the 
Y-box transcription factor ZONAB that is known to regulate the differentiation of PT cells (27,28), 
an overproduction of ROS by dysfunctional mitochondria might alter tight junction integrity and 
trigger ZONAB-mediated signaling. To test this hypothesis, we immunoprecipitated ZO-1 from 




 cells (Fig. 7a). 
This result was supported by the proximity ligation assay (PLA) revealing an increased cytoplasmic 
phosphorylation of ZO-1 in Ctns
-/-
 cells (Fig. 7b). ZO-1, which is normally located at cell 
membrane boundaries as shown in Ctns
+/+
 cells, was found to be trapped in LAMP1-positive 
compartments in Ctns
-/-
 cells (Fig. 7c). Consistent with the loss of integrity of tight junctions, there 
was a nuclear translocation of ZONAB (Fig. 7d) with subsequent increase in its transcriptional 
targets Ccdn1, Pcna and Lrp2 (Fig. 7e). These changes in Ctns
-/-
 cells were coupled to increased 
proliferation, as evidenced by measuring cell growth curves (Fig. 7f) or by the nuclear enrichment 
of PCNA (Fig. 7h; Suppl. Fig. 1e), contrasting with decreased receptor-mediated endocytosis of 
albumin (Fig. 7i; Suppl. Fig. 1f). The link between defective autophagy, compromised mitochondria 
and oxidative stress was substantiated by the increased phosphorylation rate of ZO-1 induced by 
knockdown of Atg7 in mPTCs (Suppl. Fig. 8a) or treatment of the cells with autophagy inhibitors 
(SAR-405 and Spautin-1; Suppl. Fig. 8b); with H2O2 (Suppl. Fig. 8c); or with the mitochondrial 
complex I inhibitor Rotenone stimulating mitochondria-derived ROS (Suppl. Fig. 8d,e). Treatment 
with rotenone induced ZONAB translocation and signaling (Suppl. Fig. 8f,g), reflected by increased 
proliferation (Suppl. Fig. 8h) and decreased endocytic uptake (Suppl. Fig. 8i). The relevance of the 
abnormal tight junction signaling in Cystinosis was substantiated by gain- and loss-of-function 
experiments in mPTCs. Knock-down (shRNA) of Csda encoding ZONAB (Fig. 7g-i; Supp. Fig. 9a-
c) or overexpression of exogenous TJP1 encoding ZO-1 (Suppl. Fig. 9d,e), which functionally 
inhibits ZONAB (27,28), significantly decreased the proliferation markers and rescued the 
endocytic uptake in Ctns
-/-
 cells. Conversely, depletion of ZO-1 (shRNA-mediated knock-down of 
Tjp1; Suppl. Fig. 10a-c) or overexpression of Csda (Suppl. Fig. 10d) triggered the activation of 
ZONAB signaling (Suppl. Fig. 10e) with increased cell proliferation and decreased endocytic 




Mitochondrial ROS disrupt tight junctions through G12 /Src activation. 
Finally, we investigated how aberrant mitochondria-producing ROS disrupt tight junctions in 
Cystinosis epithelial cells. Given the accumulation of abnormal mitochondria-producing ROS (Fig. 
6) and higher phosphorylation rate of ZO-1 (Fig. 7) in Ctns
-/-
 PT cells, we hypothesized that high 
levels of mitochondrial ROS may stimulate the G12 protein that triggers the disruption of tight 
junctions through Src-mediated phosphorylation of ZO-1 (29-31). This would in turn activate 
ZONAB signaling and drives the epithelial dysfunction. Consistent with this hypothesis, mPTCs 
from Ctns
-/- 
kidneys (Fig. 8a,b) displayed an increased protein abundance of G12 and activated Src 
tyrosine kinase (monitored by the increased phosphorylation rate of pTyr
416
-Src; Fig. 8a,b). 
Likewise, wild-type mPTCs treated with Rotenone (Fig. 8c) or accumulating aberrant 
mitochondria-producing ROS (Atg7 knockdown; Fig. 8d) also exhibited an abnormal activation of 
G12/Src. This activation paralleled the increased phosphorylation of ZO-1, tight junction 
disruption and epithelial dysfunction described above (Fig. 5; Suppl. Fig. 8). Having verified that 
the high level of mitochondrial ROS drives epithelial dysfunction by activating G12/Src kinase 
pathway, we tested whether the neutralization of mitochondrial ROS/G12/Src signaling loop may 
avert the loss of tight junction integrity and rescue the epithelial dysfunction in Cystinosis cells. We 
incubated Ctns
-/-
 mPTCs with mitochondria-localized-oxygen scavenger Mito-TEMPO (MT, 10M 
for 24h; Suppl. Fig. 11a,b; ref. 32) or with a selective c-Src family kinase inhibitor SU6656 (5M 
for 24h; ref. 33) or transduced the cells with Ad-shRNA against Gna12. The blockage of the 
mitochondrial ROS/G12/Src signaling loop by these pharmacologic or genetic interventions 
reversed the abnormal activation of G12/Src (Fig. 8a,b), preventing the phosphorylation of ZO-1 
(Fig. 8e; Suppl. Fig. 11c) and its lysosomal accumulation - which increased ZO-1 abundance at cell 
boundaries (Suppl. Fig. 11d). In turn, these changes inhibited the nuclear translocation of ZONAB 
(Fig. 8f) and restored the differentiation and endocytic capacity of Cystinosis cells (Fig. 8g,h). Of 
note, the rescue induced by MT treatment was prevented by overexpressing Csda-HA in Ctns
-/-
 
mPTCs (Suppl. Fig. 12a,b), supporting the role of ZONAB. Taken together, these data suggest that 
the excess of mitochondrial ROS, resulting from impaired lysosome mediated autophagic 
degradation of damaged mitochondria, triggers G12/Src-mediated phosphorylation of ZO-1, 
which disrupts tight junction integrity and activates ZONAB signaling, in turn causing epithelial 
dysfunction in Cystinosis cells.  
 
Neutralizing mitochondrial oxidative stress improves epithelial dysfunction in Cystinosis. 
To enhance the translational potential of these findings, we administered MT (1mg/kg body weight) 
to 16-week-old Ctns mice by daily i.p. injections (Fig. 9a). After 30 days of treatment, mPTCs were 
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isolated from the Ctns
-/-
 kidneys to score the epithelial function by measuring the endocytic uptake 
of albumin. Treatment with MT effectively reduced ROS production and oxidative stress (Fig. 
9b,c), lowered levels of the kidney injury marker lipocalin-2 (34) (Fig. 9c), abrogated abnormal cell 
proliferation (Fig. 9d) and restored abundance of endocytic receptor megalin (Fig. 9e), reflected by 
a significant recovery of the ligand uptake (Fig. 9f) in Ctns
-/-
 cells. Thus, modulation of 





The endolysosomal system regulates the transport activity of specialized epithelial cells, sustaining 
their role in homeostasis. Congenital defects in lysosomal transporters, as exemplified by 
Cystinosis, cause PT cell dysfunction and RFS. By combining genetic and pharmacologic 
approaches in vitro and in vivo, we deciphered the link between lysosomal disease and epithelial 
dysfunction in Cystinosis. We demonstrate that lysosomal dysfunction results in defective 
autophagy-mediated clearance of damaged mitochondria, mitochondrial oxidative stress, disruption 
of tight junction integrity and activation of a signaling pathway causing epithelial cell proliferation 
and dedifferentiation, with loss of reabsorptive capacity (Fig. 10). These data reveal the 
fundamental importance of autophagic clearance in maintaining epithelial differentiation and offer 
novel therapeutic perspectives to restore epithelial transport capacity downstream of the primary 
lysosomal defect. 
Cystinosin deficiency induces a major alteration in lysosomal dynamics (9,35,36),paralleled 
by increased numbers of autophagosomes in the proximal tubules of Ctns
-/-
 mice and in the 
pronephric tubules of ctns-deficient zebrafish. The accumulation of the autophagy substrate 
SQSTM1, which is normally degraded within autolysosomes, suggests an abnormal autophagy flux 
in cystinosin-deficient PT cells, in line with recent observations stating an impairment of autophagy 
flux in many lysosome storage diseases (37,38) and evidence in human cells and kidney biopsies 
from Cystinosis patients (16). Evidence supporting the failure to degrade autophagy cargoes in 
primary PT Ctns
-/-
 cells include: abnormally elevated numbers of mature autophagosomes under-
normal growth conditions; failure to clear autophagic vesicles (AVs) formed after starvation-
induced autophagy, mimicking BfnA1 action; inability of BfnA1 to further induce the LC3II protein 
levels; and impaired degradation of the resting AVs by a selective PI3K3/Vps34 inhibitor. In 
contrast, upstream events regulating autophagosome biogenesis, including Atg7-Atg12 conjugation 
and phagophore formation were not affected. Altogether, these data indicate that the functional loss 
of cystinosin, causing lysosomal cystine storage, delays the autophagy flux, causing an 
accumulation of autophagosomes in vitro and in vivo. Of note, the autophagy flux was found to be 
fully functional in fibroblasts derived from Ctns mice (39), in contrast with the predictions based on 
the defective mTORC1 signaling in Cystinosis cells (17). The reason for these discrepancies would 
require further studies to understand the cell-specific effects of cystinosin depletion. 
 The question remained how the lysosomal defect could impair autophagy flux and lead to 
epithelial dysfunction. A blockage of the degradation of autophagic material may occur at any step 
after autophagosome formation, due to factors regulating the trafficking of autophagosomes to 
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lysosomes or the fusion between both compartments. For instance, accumulation of LC3-positive 
organelles unable to fuse with lysosomes has been observed in many LSDs (40). Accordingly, a 
potential cause for the impaired autophagy flux observed in Cystinosis could be a delayed fusion 
between lysosomes and autophagosomes. However, when treating Ctns
-/-
 cells with short 
incubations of BfnA1, which accurately measure the autophagy flux (41), we observed a substantial 
co-localization of LC3-positive vesicles with the lysosome marker LAMP1, suggesting that the 
delivery and autophagosome-lysosome fusion is not compromised in cystinotic cells. Another 
indication is the perinuclear lysosomal clustering in Ctns
-/-
 cells: such centripetal movement of 
lysosomes has been shown to mediate the autophagic degradation of biomacromolecules (20,42).  
 Because the autophagy flux also relies on the degradative capacity of lysosomes (11), an 
impaired lysosomal function may explain the accumulation of autophagosomes in Cystinosis cells. 
We postulated that cystinosin deficiency may affect lysosome function either by controlling the 
delivery of newly synthesized lysosomal cathepsins from Golgi to the lysosome or by inhibiting the 
processing/maturation of cathepsins within endolysosome compartment. Our results support the 
latter hypothesis, evidencing an impairment of lysosome proteolysis (observed both in vitro and in 
vivo) as a result of defective cathepsin activation despite an efficient delivery of newly synthesized 
cathepsins from Golgi to lysosomes. Furthermore, the rescue of lysosomal cystine homeostasis 
through the transient expression of cystinosin in Ctns
-/-
 cells resulted in multi-level reactivation of 
the autophagy-lysosome degradative pathway. Taken together, these findings support a role of 
cystinosin -beyond its function in cystine transport- in maintaining the lysosomal response to the 
arrival of the autophagy cargoes, hence in cellular homeostasis.  
 The conjugation of impaired lysosomal dynamics and altered lysosomal degradative 
capacity is strikingly similar to the cellular changes resulting from the accumulation of monoclonal 
light chains (LCs) within endolysosomes of PT cells, causing a similar epithelial dysfunction (22). 
Furthermore, the uncontrolled increase in lysosomal PtdIns(4,5)P2 that results from the loss-of-
function of the PtdIns (4,5)P2 5-phosphatase OCRL, leads to lysosomal dysfunction and 
autophagosome accumulation in PT cells from patients with Lowe syndrome, another congenital 
disorder causing PT dysfunction and RFS (43). These data suggest that lysosomal accumulation of 
cystine or specific LCs or PtdIns (4,5)P2 may have similar functional consequences on the 
epithelial phenotype, emphasizing the role of endolysosomes as crucial signaling hub to ensure 
cellular homeostasis. Since lysosomal acidification is necessary for the activation of cathepsins, one 
could speculate that the V-ATPase complex might be altered in absence of cystinosin (44). Potential 
factors affecting V-ATPase efficiency in LSD may include: storage of cholesterol in the 
endolysosome membranes (45); luminal oxidation of lysosomal thiols by free cystine (46); and 
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accumulation of cystine sustaining mTORC1activity and negatively regulating lysosome biogenesis 
by suppressing TFE/MiTF signaling (47). Recent studies showing that cystinosin is a member of the 
lysosomal machinery that controls mTORC1 activity in vitro (17) and that overexpression of TFEB 
stimulates lysosomal cargo processing (48) support the concept. Regardless of the mechanism, 
impaired cellular clearance leads to accumulation of autophagy substrates, such as dysfunctional 
mitochondria and ubiquitinated proteins. Although autophagy deficits have been reported in LSDs 
(37,38,49), the impact of lysosome-autophagy defects on epithelial cell function remains unknown. 
Basal autophagy operates to preserve the integrity of subcellular compartments, including damaged 
mitochondria (50,51). Lack of autophagy completion, due to impaired lysosomal degradation 
capacity or through inactivation of essential genes, leads to the  persistence of ubiquitinated proteins 
(including p62/SQSTM1) and dysfunctional, ROS-producing mitochondria (38). Our results 
demonstrate the importance of this cellular quality-control mechanism for the function of epithelial 
cells. Genetic or pharmacologic blockage of basal autophagy resulted in accumulation of 
ubiquitinated proteins and damaged/dysfunctional mitochondria, leading to abnormal cell 
proliferation and apical dedifferentiation reflected by decreased uptake capacities. Similar to the 
changes observed in autophagy-deficient cells, there was a remarkable accumulation of SQSTM1- 
and ubiquitin-forming aggregates in Ctns
-/-
 cells, with dysfunctional mitochondria accumulating 
within enlarged, non-degradative lysosomes and generating enhanced levels of mitochondrial ROS. 
These results indicate the importance of maintaining a healthy mitochondria repertoire to 
substantiate the solute transport activity in PT cells (52). In fact, primary mitochondrial diseases 
cause epithelial transport defects and RFS (4,52).  
The link between abnormal mitochondrial autophagy and oxidative stress is well-
documented (53,54), but how excessive mitochondrial ROS production may cause epithelial cell 
dysfunction? Highly specific junctions modulate the epithelial phenotype along the renal tubule 
segments. The levels of the tight junction adaptor protein ZO-1 and the localization of ZONAB, a 
Y-box transcription factor that interacts with ZO-1, modulate the switch from a proliferative to 
differentiated state in PT cells (28). For instance, absence of the endosomal channel CFTR (55) 
leads to reduced ZO-1 stability, promoting nuclear translocation of ZONAB and cell proliferation 
(56). Similarly, knockdown of Tjp1 encoding ZO-1 in primary PT cells triggers an aberrant 
activation of tight junction-associated (ZONAB) signaling, with subsequent induction of a 
phenotype switch associating abnormal cell proliferation and dedifferentiation, mimicking the 
epithelial dysfunction associated with Cystinosis. An abnormal activity of ZONAB has also been 
evidenced when LCs accumulate within dysfunctional endolysosomes (22). Furthermore, gain-of-
function interventions targeting tight junction-associated ZONAB signaling rescue epithelial 
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differentiation and reabsorptive capacity in Cystinosis PT cells. Taken together, these data suggest 
that the maintenance of tight junction integrity acts an essential regulator of epithelial cell 
differentiation. 
Recent advances have illuminated the understanding of regulatory mechanisms involved in 
tight junction architecture and remodelling (29-31). In particular, changes in the cellular rate of 
G12/Src-mediated phosphorylation of ZO-1 associated with oxidative stress may disrupt tight 
junctions and cause cell damage (29-31).  In line with these observations , our results substantiate 
that the aberrant production of mitochondrial-ROS enhances the G12/Src-mediated 
phosphorylation of ZO-1 and its subsequent mistargeting to enlarged, non-degradative 
endolysosomes. In turn, the loss of tight junction integrity promotes ZONAB signaling and 
transcription of target genes increasing cell proliferation and decreasing cell differentiation (27,28) 
resulting in defective endocytosis in Ctns
-/-
 cells. The relevance of this abnormal cascade is 
supported by the gain- and loss-of-function approaches targeting G12 or ZO-1/ZONAB or by 
pharmacological interventions impeding the activation G12/Src signaling axis in Ctns-/- PT cells 
and also in Ctns
+/+
 PT cells under mitochondria-derived oxidative stress conditions (Rotenone or 
blockade of autophagy). Consistent with this, treatment of Ctns
-/- 
mice and their derived mPTCs 
with mitochondrial-targeted antioxidants, which are clinically tested in various mitochondrial 
diseases (57), not only repaired dysfunctional mitochondria and averted mitochondrial oxidative 
stress, but also rescued the integrity of tight junctions and the differentiation and endocytic uptake 
capacity of the cells. These data extend the previous findings showing that swan-neck deformities 
of PT segments (58) could be delayed in Ctns-knockout mice by administrating mitoquinone, an 
anti-oxidant compound that acts on mitochondria.  
  In conclusion, we identified a novel link between lysosomal storage and dysfunction, 
impaired autophagic clearance and loss of transport capacity in epithelial cells. These findings 
substantiate the role of endolysosome system in preserving the autophagy-mediated quality control 
of mitochondria, which are crucial for the high transport activities performed by specialized 
epithelial cells. They also demonstrate the cross-talk between mitochondria and tight-junction 
associated signal transduction pathways regulating the epithelial phenotype. The effect of an 
antioxidant compound specifically targeting mitochondria on the function of Ctns
-/-
 cells provides a 





Antibodies and reagents. The following antibodies were used in this study: rat anti-LAMP1 (sc-19992, Santa Cruz 
Biotechnology); rabbit anti-LC3(PM036, MBL), rabbit anti-LC3 (NB100-2331, Novus Biologicals), rabbit anti-
p62/SQSM1 (PM045, MBL); rabbit anti-GAPDH (2118, Cell Signaling Technology); mouse anti--actin (A2228, 
Sigma-Aldrich); goat anti-cathepsin-D (CtsD; sc-6486, Santa Cruz Biotechnology); rabbit anti-GM130 (ab52649, 
Abcam); mouse anti-Ubiquitin (sc-8017, Santa Cruz Biotechnology); mouse anti-PCNA (M0879, DAKO); rabbit anti-
Histone-3 (H3; ab4729, Abcam); mouse anti-α-tubulin (T5168, Sigma-Aldrich); rabbit anti-Prohibitin (ab28172, 
Abcam); rabbit anti-ATG16L (D6D5) (#8089, Cell Signaling); rabbit anti-ATG7 (A2856, Sigma-Aldrich); mouse anti-
BECN1(sc-48341, Santa Cruz Biotechnology); rat anti-Hemagglutinin (HA; 11867423001, Roche); rabbit anti-
Calnexin (C4731, Sigma-Aldrich); mouse anti-Phospho-Tyr-99 (PY99; sc-7020, Santa Cruz Biotechnology); rabbit 
anti-ZO-1(sc-10804, Santa Cruz Biotechnology); rabbit anti-ZONAB (A303-070A, Bethyl Laboratories); mouse anti-
Gα12 (sc-515610, Santa Cruz Biotechnology); rabbit anti-Phospho-Src Family (pTyr416; #6943, Cell Signaling), rabbit 
anti-Src (#2109, Cell Signaling);  mouse anti-PtdIns-3P (Z-P003, Echelon Biosciences Inc.); rabbit anti-Heme 
Oxygenase-1 (HO1; ab13243, Abcam); rabbit anti-Lipocalin-2 (ab63929, Abcam); goat anti-GFP (AB0020-500, 
SICGEN). Sheep anti-LRP2 antibody was kindly provided by P. Verroust and R. Kozyraki (INSERM, Paris, France). 
Compounds included Bafilomycin-A1 (ALX-380-030, Enzo Life Sciences), PIK3C3/Vps34 inhibitor SAR-405 (A8883, 
APExBIO), autophagy inhibitor Spautin-1 (S7888, Selleckchem.com), hydrogen peroxide (H1009 Sigma-Aldrich), 
Rotenone (R8875, Sigma-Aldrich), SU6656 (s9692, Sigma-Aldrich) and mito-TEMPO (MT; ALX-430-150-M005, 
Enzo Life Sciences).  
 
Generation and maintenance of ctns zebrafish. ctns-specific left and right TALENs (ctns-TALENs) were constructed 
in according to Golden Gate TALEN assembly protocol and using the Golden Gate TALEN and TAL Effector Kit 2.0 
(Addgene, Kit # 1000000024). CIscript-GoldyTALEN was a gift from Daniel Carlson & Stephen Ekker (Addgene, 
plasmid # 38142). TALENs were designed with the TAL Effector Nucleotide Targeter 2.0 software on the Website of 
Cornell University. The TALENs target the exon 3 of zebrafish ctns gene, with sequence left TALEN-F: 
TCTTTTAATCCTTTGTGTTCACA and right TALEN-R: CATCTGTAACGGTTTATTTCAAT. The spacer between 
two TALEN target sites is ~15 nucleotides and contains an AciI restriction site in the middle, which is used for mutant 
screening. The TALEN expression plasmids were linearized with BamHI and then used for in vitro transcription 
(mMESSAGE mMACHINE T3 kit, Ambion). Approximately 1 nL of TALEN messenger ribonucleic acid (mRNAs, 
400 ng/µL) was injected into one-cell stage zebrafish (Danio rerio) embryos. After 24 h, genomic DNA was extracted 
from injected embryos with normal appearance. Targeted genomic loci were amplified by using primers designed to 
anneal approximately 240 base pair, and mutant allele was detected by AciI digestion of PCR product. The TALEN 
injected embryos were raised to adulthood (F0) and outcrossed with wild-type fish. The embryos were then raised to 
adulthood (F1) for screening of heterozygous carriers. We identified a heterozygous carrier harboring ctns
 +/del8
 mutation 
and (F1) generations were crossed for obtaining homozygous mutant carrying ctns
del8/del8
. Zebrafish were kept at 
day/night cycle of 14/10 h at 28°C (Westerfield M. 2007). Where indicated, the zebrafish embryos were obtained 
through natural spawning in the facility of the University of Zurich and raised in E3 medium containing 0.01% 
methylene blue and prepared for analyses. Where indicated, adult zebrafish were produced in the zebrafish facility of 
Hubrecht Institute (Utrecht, Netherlands). Zebrafish were euthanatized by immersion in system water containing 
300µg/ml tricaine methane sulfonate (MS222). The experiments were approved by the Animal Experimentation 
Committee of the Royal Netherlands Academy of Arts and Sciences.  
 
Rescue experiments in ctns zebrafish. The plasmids containing wild type or mutant (VVF346-349) human CTNS 
cDNA were kindly provided by C. Antignac (INSERM, Paris, France). The T3 promoter sequence was cloned into the 
XhoI restriction site of the EGFP vector by using forward primer: 
TCGAGGATCCATTAACCCTCACTAAAGGGAAC and reverse primer: 
TCGAGTTCCCTTTAGTGAGGGTTAATGGATCC. Either wild type or mutant CTNS messenger RNA was 
synthesized by using the mMESSAGE mMACHINE T3 transcription Kit (Invitrogen). The microinjection of wild type 
or mutant CTNS mRNA was performed in ctns 
del8/del8
 zebrafish embryos at one-cell stage and subsequently collected at 
5 days post fertilization (d.p.f.) for cystine measurements. Where indicated, a working solution of cysteamine at 1mM 
was prepared by diluting the stock solution within E3 medium. After dechorionation, ctns zebrafish larvae at 2 dpf were 
incubated in the E3 medium in presence or in absence of cysteamine until to the sampled day (5 dpf), and the zebrafish 
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media were renewed daily. Twenty zebrafish embryos per group were pooled and homogenized by sonication, and 
prepared for cystine measurements. 
 




 littermates (C57BL/6 
background; 8,9). Mice were maintained under temperature-and humidity-controlled conditions with 12 h light/12 h 
dark cycles with free access to appropriate standard diet in accordance with the institutional guidelines of National 
Institutes of Health Guide for the Care and Use of Laboratory Animals. Mice aged 16 weeks were treated by daily 
intraperitoneal injection of mito-TEMPO (1mg/kg body weight in NaCl 0.9%) or vehicle (NaCl 0.9%) (n=4 for each 
group), and sacrificed after 30 days. Kidney tissues and/or urines were collected for analyses (see below). The protocols 
were approved by the Animal Ethics Committees of the UCL Medical School (Brussels) and the University of Zurich.  
 
Renal function. The mice were placed overnight in metabolic cages with ad libitum access to food and drinking water; 
urine was collected over ice (9,22). The urine parameters were measured using a UniCel DxC 800 pro Synchron 
(Beckman Coulter, Fullerton, CA, USA), whereas Clara cell protein (CC16) concentration was measured in duplicate 
by enzyme-linked immunosorbent assay (ELISA; BIOMATIK EKU03200).  
 





mice as previously described (9,22). One kidney was split transversally and one half was fixed and processed for 
immunostaining while the other half was flash-frozen, homogenized by Dounce homogenizer in 1 mL of RIPA buffer 
that contains protease and phosphatase inhibitors and processed for western blot analysis. The contralateral kidney was 
taken to generate primary cultures of mPTCs as described (22). Freshly micro-dissected PT segments were seeded onto 
collagen-coated chamber slides (C7182, Sigma-Aldrich) and/or collagen-coated 6- or 24-well plates (145380 or 142475, 
Thermo Fisher Scientific), and cultured at 37°C and 5% CO2 in DMEM/F12 (21041-025, Thermo Fisher Scientific) 
with 0.5% dialyzed FBS, 15mM HEPES (H0887, Sigma-Aldrich), 0.55mM sodium pyruvate (P2256, Sigma-Aldrich), 
0.1ml/L non-essential amino acids (M7145, Sigma-Aldrich), hydrocortisone, human EGF, epinephrine, insulin, 
triiodothyronine, TF, and gentamicin/amphotericin (Single Quots® kit, CC-4127, Lonza), pH 7.40, 325mOsm/kg. The 
medium was replaced every 48 h. Confluent monolayers of mPTCs were expanded from the tubular fragments after 6–7 
days, characterized by a high endocytic uptake capacity. These cells were mycoplasma free. All experiments were 
performed on confluent monolayers grown on chamber slides or plates.  
Starvation of primary PT cells and treatments. Serum and amino acid removal was performed by washing mPTCs with 
Hank’s balanced salt solution (HBSS; 55021C, Sigma-Aldrich) and placing them in nutrient-deprived medium. Where 
indicated, macroautophagy was inhibited by addition of either PIK3C3/Vps34 inhibitor SAR-405 (5M in cell culture 
medium for 16h, unless otherwise specified; ref. 59) or Spautin-1(25M in cell culture medium for 16 h; ref. 60). 
Lysosomal proteolysis was inhibited by addition of Bafilomycin A1 (BfnA1; 250nM for 4h, unless otherwise stated). 
Where indicated, oxidative stress was triggered by treating mPTCs with either hydrogen peroxide (0.5mM for 1 h) or 
with Rotenone (250nM for 8 h).Where indicated, mPTCs were treated with either the mitochondria-targeted oxidant 
scavenger mito-TEMPO (10M in culture medium for 12h, Enzo Life Sciences) or with a selective Src-family kinase 
inhibitor SU6656 (5
as described below.   
 
Adenovirus transduction in primary PT cells. For RNA interference studies, adenovirus constructs used include GFP 
U6-scrambled short hairpin (shRNA) (control vector) or an individually encoding mouse Atg7 shRNA or encoding 
mouse Ybx3/Csda shRNA or encoding mouse Gna12 shRNA or encoding mouse Tjp1 shRNA. For expression studies, 
adenovirus constructs used include CMV (null vector) or an individually carrying mouse green fluorescent protein 
(GFP) tagged-Map1lc3b or carrying mouse red fluorescent protein (RFP)/2xFLAG tagged-Lamp1 or carrying green 
fluorescent protein (GFP) tagged-Csda or carrying human hemagglutinin (HA) tagged-TJP1 or carrying mouse 
hemagglutinin (HA) tagged-Ctns. The aforementioned adenovirus constructs were purchased from Vector Biolabs 
(University City Science Center, Philadelphia, USA). Briefly, primary mouse PT cells were plated onto collagen-coated 
chamber slides or 24-well or 6-well tissue culture plates. Adenovirus transduction was performed 24 h after plating 
when the cells reach approximately 70-80% confluence. The cells were subsequently incubated for 16 h at 37°C with 
culture medium containing the virus at the concentration (0.2125×10
9
 PFU/mL). The cells were afterwards provided 




Quantitative real-time PCR. Total RNA was extracted from mouse and zebrafish kidney tissues using Aurum 
TM
 Total 
RNA Fatty and Fibrous Tissue Kit (Bio-Rad, Hercules, CA). DNAse I treatment was performed to eliminate genomic 
DNA contamination. Total RNA was extracted from primary cell cultures with RNAqueous
R
 kit (Applied Biosystems, 
Life Technologies). Oneg of RNA was used to perform the reverse transcriptase reaction with iScript TM cDNA 
Synthesis Kit (Bio-Rad). Changes in target genes mRNA levels were determined by relative RT-qPCR with a CFX96
TM
 
Real-Time PCR Detection System (Bio-Rad) using iQ 
TM
 SYBR Green Supermix (Bio-Rad). RT-qPCR analyses were 
performed in duplicate with 100nM of both sense and anti-sense primers in a final volume of 20µl using iQ
TM
 SYBR 
Green Supermix (Bio-Rad). Specific primers were designed using Primer3 (Suppl. Table 1,2). PCR conditions were 
95°C for 3 min followed by 40 cycles of 15 sec at 95°C, 30 sec at 60°C. The PCR products were sequenced with the 
BigDye terminator kit (Perkin Elmer Applied Biosystems) on an ABI3100 capillary sequencer (Perkin Elmer Applied 
Biosystems). The efficiency of each set of primers was determined by dilution curves (Suppl. Table 1,2). The program 
geNorm version 3.4 was applied to characterize the expression stability of the candidate reference genes in kidney and 
six reference genes were selected to calculate the normalization factor (61). The relative changes in targeted genes over 
Gapdh mRNAs were calculated using the 2
-
Ct formula.  
 
Endocytosis assay. The endocytic uptake was monitored in mPTCs cells following incubation for 60 min at 4°C with 
50 g/mL Bovine Serum Albumin (BSA)-Alexa-Fluor-647 (A34785, Thermo Fisher Scientific) or with 50 g/mL 
BSA–Alexa-Fluor-488 (A13100, Thermo Fisher Scientific) in complete HEPES-buffered DMEM. The cells were given 
an acid wash and warmed to 37°C in growth cell medium for 15 min before being fixed and processed for 
immunofluorescence analyses (22).  
 
Lysosomal activity. In mPTCs: The detection of lysosomal activity was performed using Bodipy-FL-PepstatinA 
(P12271, Thermo Fischer Scientific) or Magic Red-(RR)2 substrate ( MR-CtsB; #938, Immunochemistry Technologies) 
according to the manufacturer's specifications. Briefly, the cells were pulsed with 1μM Bodipy-FL-Pepstatin A or with 
1M Magic Red-(RR)2 in Live Cell Imaging (A14291DJ, Thermo Fischer Scientific) medium for 1h at 37°C followed 
by fixation and immunostaining with anti-LAMP1 or anti-HA antibody, and subsequently analyzed by confocal 
microscopy (22). In zebrafish: Bovinelactoglobulin (Sigma-Aldrich) was labeled with Cy5 using TM2 Ab labelling 
kit (Amersham) in accordance to the manufacturer’s instructions. After anesthesia (0.2mg/mL tricaine (3-amino benzoic 
acid ethyl ester, Sigma-Aldrich), cdh17::GFP-expressing ctns zebrafish embryos were injected at 5dpf with Cy5-
lactoglobulin (5μg/μl) via the common cardinal vein. Tracer injection into larvae blood was validated by monitoring the 
fluorescent vessels after injection. Larvae were incubated in fresh E3 medium for 20 or 120 min and subsequently fixed 
overnight in 2%PFA/PBS containing 0.1% Tween-20, and analyzed by fluorescent microscope (Zeiss, Germany).The 
fluorescence intensities and the numbers of β-lactoglobulin+ structures were quantified by using cell image analysis 
software Imaris (Bitplane). 
 
Extracellular flux analysis and metabolic measurement. Oxygen consumption rate (OCR) was measured in XFp 
Extracellular Flux Analyzers (Agilent Seahorse Biosciences) in mPTCs incubated with XF-Base Medium (non-buffered 
RPMI 1640 containing either 2mM L-glutamine, 1mM sodium pyruvate and 10mM glucose, pH 7.4). Three 
measurements were measured under basal conditions and upon addition of 2μM Oligomycin, 0.5μM FCCP, and 1μM 
rotenone/antimycin A. All the reagents were provided by XFp Cell Mito Stress Test Kit (Agilent Seahorse biosciences). 
OCR measurements were normalized over the numbers of the cells (TC10
TM 
automated cell counter, Bio-Rad). 
 
Mitochondrial membrane potential measurement. The mitochondrial membrane potential () was measured 
according to the manufacturer's specifications. Briefly, the cells were pulsed with 50nM Tetramethylrhodamine Methyl 
Ester Perchlorate (TMRM, T668 Thermo Fisher Scientific) for 30 min in live cell imaging at 37°C. After washing, the 
cells were subsequently analysed by confocal microscopy (62). The fluorescence intensity was quantified by using the 
open-source cell image analysis software CellProfiler
TM
 (63) as described below. 
 
ROS detection. The cells were pulsed with 5µM CellROX® Green Reagent (C10444, Thermo Fisher Scientific) or with 
2.5M MitoSOX Red Mitochondrial Superoxide Indicator (M36008, Thermo Fisher Scientific) for 10 min in live cell 
imaging at 37°C. After washing, the cells were subsequently analysed by confocal microscopy (62). The fluorescence 
intensity was quantified by using the open-source cell image analysis software CellProfiler
TM




Immunofluorescence and confocal microscopy. Mouse kidney tissues. Fresh mouse kidneys were fixed by perfusion 
with 50-60 ml of 4% paraformaldehyde in PBS (158127, Sigma-Aldrich). The organs were dehydrated and embedded 
in paraffin at 58C°. Paraffin blocks were sectioned into consecutive 5m-thick slices with a Leica RM2255 rotary 
microtome (Thermo-Fisher Scientific) on Superfrost Plus glass slides (Thermo-Fisher Scientific). Before staining, slides 
were deparaffinized in changes of CitriSolv (22-143-975, Thermo-Fisher Scientific) and 70% isopropanol. Antigen 
retrieval was accomplished by incubating in sodium citrate buffer (1.8% 0.1M citric acid, 8.2% 0.1M sodium citrate, in 
distillated water, pH 6.0) in a rice cooker for 30 minutes. The slides were quenched with 50 mM NH4Cl, blocked with 
0.5% BSA in PBS Ca/Mg (D1283, Sigma-Aldrich) for 30 min and stained with primary antibodies specific for PCNA, 
LRP2, LC3 and p62/SQSTM1 diluted in blocking buffer overnight at 4°C. After two washes in 0.1% Tween 20 (v/v in 
PBS), the slides were incubated  with corresponding fluorophore-conjugated Alexa secondary antibodies (Invitrogen) 
diluted in blocking buffer at room temperature for 1h and counterstained with 1g Biotinylated Lotus Tetragonolobus 
Lectin (LTL) ( B-1325 Vector Laboratories; marker of the PT apical membrane) and 1µM DAPI (#D1306, Thermo 
Fischer Scientific). The slides were mounted in Prolong Gold Anti-fade reagent (P36930, Thermo Fisher Scientific ), 
acquired on Leica SP8 confocal laser scanning microscope (Center for Microscopy and Image Analysis, University of 
Zurich) equipped with a Leica APO 63x NA 1.4 oil immersion objective at a definition of 1,024 x 1,024 pixels (average 
of eight or sixteen scans), adjusting the pinhole diameter to 1 Airy unit for each emission channel to have all of the 
intensity values between 1 and 254 (linear range). The micrographs were processed with Adobe Photoshop (version 
CS5, Adobe System Inc., San Jose, USA) software. Quantitative image analysis was performed by selecting randomly 
5 visual fields per each slide that included at least 3-5 PTs (LTL-positive), using the same setting parameters (i.e. 
pinhole, laser power, and offset gain and detector amplification below pixel saturation). The numbers of LC3 or 





Primary cultured cells. The mPTCs were fixed for 10 min with 4% paraformaldehyde in PBS, quenched with 50 mM 
NH4Cl and permeabilized for 20 min in blocking buffer solution containing 0.1% Triton X-100 and 0.5% BSA 
dissolved in PBS. Subsequently, mPTCs were incubated overnight with the appropriate primary antibodies at 4°C. After 
repeated washing with PBS, the slides were incubated for 45 min with the suitable fluorophore-conjugated Alexa 
secondary antibodies (Invitrogen), counterstained with 1µM DAPI for 5 min,  mounted with the Prolong Gold Anti-fade 
reagent and analyzed by a Leica SP8 confocal laser scanning microscope (Center for Microscopy and Image Analysis, 
University of Zurich) using the settings described above. Quantitative image analysis was performed by selecting 
randomly 5 visual fields pooled from biological triplicates, with each field including at least 20-25 cells, using the same 
setting parameters (i.e. pinhole, laser power, and offset gain and detector amplification below pixel saturation). Three-
dimensional (3-D) reconstructions of LAMP1-positive vesicles were generated in Imaris software using full confocal z-
stacks (around 20) of each cell. The quantitative cell image analyses were performed using the open-source cell image 
analysis software CellProfiler
TM 
(63). In particular, the specific module “Measure-Object-Intensity-Distribution” was 
used to score the number and the vesicle size of LAMP1or CtsD positive structures and the fractions of LAMP1-
positive structures contained into perinuclear region (area within 10m of the nucleus) and peripheral region (area ≥ 
15m from the nucleus), respectively. The pipeline “Speckle counting” was used to identify smaller objects (LC3 or 
p62/SQSTM1 or Prohibitin or BSA or CtsD or MR-CtsB or ATG16L-positive structures) surrounding larger objects 
and to perform per-object aggregate measurements. The pipeline “Cell/particle counting, and scoring the percentage of 
stained objects” was used to score either the numbers of LAMP1+ vesicles containing LC3+ autophagosomes or 
PepstatinA or CtsD 
+ 
vesicles or tight junction-ZO-1
+
 structures, or Prohibitin
+
 mitochondria, or the numbers of CtsD
+
 
vesicles containing MR-CtsB peptides or Golgi protein GM130. The “Cytoplasm-Nucleus Translocation Assay” was 
used to score the numbers of ZONAB or BrdU or PCNA-positive nuclei. 
 
Electron microscopy and tomography. Zebrafish kidney sections and cultured mPTCs were fixed in 4% 
paraformaldehyde/0.1% glutaraldehyde in 100nM sodium cacodylate, at pH=7.43, dehydrated and embedded in LR-
White resin (LADD Research Industries). The grids were viewed on a Philips CM100 transmission electron microscope 
at 80kV. Autophagic vacuoles were identified and categorized as autophagosomes or autophagolysosomes according to 
standard criteria (23). The term autophagic vacuole was used when differentiation between autophagosome and 
autophagolysosomes was not possible. Primary and secondary lysosomes (identified as single-membrane vesicle of 
higher density and smaller average diameter) were excluded from the quantification. The number of autophagic 
vacuoles was determined by using i-TEM software (Olympus, Germany). For electron tomography, 200-250nm thick 
sections were collected on formvar-coated copper slot grids using a Leica EM UC7 ultramicrotome (Leica Microsystem 
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GmbH Vienna, Austria). Colloidal gold particles (10nm) were applied as fiducials on both surfaces of the grids and  the 
samples were imaged on a 200 kV Tecnai G2 20 electron microscope (FEI, Eindhoven) at a magnification of 11500x, 
resulting in pixel sizes of 1.95nm. Single tilted image series (±60° according to a Saxton scheme with the initial tilt step 
of 2°) were acquired using Xplorer3D (FEI, Eindhoven) with an Eagle 2,048 × 2,048 CCD camera (FEI, Eindhoven). 
Tilted series alignment, tomographic reconstructions, image segmentation and visualization were done with the IMOD 
software package.  
 
Correlative light-electron microscopy. The cells were grown on finder grids and prepared for confocal microscopy 
analyses. Z-stacks of cells of interest were taken with the PerkinElmer UltraView ERS confocal microscope. The 
coordinates of the cells on the finder grid were determined by bright-field microscopy. Cells were fixed in 1% 
glutaraldehyde in 0.1M cacodylate buffer (Sigma) and post-fixed with 1.5% potassium ferricyanide, 1% OsO4 in 0.1M 
cacodylate buffer. Cells were stained with 0.5% uranyl acetate overnight, dehydrated in ethanol and embedded in epon. 
After baking for 48 h at 60 °C, the resin was released from the glass coverslip by temperature shock in liquid nitrogen. 
Serial sections (70–90 nm) were collected on carbon-coated formvar slot grids and imaged with a Zeiss LEO 512 
electron microscope. Images were acquired by a 2k × 2k bottom-mounted slow-scan Proscan camera controlled by 
EsivisionPro 3.2 software. 
 
Soluble and insoluble fractionation. Cells were lysed in buffer containing 50mM Tris-HCl, pH=7.5, 150mM  NaCl, 
0.1% SDS, 1% Triton X-100, 1% sodiumdeoxycholate supplemented with protease and phosphatase inhibitors and 
centrifuged at 16,000 rpm at 4°C for 20 min to collect the soluble fraction (supernatant). The pellet was re-suspended in 
a buffer containing 4% SDS and 20mM HEPES, pH=7.5, protease and phosphatase inhibitors and further centrifuged at 
18,000 rpm at room temperature for 10 min to collect the insoluble fraction (supernatant). The samples were boiled at 
95°C for 5 min and analyzed by western blotting. 
 
Immunoprecipitation. The cells were lysed in a buffer containing 25mM Tris/HCl adjusted to pH= 7.4, 150mM NaCl, 
1% NP-40 and 1mM EDTA, 5% glycerol, protease and phosphatase inhibitors for 10 min at 4°C. Lysate were 
centrifuged at 12,000 rpm for 10 min, and the supernatants were incubated with 1.5g of primary anti-ZO-1 antibody 
for 16h at 4°C. After addition of 50μL of protein A sepharose beads (P9424, Sigma), lysates were incubated at 4°C for 
12 h with gentle shaking. Agarose beads were washed for three times and then collected through centrifugation at 4,000 
rpm for 1 min. Beads were reduced by the addition of 35μL of Laemmli sample buffer, heated at 95°C for 5min and 
resolved on 10% SDS–PAGE gel, and analyzed by western blotting. 
 
Western blotting. Immunoblotting was performed as described previously (22). Proteins were extracted from mouse or 
zebrafish kidney tissues or primary cultured cells, lysed in lysis buffer containing protease (1836153001, Roche) and 
phosphatase inhibitors (04906845001, PhosSTOP Sigma), followed by sonication and centrifugation at 12,000rpm for 
10 min at 4°C. The samples were thawed on ice, normalized for protein (20g/lane), dissolved in Laemmli sample 
buffer and separated by SDS–PAGE in reducing conditions. After blotting onto PVDF and blocking with 5% non-fat 
milk (1706404, Bio-Rad Laboratories) diluted in PBS, the membranes were incubated overnight at 4°C with primary 
antibody, washed, incubated with peroxidase-labeled secondary antibody, and visualized with enhanced 
chemiluminescence (WBKLS0050, Millipore, Life technologies). For re-probing, the membranes were rinsed, 
incubated for 30 min at 55°C in a stripping buffer (62.5mmol/L Tris-HCl, 2% SDS, 100mM  mercaptoethanol, adjusted 
to pH =7.4), before incubation with primary antibodies. Quantitative analysis was performed by scanning the blots and 
measuring the relative density of each band normalized toactin, GAPDH or α- tubulin by using ImageJ software. 
 
Proximity ligation assay. The PLA assay was performed using the Duolink in situ reagents (Olink Biosciences) 
according to the manufacturer's specifications. Briefly, cells were fixed with 4% paraformaldehyde in PBS for 15 min at 
room temperature. After blocking with 0.1% Triton X-100 and 0.5% BSA dissolved in PBS, the cells were incubated 
overnight at 4°C with primary antibodies (1:100 diluted in blocking buffer). Following incubation with Duolink PLA 
anti-rabbit Plus and anti-mouse Minus probes (1:5 dilution, Olink Bioscience) at 37°C for 1 h, ligation, rolling circle 
amplification, and detection were performed using the Duolink In Situ Detection Reagents Red (Olink Bioscience). 
Nuclei were counterstained with DAPI. PLA signals were documented by a Leica SP8 confocal microscope and 
quantified by using cell image analysis software CellProfiler
TM




PtdIns-3P detection. The detection of PtdIns-3-P was performed as described (64). Briefly, the cells were fixed with 
2% formaldehyde in PBS 15 min at RT. After washing in PBS containing 50mM NH4Cl, the cells were permeabilized 
for 5 min by the addition of 20μM digitonin in buffer-A (20mM Pipes pH 6.8, 137mM NaCl, 2.7mM KCl). Digitonin 
was removed by three rinses in buffer and cells were blocked for 45 min with buffer supplemented with 5% (v/v) FBS 
and 50mM NH4Cl. Monoclonal mouse anti-PtdIns-3-P antibody were diluted in buffer with 5% FBS for 1 h (1:300). 
After washing with buffer for three times, anti-mouse IgG secondary antibodies were applied in buffer with 5% FBS 
(1:400) for 30 min. Cells were underwent to post-fixation for 5 min in 2% paraformaldehyde, washed with PBS 
containing 50mM NH4Cl, and then mounted with the Prolong Gold Anti-fade reagent.  PtdIns-3-P levels were analyzed 




Proliferation assay. To measure cell proliferation, the cells were seeded in 24-well plates at a density of 2.0×10
4
 cells 
per well. The cells were cultured for three days and cell medium was renewed daily. Every 24 h afterwards, cells were 
trypsinized and quantified using the Countess automated cell counter TC10
TM 
automated cell counter (BIO-RAD). The 
time course experiments were repeated three times using cells derived from three individual mice per each group. 
Where indicated, cells were incubated with Bromodeoxyuridine (BrdU, 1.5μg mL−1; Sigma-Aldrich) according to the 
manufacturer’s protocol. BrdU-labelled cells were detected by immunostaining using rat anti-BrdU antibody (Oxford 
Biotechnology; 1:500), followed by the specific secondary biotinylated goat anti-rat antibody (1:300; Jackson 
Immunoresearch) and mounted with the Prolong Gold Anti-fade reagent. The slides were analyzed by using a Leica 
SP8 confocal laser scanning microscope and quantified by using CellProfilerTM .  
 
Cystine measurement. Kidney tissues from mice kidney tissue or from zebrafish embryos, and/or primary cultured cells 
were homogenized and lysed with NEM solution containing 5.2mmol/L N-ethylmaleide in 10mmol/L potassium 
phosphate buffer adjusted to pH=7.4. The lysates were collected and precipitated with sulfosalicylic acid (12% w/v), 
and centrifuged at 10.000rpm for 10 min at 10°C. The resulting supernatant was dissolved in citrate loading buffer 
(Biochrom Ltd, Cambridge, UK) and 50 µL of this solution was analyzed by Biochrom 30 Plus Amino Acid Analyzer 
(Biochrom Ltd). The protein pellet was dissolved in 0.1mol/L NaOH solution and the protein concentration was 
determined by Biuret method. The concentration of amino acids was measured by using a lithium high performance 
physiological column (Biochrom) followed by post-column derivatization with ninhydrin. The amino acids were 
identified according to the retention time and the ratio of the area between the two wavelengths (570nm and 440nm) 
and quantified by using EZChrom Elite software (Agilent Technologies Inc., Pleasanton, California, USA). Cystine 
concentration was normalized to the protein concentration and reported in nmol/mg protein.  
 
Data analysis and Statistics. The quantitative data were expressed as means ± standard error of the mean (s.e.m.). 
Differences between experimental groups were evaluated using analysis of variance followed by Bonferroni or Dunnet 
post hoc test, when appropriate. When only two groups were compared, unpaired or paired two tailed Student’s t-tests 
were used as appropriate. No statistical methods were used to predetermine the sample size. We estimated the sample 
size considering the variation and mean of the samples. Assumptions for statistical analyses were met (that is, normal 
distribution and equal variance). The sample size (n of biological replicates derived from distinct mice or zebrafish) of 
each experimental group is described in figure legends. The results are representative of at least three independent 
experiments, unless specified in the figure legends. None of the samples/animals was excluded from the experiment, 
and the animals were not randomized. The investigators were not blinded to allocation during the experiments and 
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Figure 1. Abnormal lysosome dynamics and autophagy in CTNS-deficient PT cells. (a) Left: confocal microscopy and three-dimensional (3D) reconstruction of Ctns mPTCs labelled with anti-LAMP1 (red) antibody. Right: 
Quantification of changes in vesicle size (top, each point representing the average diameter of LAMP1+ vesicles in a cell) and lysosome positioning (bottom, percent of perinuclear or peripheral distribution) (n=30 mPTCs pooled 
from 3 Ctns kidneys per group; two tailed unpaired t test, #P<0.0001 relative to Ctns+/+ mPTCs). (b-f) Ctns mPTCs were cultured in normal growth (Fed; 8h) or nutrient-deprived cell medium (Starved; 8h). (b) Representative 
confocal micrographs (left) and quantification (right) of numbers of LC3 structures (green) in Ctns mPTCs (n=100 cells pooled from three Ctns kidneys per group; each point representing the number of LC3+ vesicles in a cell; one-
way analysis of variance (ANOVA) followed by Bonferroni’s post hoc test, ***P<0.001 relative to Ctns+/+ mPTCs under fed conditions; ns, not significant.). (c) Western blotting and densitometric analyses of LC3 protein levels. -
actin was used as a loading control. Two tailed unpaired Student’s t test, *P<0.05 relative to Ctns+/+ mPTCs under fed conditions. (n=3 independent experiments). (d) Representative electron micrographs (left) and quantification 
(right) of numbers of autophagic vacuoles per cell (n=10 micrographs per each condition; one-way ANOVA followed by Bonferroni’s post hoc test, **P<0.01 and #P<0.0001 relative to Ctns+/+ mPTCs under fed conditions; ns, not 
significant). Insets: autophagic vacuoles at higher magnification. (e) Representative confocal micrographs and quantification of SQSTM1 structures (red) in Ctns mPTCs (n=100 cells pooled from three Ctns kidneys per group; two 
tailed unpaired Student’s t test, #P<0.0001 relative to Ctns+/+ mPTCs). (f) Representative western blotting of SQSTM1 in Ctns mPTCs. GAPDH was used as a loading control. (n=3 independent experiments). Plotted data represent 





Figure 2. Cystinosin deficiency alters autophagy in proximal tubules of mouse and zebrafish kidneys. (a) Representative confocal micrographs and quantification of the numbers of LC3 (left panel; red) or SQSTM1structures 
(right panel; red) in LTL (green)-positive proximal tubules in Ctns mouse kidneys (n=30 proximal tubules pooled from three kidneys per group; each point representing the number of LC3+ or SQSTM1+ vesicles in a proximal tubule; 
two tailed unpaired Student’s t test, ***P<0.001 relative to Ctns+/+ kidneys). Nuclei counterstained with DAPI (blue). (b) Western blotting and densitometric analyses of LC3 protein levels in whole kidney lysates from Ctns mice 
(two tailed unpaired Student’s t test, *P=0.029 relative to Ctns+/+ kidneys, n=3 mice per group). (c) Representative images of ctns+/+ and ctnsdel8/del8 zebrafish embryos at 5 days post fertilization (dpf) and (d) quantification of cystine 
levels by HPLC in pronephric tubules from corresponding ctns+/+ and ctns del8/del8 zebrafish embryos (two tailed unpaired Student’s t test,***P<0.001 relative to ctns+/+embryos , n=8 ctns+/+ zebrafish and n=7 ctns del8/del8 zebrafish). (e) 
Western blotting and densitometric analyses of LC3 protein levels in pronephric tubules from 3-month-old ctns+/+ and ctns del8/del8 zebrafish (n=4 per group; two tailed unpaired Student’s t test, *P=0.03 relative to ctns+/+ kidneys). (f) 
Representative electron micrographs and quantifications of the numbers and size of autophagic vacuoles in pronephric tubules of ctns+/+ and ctnsdel8/del8 zebrafish embryos at 5dpf. Dotted white squares contain images at higher 
magnification. Yellow arrowhead indicates autophagic vacuoles. Number of autophagic vesicles: n= 43 (ctns+/+) and n=42 (ctnsdel8/del8) randomly selected micrographs were pooled from eleven ctns+/+ and twelve ctnsdel8/del8 zebrafish. 
Vesicle size: n= 32 (ctns+/+) and n=33 (ctnsdel8/del8) randomly selected micrographs were pooled from eleven ctns+/+ and twelve ctnsdel8/del8 zebrafish.  Two tailed unpaired Student’s t test, ***P<0.001 and #P<0.0001 relative to ctns+/+ 





Figure 3. Cystinosin deficiency delays the clearance of autophagosomes by impairing lysosome function. (a) Western blotting and densitometric analyses for LC3 and SQSTM1 protein levels in Ctns mPTCs cultured in fed or 
starved medium in presence or in absence of 250 nM BfnA1for 4h (n=3 independent experiments). Two tailed unpaired Student’s t test, **P<0.01 (SQSTM1) and *P<0.05 (LC3) relative to fed Ctns+/+ mPTCs *P=0.05 (SQSTM1) 
and **P=0.009 (LC3) relative to starved Ctns+/+ mPTCs. (b) Correlative light-electron microscopy (CLEM) in Ctns mPTCs transduced with both RFP-tagged Lamp1 (LAMP1/RFP) and GFP-tagged Map1lc3b (Map1lc3b/GFP) 
bearing adenoviral particles for 2 days. The colocalization of GFP-LC3 and RFP-LAMP1 was monitored by confocal IF. Selected cells were further processed and serial sections analysed by electron microscopy. Dotted black 
squares contain images at higher magnification. Scale bars are 2m (top panel) and 500 nm (bottom panel). (c) Western blotting and densitometric analyses of CtsD protein levels in Ctns mPTCs; two tailed unpaired Student’s t test, 
**P<0.01 relative to Ctns+/+ mPTCs (n=3 independent experiments). (d) Ctns mPTCs were loaded with Bodipy-FL-PepA (1M, for 1h at 37°C, green), immunostained with anti- LAMP1antibody (red) and analysed by confocal 
microscopy. Quantification of numbers of PepA/LAMP1 co-localizing structures (in percentage of total lysosomes; n=5 randomly selected fields per condition, with each containing ~20-25 cells; two tailed unpaired Student’s t test, 
#
P<0.0001 relative to Ctns+/+ mPTCs). (e) 5dpf-ctns zebrafish embryos expressing cdh17::GFP (green, pronephric tubule marker) were injected with Cy5-tagged--lactoglobulin. At 120 min after the injection of the tracer, zebrafish 
embryos were imaged using light sheet fluorescent microscopy. A similar rate of internalization of Cy5-tagged--lactoglobulin was observed at 20min in both ctns+/+ and ctnsdel8/del8 zebrafish embryos, validating the uptake of the 
tracer by pronephric tubules. Representative micrographs (left) and quantification (right) of numbers of -lactoglobulin+ structures (red) in ctns zebrafish pronephric tubule (n=6 zebrafish per group; two tailed unpaired Student’s t 
test, **P=0.01 relative to ctns+/+ zebrafish). GAPDH was used as loading control in a and c. Plotted data represent mean±s.e.m. Nuclei are counterstained with DAPI (blue). Yellow indicates colocalization. Scale bars are 10m in d 







Figure 4. Rescue of lysosome-autophagy pathway by re-expressing CTNS in Ctns-/- cells. (a-f) Ctns-/- mPTCs were transduced with either Null (Ad-Null) or hemagglutinin-tagged Ctns (Ad-Ctns-HA) bearing adenoviral particles 
for 2 days. (a) Cells were immunostained with anti-HA (green) and anti-CtsD (red) antibodies and analysed by confocal microscopy. Insets: high magnification of Ctns-HA+ vesicles containing CtsD. (b) Intracellular cystine levels 
were measured by HPLC. Two tailed unpaired t test, **P<0.01 relative to Ctns+/+ mPTCs; *P<0.05 relative to Ctns-/- mPTCs transduced with Ad-Null. (c) Quantification of changes in the number of CtsD+ and (d) in the average 
vesicle size in cells from a (n=30 randomly selected cells pooled from three Ctns kidneys per condition; each point representing the number or the average diameter of CtsD+ vesicles in a cell; one-way ANOVA followed by 
Bonferroni’s post hoc test, #P<0.0001 relative to Ctns+/+ mPTCs or to HA- Ctns-/- mPTCs. (e) Ctns mPTCs were loaded with MR-CtsB peptide (1M, for 1h at 37°C) and immunostained with anti-HA antibody. Quantification of the 
number of MR-CtsB structures (n=33 randomly selected cells pooled from three Ctns kidneys per condition, each point representing the number of MR-CtsB+ dots in a cell; two tailed unpaired Student’s t test, #P<0.0001 relative to 
Ctns+/+ mPTCs or to HA- Ctns-/- mPTCs). (f) Ctns mPTCs were cultured in fed or starved medium in presence or in absence of 250 nM BfnA1 for 4h. The cells were lysed and subjected to western blotting analysis for the protein 
levels of HA, CtsD, SQSTM1and LC3. -tubulin was used as a loading control (n=3 independent experiments). Plotted data represent mean±s.e.m. The nuclei are counterstained with DAPI (blue). Yellow indicates colocalization. 






Figure 5. Failure of autophagy causes proliferation and dedifferentiation of PT cells. (a-j) mPTCs were transduced with either scrambled or Atg7 adenoviral shRNAs for 5 days. (a) Western blotting and densitometric analyses 
of ATG7, SQSTM1and LC3 levels. -actin was used as a loading control (n=4 independent experiments). (b) Representative western blotting of the soluble and insoluble fractions derived from mPTCs and immunoblotted for 
ubiquitin and GAPDH (n=3 independent experiments). (c) Cells were immunostained for SQSTM1 and analysed by confocal microscopy. The adjacent panel shows the quantification of the number of SQSTM1 structures in mPTCs. 
(d) mPTCs were immunostained with an anti-prohibitin antibody and analysed by confocal microscopy. Quantifications of the number of prohibitin structures. (e) The cells were loaded with tetramethylrhodamine methyl ester and 
analysed by live confocal microscopy. Quantification of TMRM fluorescence intensity obtained from 5 randomly selected fields per condition. (f) mPTCs were loaded with CellROX and Mito SOX analysed by live confocal 
microscopy. Quantifications of CellROX or MitoSOX fluorescence intensity obtained from three randomly selected fields per condition. (g) mPTCs were immunostained with an anti-ZONAB (green) antibody and analysed by 
confocal microscopy. The adjacent panel show the quantification of ZONAB positive nuclei (in percentage of the total nuclei) from 5 randomly selected fields per condition (h) The mRNA levels of Atg7, Clcn5, Rab5, Lrp2, Ccdn1 
and Pcna were analysed by real-time PCR (n=4 independent experiments). (i) mPTCs were loaded with bromodeoxyuridine, immunostained with anti- BrdU antibody and analysed by confocal microscopy. Quantification of numbers 
of BrdU positive cells was obtained from 5 randomly selected fields per condition. (j) The cells were loaded with Al647-BSA and imaged by confocal microscopy. Quantifications of the number of Al647-BSA. Plotted data represent 





Figure 6. Accumulation of dysfunctional ROS-producing mitochondria in Ctns-/- cells. (a) Representative western blotting of the soluble and insoluble fractions derived from Ctns mPTCs were immunoblotted for ubiquitin and 
GAPDH. (n=3 independent experiments). (b) Ctns mPTCs were immunostained with an anti-prohibitin antibody (green) and analysed by confocal microscopy. Quantifications of the number of prohibitin structures (n=240-280 cells 
randomly selected cells pooled from three mouse kidneys per condition; each point representing the number of prohibitin+ structures in a cell). (c) Representative electron micrographs of mitochondria in Ctns mPTCs. Insets: 
mitochondria at higher magnification. (d)  Ctns mPTCs were immunostained against prohibitin (green) and LAMP1 (red), and the numbers of LAMP1/prohibitin+ co-localizing structures were quantified by confocal microscopy  
(percentage of total lysosomes; n=5 randomly selected fields per condition, each containing ~20-25 cells). (e) Ctns mPTCs were loaded with tetramethylrhodamine methyl ester (TMRM; mitochondrial membrane potential 
fluorescent probe, 50nM for 30 min at 37°C) and analysed by live confocal microscopy. Quantifications of TMRM fluorescence intensity obtained from 5 randomly selected fields per condition, with each containing ~20-25 cell. (f) 
Oxygen consumption rate (OCR) and individual parameters for basal respiration, ATP production, proton leak and maximal respiration. Oxygen consumption rates (OCRs) was measured under basal level and after the sequential 
addition of oligomycin (Oligo, 1M), FCCP (0.5M) and Rotenone (ROT; 1.0M) + antimycin A (ANT; 1.0M), n=3 independent experiments. (g) Ctns mPTCs were loaded with CellROX (cellular ROS probe; 5 M for 10 min at 
37°C) and MitoSOX (mitochondrial ROS probe; 2.5 M for 10 min at 37°C) and analysed by live confocal microscopy. Quantification of CellROX or MitoSOX fluorescence intensity was obtained from 5 randomly selected fields 
per condition, with each containing ~20-25 cells.  Plotted data are mean±s.e.m. Two tailed paired Student’s t test **P<0.01, ***P<0.001 and #p<0.0001relative to Ctns+/+ mPTCs. Nuclei are counterstained with DAPI (blue). Scale bars 








Figure 7. Augmented phosphorylation rate of ZO-1 promotes epithelial dysfunction in Ctns-/- cells. (a) Tight junction ZO-1 protein was immunoprecipitated (IP) from Ctns+/+ and Ctns-/- mPTCs and its phosphorylation rate was 
examined by immunoblotting (n=2 independent experiments). (b) Representative confocal micrographs and quantifications of endogenous phosphorylation of ZO-1 by proximity ligation assay (PLA) using primary antibodies against 
ZO-1 and phopsho-Tyr (PY99). The quantifications were obtained from 5 randomly selected fields per condition, with each containing ~20-25 cells. Two tailed unpaired Student’s t test, #P<0.0001 relative to Ctns+/+ mPTCs. (c) 
Cells were immunostained for LAMP1 and ZO-1, and analysed by confocal microscopy. The adjacent panel shows the quantifications of the ZO-1/LAMP1 co-localizing structures (in percentage of the total lysosomes) assessed by 
confocal microscopy. The quantifications were obtained from 5 randomly selected fields per condition, with each containing ~20-25 cells.  Two tailed unpaired Student’s t test, #P<0.0001 relative to Ctns+/+ mPTCs (d) Ctns mPTCs 
were immunostained with an anti-ZONAB antibody (green) and analysed by confocal microscopy. Quantification of ZONAB+ nuclei (in percentage of the total nuclei) obtained from 4 randomly selected fields per condition, with 
each containing ~20-25 cells. Two tailed unpaired Student’s t test, #P<0.0001 relative to Ctns+/+ mPTCs. (e) The mRNA levels of Lrp2, Ccdn1 and Pcna in Ctns microdissected proximal tubules were analysed by real-time PCR (n=3 
mice per group). Two tailed unpaired Student’s t test, *P<0.05, **P<0.01 and ***P<0.001 relative to Ctns+/+microdissected proximal tubules. (f) Growth curves of Ctns mPTCs. Two tailed unpaired Student’s t test, *P<0.05 and 
**P<0.01 relative to Ctns+/+ mPTCs, n=3 independent experiments. (g-i) Ctns mPTCs were transduced with Scmb or Csda adenoviral shRNAs for 5 days. (g) Ctns mPTCs were immunostained with an anti-ZONAB antibody (green) 
and analysed by confocal microscopy. Quantification of ZONAB+ nuclei (in percentage of the total nuclei) obtained from 4 randomly selected fields per condition, with each containing ~20-25 cells. One-way ANOVA followed by 
Bonferroni’s post hoc test, #P<0.0001 relative to Ctns+/+ mPTCs transduced with Ad-Scmb shRNA or to Ctns-/- mPTCs transduced with Ad-Scmb shRNA. (h) Ctns mPTCs were immunostained with an anti-PCNA antibody (red) and 
analysed by confocal microscopy. Quantification of PCNA+ nuclei (in percentage of the total nuclei) obtained from 4 randomly selected fields per condition, with each containing ~20-25 cells. One-way ANOVA followed by 
Bonferroni’s post hoc test, **P<0.01 and ***P<0.001 relative to Ctns+/+ mPTCs transduced with Ad-Scmb shRNA or to Ctns-/- mPTCs transduced with Ad-Scmb shRNA. (i) The cells were loaded with Al647-BSA (50g/mL for 15 
min at 37°C) and imaged by confocal microscopy. Quantifications of the number of Al647-BSA (n=45-50 cells randomly selected field pooled from three mouse kidneys per condition; each point representing the number of BSA+ 
structures in a cell). One-way ANOVA followed by Bonferroni’s post hoc test, #P<0.0001 relative to Ctns+/+ mPTCs transduced with Ad-Scmb shRNA or to Ctns-/- mPTCs transduced with Ad-Scmb shRNA. Plotted data are 








Figure 8. Mitochondrial ROS triggers Ga12/Src-mediated destabilization of ZO-1. (a) Representative western blotting of G12, pTyr416 c-Src and c-Src protein levels in Ctns mPTCs treated with or without the mitochondria-
targeted antioxidant mito-TEMPO (MT, 10M for 24h). -actin was used as a loading control, n=3 independent experiments. (b)  Representative western blotting of  G12, pTyr416 c-Src and c-Src protein levels in Ctns mPTC 
transduced with either scrambled (Scmb) or Gna12 adenoviral shRNAs for 5 days.tubulinwas used as a loading control, n=2 independent experiments. (c) Representative western blotting of G12, pTyr416 c-Src and c-Src protein 
levels in mPTCs treated with Rotenone (250nM for 8h) or (d) transduced with Scmb or Atg7 adenoviral shRNAs for 5 days. In c and d, -actin was used as a loading control, n=3 independent experiments. (e) Tight junction ZO-1 
protein was immunoprecipitated (IP) from Ctns+/+ or Ctns-/- mPTCs and from Ctns-/- mPTCs transduced with Ad-Gna12 shRNA or treated with either mitochondria-targeted antioxidant MitoTempo (MT, 10M for 24h) or with a 
selective Src-kinase inhibitor SU6656 (5M for 24h) and the phosphorylation rate was examined by immunoblotting. (f-h) Ctns mPTCs were treated with either mitochondria-targeted antioxidant MitoTempo (MT, 10M for 24h) or 
a selective Src-kinase inhibitor SU6656 (5M for 24h). (f) Ctns mPTCs were immunostained with an anti-ZONAB (green) antibody and imaged by confocal microscopy. Quantification of ZONAB+ nuclei (in percentage of the total 
nuclei) was obtained from 5 randomly selected fields per condition, with each containing ~20-25 cells. (g) Ctns mPTCs were immunostained with an anti-PCNA antibody and imaged by confocal microscopy. Quantifications of 
PCNA+ nuclei (in percentage of the total nuclei) obtained from 5 randomly selected fields per condition, with each containing ~20-25 cells. (h) The cells were loaded with Al647-BSA (50g/mL for 15 min at 37°C) and imaged by 
confocal microscopy. Quantifications of the number of Al647-BSA (n=100 cells randomly selected cells pooled from three mouse kidneys per condition; each point representing the number of BSA+ structures in a cell). One-way 






Figure 9. Mitochondrial ROS scavenging ameliorates PT cell dysfunction in Ctns-/- mice. (a) Ctns mice were treated for 30 days with daily intraperitoneal injections of either saline or MT (1mg/kg body weight, n=4 mice for 
group). Following treatment, mPTCs obtained from microdissected Ctns kidneys were analysed. (b) The mPTCs were loaded with CellROX (5 M for 10 min at 37°C) and analysed by live confocal microscopy. Quantifications of 
fluorescence intensity were obtained from 5 randomly selected fields per condition, with each containing ~20-25 cells. (c) Western blotting and densitometric analyses of HO1 and lipocalin-2 (LPN2) protein levels. actin was 
usedas a loading control. (d) The cells were immunostained for PCNA and imaged by confocal microscopy. Quantifications of PCNA+ nuclei (in percentage of the total nuclei) obtained from 5 randomly selected fields per condition, 
with each containing ~20-25 cells. (e) Western blotting and densitometric analyses of LRP2 protein levels. tubulin was used as loading control. (f) The cells were loaded with Al488- BSA (50g/mL for 15 min at 37°C), fixed and 
analyzed by confocal microscopy. Quantification of the number of Al488-BSA (n=100 cells randomly selected cells pooled from three mouse kidneys per condition; each point representing the number of BSA+ structures in a cell). 
Nuclei counterstained with DAPI (blue) in d and f. All plotted data show mean±s.e.m. One-way ANOVA followed by Bonferroni’s post hoc test, *P<0.05, **P<0.01, ***P<0.001 and #P<0.0001 relative to mPTCs from vehicle-






Figure 10. Model bridging lysosomal defect, impaired autophagy and epithelial dysfunction in cystinosis. The black arrows identify the sequence of events that occur in proximal tubule epithelial cells. The endolysosomal 
system sustains the reabsorptive activity of specialized epithelial cells. Cystinosis is a paradigm of lysosomal storage disease, in which the loss of the cystinosin (CTNS) transport system drives the accumulation of cystine in 
lysosomes. This accumulation induces lysosome dysfunction which in turn impairs the cellular clearance of autophagosomes containing SQSTM1+ aggregates and/or damaged mitochondria. Similarly, pharmacological (with SAR-
405 and Spautin-1 inhibitors) and genetically-induced failure of autophagy (targeting Atg7) increases the amount of SQSTM1+ aggregates and/or damaged mitochondria, causing the accumulation of mitochondrial reactive oxygen 
species (mt-ROS). The increased mitochondrial oxidative stress enables the G12/Src-mediated phosphorylation of the tight junction adapter protein ZO-1, resulting in its misrouting to endolysosomal compartment. The disruption of 
tight junction integrity releases the ZO-1-associated Y-box factor ZONAB, which promotes cell proliferation and represses apical endocytic receptors such as LRP2, causing epithelial dysfunction in PT cells. Conversely, 
neutralization of excessive mitochondrial oxidative stress (mitochondria-targeted oxygen scavenger mito-TEMPO) or blockade of the Ga12/Src regulatory loop (e.g. treatment with a selective Src-kinase inhibitor Su6656) restores 
functional properties of epithelial Ctns-/- cell 
107 
 
Impaired Autophagy Bridges Lysosomal Storage Disease and  
Epithelial Dysfunction in the Kidney  
 
 
Beatrice Paola Festa, Zhiyong Chen, Marine Berquez, Huguette Debaix,  
Natsuko Tokonami, Jenny Ann Prange, Glenn van de Hoek, Alessio 
Cremonesi, Andrea Raimondi, Nathalie Nevo, Rachel H. Giles, Olivier 







Suppl. Tables 1-2 














     Suppl. Table 2: Zebrafish primer pairs for gene expression analysis. 
 





Suppl. Figure 1. Cystine storage, proliferation and dedifferentiation in Ctns-/- kidneys and derived PT cells. (a) Cystine levels in kidney cortex from 24-week-old Ctns mice (left panel) and in the derived primary mPTCs (right 
panel) were assessed by HPLC (n=5 per group). (b) The mRNA levels of Slc34a1, Erbb2, Mki67and Spp-1 in Ctns kidneys were analysed by real-time PCR (n=4 kidneys per group). (c) Ctns kidneys were immunostained with anti-
PCNA (red; left panel) or (d) anti-LRP2 (red; right panel) antibodies and stained with Lotus Tetragonolobus Lectin (LTL; proximal tubule marker, green). Scale bar, 50 m. (e) Ctns mPTCs were immunostained for PCNA and 
analysed by confocal microscopy. Quantification of PCNA+ nuclei (in percentage of the total nuclei) obtained from 5 randomly selected fields per condition, with each containing ~20-25 cells. (f) Ctns mPTCs were loaded with 
Al647-BSA (50g/mL for 15 min at 37°C) and analysed by confocal microscopy. Quantification of the number of Al647-BSA (n=45-65 cells randomly selected cells pooled from three mouse kidneys per condition; each point 
representing the number of BSA+ structures in a cell). (g) CC16 protein levels in urine from 24-week-old Ctns mice were measured by ELISA (n=7 mice per group). Plotted data are mean±s.e.m; two tailed unpaired Student’s t test, 





Suppl. Figure 2. Generation and validation of ctns knock-out zebrafish model. (a) TALEN targeting site (green) and TALEN-induced deletion (blue) generated a frameshift of the open reading frame, resulting in premature stop 
codon (TGA) within the exon 3 of ctns gene (middle panel) producing a truncated protein of 61 amino acids. The underlined sequence represents the AciI site, which is used for the detection of the TALEN-induced deletion. (b) AciI 
digestion of PCR products after the amplification of the TALEN targeting region using genomic DNA extracted from caudal of wild-type (+/+), heterozygous (+/del8) and homozygous (del8/del8) zebrafish. Wild type allele: two 
lower bands 152bp + 90bp correspond to PCR products cut by AciI, mutant allele: upper band 242bp, resistant to AciI digestion. (c) mRNA levels of ctns and clcn7 were analysed by real-time PCR in zebrafish kidneys;  n=7 ctns+/+, 
n=8 ctnsdel8/del8; two tailed unpaired Student’s t test,***P<0.001 relative to wild-type zebrafish. (d) The mRNA levels of ctns and clcn7 were analysed by real-time PCR in zebrafish kidneys (+/+: n=7, del8/del8: n=8; mean±s.e.m; 
two tailed unpaired Student’s t test, ***P<0.001 relative to wild-type zebrafish). (e) Cystine levels were assessed by HPLC in ctns zebrafish injected with wild type or mutant (Δ346-349) human CTNS mRNA or incubated in the E3 
medium in presence of 1mM cysteamine; n=14 ctns+/+ zebrafish, n=10 ctnsdel8/del8 zebrafish, n=6 ctnsdel8/del8 zebrafish injected with wild-type CTNS, n=8 ctnsdel8/del8 zebrafish injected with mutant CTNS, n=5 ctnsdel8/del8 zebrafish 
treated with cysteamine. Each point represents the average cystine levels pooled from 20 zebrafish embryos. Plotted data represent mean±s.e.m. One-way ANOVA followed by Bonferroni post hoc test #P<0.0001 relative to ctns+/+ or 






Suppl. Figure 3. Validation of the PIK3C3/Vps34 inhibitor SAR405 and its effect on autophagy in Ctns PT cells. (a) Primary mPTCs -PtdIns-3P antibody (red) 
and analysed by confocal microscopy. The adjacent panel shows the quantification of the PtdIns-3P-positive structures per cell (n=20 cells pooled from three mouse kidneys per each condition; each point representing the number of 
PtdIns-3P+ dots in a cell; mean±s.e.m; two tailed paired t-test, ***p< 0.001 relative to untreated cells). (b-c) mPTCs from Ctns -405 for the indicated 
times and subjected to western blotting and confocal microscopy analyses. (b) Representative western blotting of LC3 protein levels. -actin was used as a loading control; n= 2 independent experiments. (c) The cells were 
immunostained for LC3 (green) and analysed by confocal microscopy. The adjacent panel shows the quantification of the LC3-positive structures per cell (n=33 cells from three Ctns kidneys per condition; mean±s.e.m; one-way 
ANOVA followed by Bonferroni’s post hoc test, **P<0.01 relative to starved Ctns+/+ mPTCs; #P<0.0001 relative to fed Ctns+/+ mPTCs; #P<0.0001 relative to starved Ctns+/+ mPTCs; ns, not-significant. Nuclei counterstained with 




Suppl. Figure 4. Cystinosin deletion does not alter autophagosome biogenesis. (a) The mRNA levels of Becn1, Map1lc3b, Map1lc3a and Atg7 in microdissected proximal tubules from 24-week-old Ctns mouse kidneys were 
analysed by real-time PCR (n=3 Ctns kidneys per group). (b) Cells were immunostained with anti-ATG16L antibody (red) and analysed by confocal microscopy. Nuclei counterstained with DAPI (blue). Scale bar, 10m. The 
adjacent panel shows the quantification of the ATG16L positive structures per cell (n=40 cells pooled from three Ctns kidneys per condition); ns, not-significant. (c)Western blotting and densitometric analyses of the ATG7 and 





Suppl. Figure 5. Cystinosin deletion  affects neither the autophagosome-lysosome fusion nor Golgi-to-lysosome trafficking of lysosomal cathepsins in PT cells. (a) Representative confocal micrographs and quantification of 
LC3/LAMP1 positive structures (in percentage of total lysosomes) in cells cultured with non-saturating concentrations of BfnA1 (50 nM for 1h). Quantification obtained on 5 randomly selected fields per condition, with each 
containing ~20-25 cells; one way ANOVA followed by Bonferroni post hoc test, ***P<0.001 or #P<0.0001 relative to untreated Ctns+/+ mPTCs; ns, not-significant). (b) Representative electron tomography micrographs and 3-D 
reconstructed tomograms showing the presence of enlarged, single membranous structures (reminiscent of autolysosome; green) filled with undegraded cellular debris (blue and pink) in Ctns-/- mPTCs. (c) Cells were immunostained 
for GM130 (Golgi marker; green) and cathepsin-D (CtsD; red) or (d) for CtsD (green) and LAMP1 (late endosome/lysosome marker; red). Yellow indicates colocalization. Nuclei counterstained with DAPI (blue). The dotted white 
squares show images at higher magnification. Quantifications of the GM130/CtsD co-localizing structures (expressed as percentage of total CtsD+ structures) and of CtsD/LAMP1 co-localizing structures (expressed as percentage of 






Suppl. Figure 6. Subcellular compartmentalization of rescued CTNS protein in Ctns-/- cells. mPTCs from Ctns-/- kidneys were transduced with hemagglutinin-tagged Ctns (HA-Ctns)-bearing adenoviral particles for 2 days. The 
cells were immunostained for HA (green) and CtsD (red; top panel) or for HA and Calnexin (red; middle panel) or for HA and GM130 (red; bottom panel) and analysed by confocal microscopy. Yellow indicates colocalization. 






Suppl. Figure 7. Pharmacological blockage of autophagy causes mitochondria-derived oxidative stress, leading to proliferation and dedifferentiation of PT cells. (a-b) mPTCs were cultured in fed or starved medium (for 
8h), or in starved medium in the presence of PIK3C3/Vps34 inhibitor SAR-405 (5M, for 8h) or with autophagy inhibitor Spautin-1 (25M, for 8h). (a) Representative western blotting of LC3 protein levels. -actin was used as a 
loading control; n= 3 independent experiments. (b) Representative micrographs (left) and quantifications (right) of the LC3 structures in mPTCs by confocal microscopy (n=35 cells pooled from three mouse kidneys per condition; 
each point representing the number of LC3+ dots in a cell; one-way ANOVA followed by Bonferroni’s post hoc test, #P<0.0001 relative to mPTCs under fed conditions or to starved mPTCs). (c-h) mPTCs were cultured in presence 
of either SAR-405 or Spautin-1. (c) Representative western blotting of soluble and insoluble fractions obtained from mPTCs and immunoblotted for ubiquitin, SQSTM1 and GAPDH; n= 2 independent experiments. (d) The cells 
were loaded with tetramethylrhodamine methyl ester and analysed by live confocal microscopy. Quantification of TMRM fluorescence intensity obtained from 5 randomly selected fields per condition, with each containing ~20-25 
cells. Two tailed paired Student’s t test, **P<0.01 relative to untreated mPTCs. (e) mPTCs were loaded with CellROX and Mito SOX analysed by live confocal microscopy. Quantifications of CellROX or MitoSOX fluorescence 
intensity obtained from three randomly selected fields per condition, with each containing ~20-25 cells). Two tailed paired Student’s t test, **P<0.01 relative to untreated mPTCs.  (f) The mRNA levels of Lrp2, Ccdn1 Clcn5 and 
Pcna were assessed by real-time PCR (n=4 independent experiments). (g) The cells were loaded with bromodeoxyuridine, immunostained with anti- BrdU antibody and analysed by confocal microscopy. Quantification of numbers of 
BrdU positive cells (in percentage of total nuclei) was obtained from 5 randomly selected fields per condition, with each containing ~20-25 cells. (h) The cells were loaded with Al647-BSA and imaged by confocal microscopy. 
Quantification of the number of Al647-BSA (n=68-105 cells randomly selected cells pooled from three mouse kidneys per condition; each point representing the number of BSA+ structures in a cell). All the plotted data represent 
mean±s.e.m. Plotted data represent mean±s.e.m. Unless otherwise stated, one-way variance (ANOVA) followed by Dunnett’s post hoc test, *P<0.05, **P<0.01 and ***P<0.001 relative to untreated mPTCs. Nuclei are counterstained 





Suppl. Figure 8. Augmented phosphorylation rate of tight junction ZO1 proteins in cystinosis cells or in PT cells experiencing oxidative stress. The cells were transduced with scrambled (Scmb) or Atg7 adenoviral shRNAs, 
or (b) cultured in presence of PIK3C3/Vps34 inhibitor SAR-405 (5µM, for 16h) or with the autophagy inhibitor Spautin-1 (25µM for 16h), or in presence (c) of hydrogen peroxide (0.5mM for 1h) or (d-e) with mitochondrial complex 
I inhibitor Rotenone (250 nM for 8h). (a,c,e) Tight junction ZO-1 protein was immunoprecipitated (IP) from mPTCs and its phosphorylation rate was examined by immunoblotting; n=2 independent experiments. (b) Representative 
confocal micrographs and quantifications of endogenous phosphorylation of ZO-1 by proximity ligation assay (PLA) using primary antibodies against ZO-1and phopsho-Tyr (PY99). One-way ANOVA followed by Dunnett’s post 
hoc test, ***P<0.001 relative to untreated mPTCs. (d) The cells were loaded with MitoSOX (mitochondrial ROS probe; 2.5 µM for 5 min at 37°C) analysed by live confocal microscopy. Quantification of MitoSOX fluorescence 
intensity obtained from three randomly selected fields per condition, with each containing ~20-25 cells. Two tailed unpaired Student’s t test, ***P<0.0001 relative to untreated mPTCs. (f) The cells were immunostained with an anti-
ZONAB (green) antibody and analysed by confocal microscopy. The adjacent panel the quantification of numbers of ZONAB-positive cells (in percentage of total nuclei) was obtained from 5 randomly selected fields per condition, 
with each containing ~20-25 cells. Two tailed paired Student’s t test, ***P<0.001 relative to untreated mPTCs. (g) The mRNA levels of Clcn5, Rab5, Lrp2 and Pcna were analysed by real-time PCR (n=4 independent experiments). 
Two tailed unpaired Student’s t test, *P<0.05, **P<0.01 relative to untreated mPTCs; ns, not significant. (h)The cells were immunostained with an anti-PCNA (red) antibody and imaged by confocal microscopy. Quantifications of 
PCNA+ nuclei (in percentage of the total nuclei) obtained from 5 randomly selected fields per condition, with each containing ~20-25 cells. Two tailed unpaired Student’s t test, ***P<0.0001 relative to untreated mPTCs. (i) The 
cells were loaded with Al647-BSA (50µg/mL for 15 min at 37°C) and imaged by confocal microscopy. Quantifications of the number of Al647-BSA (n=100 cells randomly selected cells pooled from three mouse kidneys per 





Suppl. Figure 9. Knockdown of Csda and the exogenous overexpression of TJP1 in cystinosis PT cells rescue the epithelial functions. (a,b,c) Ctns cells were transduced with Scmb or Csda adenoviral shRNAs for 5 days. (a) 
The mRNA levels of Csda were analysed by real-time PCR (n=4 independent experiments). (b) Representative micrographs of Ctns cells stained with an anti-ZONAB (green) and anti-PCNA (red) antibodies or (c) loaded with 
Al647-BSA (red) and stained afterwards with anti-ZONAB (green) antibody. (d-e) Ctns cells were transduced with a Null or human HA-(TJP1)-bearing adenoviral particles for 2 days. (d) The cells were immunostained with an anti-
PCNA (red) and anti-HA (green) antibodies and imaged by confocal microscopy. Quantifications of PCNA+ nuclei (in percentage of the total nuclei) obtained from 5 randomly selected fields per condition, with each containing ~20-
25 cells. (e) The cells were loaded with Al647-BSA (red; 50µg/mL for 15 min at 37°C), stained with an anti-HA antibody (green) and imaged by confocal microscopy. Quantifications of the number of Al647-BSA (n=50 cells 
randomly selected cells pooled from three mouse kidneys per condition; each point representing the number of BSA+ structures in a cell). Plotted data show mean±s.e.m. One-way ANOVA followed by Bonferroni post hoc test, 







Suppl. Figure 10. Knockdown of Tjp1 and the exogenous overexpression of Csda in PT cells promote epithelial dysfunctions. (a,b,c) mPTCs were transduced with Scmb or Tjp1 adenoviral shRNAs for 5 days. (a) The mRNA 
levels of Pcna, Clcn5, Lrp2 and Tjp1 were analysed by real-time PCR (n=4 independent experiments). (b) The cells were immunostained with an anti-ZO-1(green) and PCNA (red) antibodies and imaged by confocal microscopy. 
Quantification of PCNA+ nuclei (in percentage of the total nuclei) obtained from 5 randomly selected fields per condition, with each containing ~20-25 cells. (c) The cells were loaded with Al647-BSA (red; 50µg/mL for 15 min at 
37°C), stained with an anti-ZO-1 (green) antibody and imaged by confocal microscopy. Quantification of the number of Al647-BSA+ structures (n=50 randomly selected cells pooled from three mouse kidneys per condition; each 
point representing the number of BSA+ structures in a cell). (d-f) mPTCs were transduced with Ad-GFP or GFP-tagged-(Csda)-bearing adenoviral particles for 2 days. (d) The cells were stained with an anti-GFP antibody and 
imaged by confocal microscopy. Quantification of the number with nuclear GFP (in percentage of the total nuclei; n=20 randomly selected cells per condition). (e) The mRNA levels of Ccdn1, Pcna, Clcn5, Lrp2 were analysed by 
real-time PCR (n=4 independent experiments). (f) The cells were loaded with Al647-BSA (red; 50µg/mL for 15 min at 37°C), stained with an anti-GFP antibody and imaged by confocal microscopy. Quantification of the number of 
Al647-BSA+ positive structures (n=20 randomly selected cells pooled from three mouse kidneys per condition; each point representing the number of BSA+ structures in cell). Plotted data show mean±s.e.m. Two tailed paired 





Suppl. Figure 11. Inhibition of mitochondrial ROS restores epithelial functions in cystinosis PT cells. (a-b) mPTCs from Ctns kidneys were treated with or without the mitochondria-targeted antioxidant Mito-TEMPO (MT, 
10µM for 24h). (a) The cells were loaded with MitoSOX (2.5µM for 5 min at 37°C) and analysed by live confocal microscopy. Quantification of fluorescence intensity from 5 randomly selected fields per condition, with each 
containing ~20-25 cells; one-way ANOVA followed by Bonferroni post hoc test, **P<0.01 relative to Ctns+/+ mPTCs; ***P<0.001 relative to untreated-Ctns-/- mPTCs. (b) Representative western blotting of HO1 protein levels. 
H3was used as a loading control. (n=2 independent experiments). (c- d) Ctns cells were treated with MT (10µM for 24h) or with a selective Src kinase inhibitor SU6656 (5µM for 24h). (c) Representative confocal micrographs and 
quantifications of endogenous phosphorylation of ZO-1 by proximity ligation assay (PLA) using primary antibodies against ZO-1 and phopsho-Tyr (PY99). (d) Cells were immunostained with an anti-LAMP1 (red) and ZO-1 (green) 
antibodies, and analysed by confocal microscopy. The adjacent panel shows the quantification of the ZO-1/LAMP1 co-localizing structures (in percentage of the total lysosomes) assessed by confocal microscopy. The quantifications 
were obtained from three randomly selected fields per condition, with each containing ~20-25 cells. Plotted data represent mean±s.e.m. In c and d, one way-variance ANOVA, #P<0.0001 relative to untreated Ctns+/+ or Ctns-/- 





Suppl. Figure 12. Csda overexpression abolishes the effects of Mito-TEMPO on the epithelial functions in cystinosis PT cells. (a-b) Mito-TEMPO-treated mPTCs were transduced with Ad-GFP or GFP-tagged-(Csda)-bearing 
adenoviral particles for 2 days. (a) The cells were immunostained with an anti- PCNA (red) antibody and imaged by confocal microscopy. Quantification of PCNA+ nuclei (in percentage of the total nuclei) obtained from 15 cells 
negative or positive for nuclear GFP enrichment. One-way ANOVA followed by Bonferroni post hoc test, #P<0.0001 relative to Ctns+/+ or ***P<0.0001 relative to Ctns-/- mPTCs or relative to GFP-/Ctns-/-mPTCs treated with MT. 
(b) The cells were loaded with Al647-BSA (red; 50µg/mL for 15 min at 37°C), stained with an anti-GFP (green) antibody and analysed by confocal microscopy. Quantification of the number of Al647-BSA+ positive structures 
(n=20 cells negative or positive for nuclear GFP enrichment; each point representing the number of BSA+ structures in cell). Plotted data show mean±s.e.m. #P<0.001 relative to Ctns+/+ or Ctns-/- mPTCs or relative to GFP-/Ctns-/-




III.2.2 mTORC1: a novel druggable target for nephropathic cystinosis 
 
Aberrant mTORC1 Activation Underlies Proximal Tubule 
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The reabsorptive function of kidney PT cells relies on the endolysosomal system. Mutations in the 
CTNS gene encoding the lysosomal cystine transporter cystinosin (Nephropathic Cystinosis), 
disrupts cystine homeostasis in the lysosomal lumen and causes a generalized dysfunction of PT 
cells resulting in Renal Fanconi Syndrome. In our previous work, we deciphered the pathogenic 
cascade bridging lysosomal defects and the loss of epithelial transport in cystinosis. However, how 
the primary loss of cystinosin function disrupts the identity of the lysosomal network was not 
investigated, preventing the development of causal treatments. 
Here we demonstrate, by combining genetic and pharmacological approaches in vivo and in vitro, 
that cystine accumulation in cystinosis triggers the hyper-activation of mTORC1, which in turn, 
drives the progression of the lysosomal disease leading to autophagy defects and consequent PT 
dysfunction. Alterations of mTORC1 were detected in Ctns
-/-
 mouse and rat models, demonstrating 
the evolutionary conservation of this disease-mechanism. Finally, in vitro treatment with specific 
and powerful mTORC1 inhibitors rescued the primary lysosomal defect and consequently restored 
the downstream pathogenic cascade associated to it, thus improving the PT function.   
Altogether, these studies unveiled a novel link between defective mTORC1 activity, lysosome-
autophagy degradation pathways and epithelial dysfunction in cystinosis, thus providing new 






The reabsorptive properties of the kidney PT rely on the endolysosomal system, a dynamic network 
that receives and degrades macromolecules from the endocytic and autophagy pathways with the 
capacity to promote the recycling of cellular nutrients and to safeguard the cellular homeostasis. By 
reabsorbing a large amount of filtered ions and solutes from the urine, PT cells play a pivotal role in 
maintaining body homeostasis. Alterations in the transport activity lead to disrupted PT function 
(renal Fanconi syndrome, RFS), characterized by the loss of solutes and LMW proteins in the urines 
and often leading to CKD (1). PT dysfunctions are usually observed in congenital disorders caused 
by defective endolysosomal proteins, such as nephropathic cystinosis. Cystinosis (OMIM #219800) 
is caused by autosomal recessive mutations in the CTNS gene, which encodes cystinosin (CTNS), a 
lysosomal cystine-proton symporter exporting cystine into the cytosol. Loss of cystinosin results in 
the lysosomal accumulation of cystine crystals leading to progressive dysfunction of multiple 
organs including the kidney. Children with nephropathic cystinosis, the most severe and frequent 
form of cystinosis, develop PT dysfunction and RFS before 1 year of age, often followed by CKD 
(2).  
We have recently demonstrated that a Ctns knock-out mouse model shows an accumulation 
of cystine within kidney proximal tubule (PT) epithelial cells, which is accompanied by 
endolysosomal aberrations impairing autophagy flux and disrupting mitochondria homeostasis 
causing an excessive production of oxidative stress. The latter affect the integrity of the TJs, by 
phosphorylation of ZO-1, which, in turn, promotes the release of ZO-1-associated nucleic acid 
binding protein (ZONAB), a Y-box transcription factor known to cause proliferation and apical 
dedifferentiation in PT cells (3). This work highlights the central role of the lysosomal-autophagy 
network in maintaining cellular homeostasis in PT cells and deciphers the mechanism bridging 
lysosome dysfunction with the loss of PT transport activity in cystinosis. However, how the loss of 
cystinosin impairs the lysosomal identity remains unclear. 
Cystinosin has recently been shown to interact with components of the lysosomal V-ATPase 
controlling mTORC1 signaling (4). mTORC1 is a master regulator of cell growth and metabolism, 
which regulates the functional activity of lysosomes and related autophagy pathway by controlling 
the activity and subcellular localization of the helix-loop-helix (HLH) transcription factor TFEB. In 
various models of lysosomal storage disease, including immortalized cells from cystinotic patients, 
the overexpression of TFEB activates the lysosomal-autophagy pathway and promotes the clearance 
of accumulated substrates (5-7).The activity of mTORC1 activity is modulated by lysosomal levels 
of amino acids. Under amino acid-rich conditions, mTORC1 translocates on the lysosome in its 
active state and promotes cell growth by stimulating biosynthetic pathways while inhibiting cellular 
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catabolism through the repression of TFEB, hence, downregulation of lysosomal biogenesis and 
autophagy. Conversely, amino acid- starvation leads to mTORC1 detachment from lysosomes and 
to its inactivation, which stimulates TFEB nuclear translocation, thus enhancing lysosomal function 
and autophagy which are essential for cell survival (8). Given that the functional loss of CTNS 
disrupts the lysosomal exit of cystine, we reasoned that the storage of this amino acid might sustain 
mTORC1 activity. In turn, hyperactive mTORC1 could exert a negative feedback on the lysosomal 
function and disrupt the autophagy clearance of damaged organelles and mitochondria leading to 
the pathologic cascade of events previously described in cystinosis (3). 
A current limitation to investigate the contribution of the mTORC1-lysosome-autophagy 
axis in the pathogenesis of PT dysfunction is due to the use of cystinotic cellular models, which are 
not suitable for the analysis of this signaling. Indeed the methods used to immortalize CTNS-
deficient cells derived from mice or patients could per se affect the activity of mTORC1, resulting 
in misleading interpretations of the data. Moreover, immortalized PT cell systems, which lose 
transport properties and their capacity of saturable endocytic uptake, yield discordant results - 
particularly in terms of processes involved in cell differentiation (9). In the last years, we 
participated in the establishment of faithful rodent models of cystinosis, and validated a well-
differentiated primary PT cell culture system (mPTCs) obtained from mouse kidneys (10). The 
combination of these tools, allowed us to identify the link between loss of cystinosin function, 
mTORC1 activity, impairment of lyso-autophagy pathway and loss of transport capacity in PT 
cells. These findings are important as they open realistic therapeutic opportunities for patients with 
cystinosis. Since mTORC1 inhibitors are clinically used in other pathologic conditions, their 







Time course of lysosomal and autophagy dysfunction in the kidneys of Ctns
-/-
 mice   
In order to identify the initial biological aberration caused by the absence of cystinosin, we analysed 
lysosomal and autophagy activity in a time course experiment performed in Ctns
-/- 
mice. For this 
purpose, we analysed Ctns
-/-
 mice at a presymptomatic stage (6 week-old), without signs of 
significant PT dysfunction, and at symptomatic stage (16 week-old), in presence of manifestations 
of PT dysfunction, as scored by a massive loss of CC16 low molecular weight protein (LMW) in 
the urines (Suppl. Fig. 1A). Compared to controls, PTs from Ctns
-/- 
presymptomatic mice did not 
exhibit changes in lysosomal dynamics. In contrast, PTs from Ctns
-/- 
symptomatic mice showed 
altered lysosomal size and increased mass, as scored by the size of LAMP1 + vesicles and by 
LAMP1 immunoblotting performed on the kidney lysates (Figs. 1A-1B). Although changes in 
lysosomal dynamics were observed only at later stage, the lysosomal function was already 
perturbed in presymptomatic Ctns
-/- 
mice and clearly disrupted in symptomatic Ctns
-/- 
mice, as 
evidenced by the decreased proteolytic generation of the 32 kDa mature form of cathepsin D (CtsD) 
(Fig. 1B). Given that the autophagy degradative pathway is directly connected to the lysosomal 
function, we were surprised to see that the homeostasis of autophagy proteins was unchanged in 
presymptomatic Ctns
-/- 
mice (Figs. 1C-1D) but it was disrupted in symptomatic Ctns
-/- 
 mice, as 
shown by the increased levels of LC3-II as well as the greater amount of LC3-labelled 
autophagosomes compared to control mice (Figs. 1C-1D). Later appearance of aberrant autophagy 
was confirmed by the analysis of the autophagic receptor SQSTM1, whose increase was detected 
exclusively in the PTs of symptomatic Ctns
-/- 
mice (Suppl. Fig. 1B). Altogether, these data show 
that the lack of cystinosin in PTs leads to an early aberration of the lysosomal function, followed by 
alterations in lysosomal dynamics and autophagy. 
 
Progressive cystine accumulation and mTORC1 activation in the kidneys of Ctns
-/- 
mice   
Our next aim was to investigate the molecular pathway driving the progression of lysosomal 
dysfunction and dysregulation of autophagy flux in the PTs of symptomatic Ctns
-/- 
mice. We 
focused our analyses on the serine/threonine kinase mTORC1 because: (i) mTORC1 is a master 
regulator of lysosomal function and autophagy (12), (ii) mTORC1 activity is known to be 
modulated by the intra-lysosomal levels of amino acids and loss of cystinosin function increases the 
intra-lysosomal levels of the amino acid cystine (13). Furthermore, cystinosin has been shown to 
interact with mTORC1 regulatory subunits and could play a role in modulating its activity (4). 
We showed that cystine accumulation in our model correlated with disease severity as we detected 
increased levels in the kidney of symptomatic Ctns
-/- 
mice, whereas in the kidney of 
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presymptomatic mice the levels of cystine were unchanged (Fig. 2A). Interestingly, mTORC1 
activation, as assessed by the phosphorylation state of its direct substrate S6, was abnormally 
increased in symptomatic Ctns
-/- 
kidneys but unaltered in presymptomatic kidneys (Fig. 2B). The 
time-dependent upregulation of mTORC1 signaling was confirmed in the LTL-positive proximal 
tubules (Fig. 2C). These data showing physiologic mTORC1 activity in presymptomatic Ctns
-/- 
mice 
prove that the absence of cystinosin per se is not sufficient for mTORC1 activation. On the other 
hand, as the alteration of mTORC1 pathway in the PT is temporally associated to cystine levels, we 
suggest that lysosomal accumulation of this amino acid is required to activate mTORC1 in Ctns
-/- 
mice. Of note, abnormal mTORC1 activation could exert a negative feedback on the lysosomal 
function of Ctns
-/- 
kidneys and contribute to the progressive lyso-autophagy defects, thus installing a 
pathogenic vicious circle.  
 
Novel rat model of cystinosis with aberrant mTORC1 activation and dysfunctional lyso-
autophagy path  
To further explore the consequences of absent cystinosin in vivo, we established a novel Ctns 
knock-out rat model by using CRISPR/CAS9 (clustered regularly interspaced short palindromic 
repeats/ CRISPR associated protein 9) technology. This model was generated by deleting a 12bp 
sequence, which was replaced by an 8bp insertion resulting in a premature stop codon in exon 3 of 
Ctns and leading to nonsense-mediated decay of the mRNA and a complete deletion of the protein 
(Suppl. Figs. 2A-2C). 20 weeks old Ctns
-/- 
rats exhibited reduced body weight and impaired PT 
reabsorption, as scored by the massive loss of Albumin and LMW proteins in the urine (Suppl. Figs. 
2D-2G).  Phenocopying the cystinotic murine model, the PT dysfunction observed in Ctns
-/- 
rats was 
explained by the decreased expression of PT components, including megalin and cubilin endocytic 
receptors, and increased expression of proliferative genes (Suppl. Figs. 2H-2J). Similar to mice, 
depletion of cystinosin in rats provoked an accumulation of renal cystine associated with an 
increased rate of phosphorylation of S6, specifically observed in the megalin+ PT, decreased 
production of the mature form of lysosomal cathepsin D and abnormal LC3-II levels (Figs. 3A-3E). 
These results suggest that (i) cystine storage, (ii) altered mTORC1 pathway and (iii) disrupted lyso-
autophagy network are evolutionary conserved pathogenic aberrations characterizing cystinosis.  
 
Disrupted mTORC1 sensing in primary culture of proximal tubule cells (mPTCs) derived from 
the kidney of Ctns
-/- 
mice 
mTORC1 signaling is tightly regulated by the availability of amino acids. Under amino acids-rich 
conditions, mTORC1 translocates on the lysosome in its active state and promotes cell growth by 
stimulating biosynthetic pathways while inhibiting cellular catabolism through the repression of 
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autophagy and lysosomal biogenesis. Conversely, amino acids starvation leads to mTORC1 
detachment from lysosomes and to its inactivation, which stimulates autophagy and lysosomal 
function-essential to regenerate nutrients and new energy for cell survival (13). In order to 
investigate whether the mTORC1 dysregulation reported in the kidney of symptomatic Ctns
-/- 
mice 
involved mTORC1 response to amino acids, we derived primary cultures of proximal tubule cells 
(mPTCs) from mice at this stage and analyse them under starvation and fed conditions (3). 
Importantly, these cells recapitulated the cystine accumulation observed in the kidneys of 
symptomatic Ctns
-/- 
mice (Suppl. Fig. 3A). As expected, in amino acids deprived Ctns
+/+
 mPTCs, 
mTORC1 was deactivated and localized outside the lysosomes. Refeeding starved Ctns
+/+
 mPTCs 
with amino acids, restored mTORC1 signaling and its recruitment on the lysosomal membranes. 
Conversely, in Ctns
-/- 
mPTCs mTORC1 was active and maintained its lysosomal localization in 
both starved and amino acids conditions (Figs. 4A-4B). Next, we examined whether sustained 
activation of mTORC1 in these cells was maintained after prolonged starvation.  In control cells, 
amino acids removal acutely inhibited mTORC1 signaling at each time point analysed over 24 
hours, apart from the 12h period, where mTORC1 is probably re-activated by the amino acids 
derived by the autophagic degradation (Fig. 4C), as shown before (14). Conversely, prolonged 
starvation of Ctns
-/- 
mPTCs did not decrease mTORC1 activity, which remained high at all the time 
points of the fasting protocol (Fig. 4C). Interestingly, in Ctns
-/- 
mPTCs derived from mice at 
presymptomatic stage, which did not exhibit a significant cystine accumulation, mTORC1 response 
to amino acids was indistinguishable from the control (Suppl. Fig. 3A-3B). In line with our data in 
the kidneys, these results indicate that loss of cystinosin affects mTORC1 sensing and signaling 
only at later stage, when its absence results in a dramatic accumulation of cystine in PT cells. 
 
Cystinosin transport activity is required for maintaining mTORC1 function and lysosomal 
degradation of autophagy substrates 
In order to assess whether the transport function of CTNS was required to maintain mTORC1 
function and whether changes in this axis had an impact on the lysosomal degradation of autophagy 
substrates, we transduced Ctns
-/- 
mPTCs with an adenovirus that expresses either mouse 
hemagglutinin (HA)-tagged wild type cystinosin or mutant cystinosin G339R. This missense 
mutation, previously identified in patients with infantile cystinosis, abolishes the transport activity 
of cystinosin and generates cystine accumulation without altering the lysosomal localization of the 
transporter (15) (Fig. 5A). Compared to Ctns
-/- 
mPTCs transduced with the empty vector, the 
functional re-expression of HA-CTNS protein rescued the mTORC1 response to amino acid 
availability, as shown by the decreased rate of phosphorylation of S6 ribosomal protein during 
starvation and its increase upon replenishment with amino acids (Fig. 5B). Furthermore, expression 
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of wild type HA-CTNS restored the degradation of autophagy substrates during starvation, as 
assessed by the decreased levels of SQSTM1 and LC3-II (Fig. 5C). In contrast, insertion of mutant 
HA-CTNS G339R in Ctns
-/- 
mPTCs did not rescue the altered mTORC1 signaling neither improved 
the impaired lyso-autophagy flux (Figs. 5B-5C). These data indicate that: (i) abnormal mTORC1 
signaling and impaired lysosomal clearance of autophagy cargo are interconnected events, which 
are strictly related to the lack of cystinosin transport activity; (ii) absent CTNS transporter function, 
previously shown to result in lysosomal cystine accumulation (15) is sufficient for mTORC1 
dysregulation. 
 
Cystine accumulation drives mTORC1 activation 
Next, we investigated whether the cystine storage, resulting from the loss of cystinosin transport 
activity, might be the direct mediator of mTORC1 dysregulation in Ctns
-/- 
mice. In order to test this 
hypothesis, we analysed mTORC1 activity in starved Ctns
-/- 
mPTCs treated with the cystine-
lowering drug cysteamine. This drug converts the lysosomal cystine into cysteine and cysteamine-
cystine mixed disulfide, which is analogous to lysine and thus able to exit lysosomes through the 
cationic amino acid PQLC2/LAAT-1 transporter. The depletion of the intracellular cystine-storage 
by cysteamine (Fig. 6A) abolished mTORC1 activity similarly to the treatment with Torin1, which 
directly inhibits mTORC1 through an ATP-competitive mechanism (Fig. 6B). Of note, Torin1 
treatment did not decrease the elevated cystine levels observed in Ctns
-/- 
mPTCs (Fig. 6A). These 
results suggest that cystine accumulation signals upstream of mTORC1 and acts as the trigger for 
mTORC1 dysregulation in cystinosis. To provide a direct proof that cystine accumulation is 
sufficient for mTORC1 activation, we artificially raised lysosomal cystine levels in Ctns
+/+
 mPTCs 
and subsequently analysed mTORC1 signaling and localization. To increase the level of lysosomal 
cystine, mPTCs were treated with an alcohol ester derivate of cystine (CDME), which diffuses 
across the cellular membranes and quickly accumulates in the lysosomes in its native form (5). As 
control, we used wild-type mPTCs treated with the same concentration of normal cystine. Starved 
Ctns
+/+
 mPTCs supplemented with normal cystine for 30 minutes exhibited a rapid translocation of 
active mTORC1 to the lysosomal surface. This event correlated with a significant increase of 
intracellular cystine compared to starvation condition. mTORC1 activation decreased over time 
until disappearance at 6h, when intracellular cystine concentration decreased at the level of starved 
cells (Figs. 6C-6E). The transitory activation of mTORC1 in the first points of the time-course 
could be explained by the rapid metabolism of cystine. Indeed, the permanence of this amino acid in 
the lysosome is short as it is rapidly transported in the cytosol where it is converted in cysteine used 
for GSH synthesis (16, 17). By contrast, when starved Ctns
+/+
 mPTCs were exposed to CDME, 
which causes a time-dependent accumulation of cystine in the cells, mTORC1 kinase activity and 
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its clustering onto the lysosomal surface progressively increased and reach the peak at 6h, when 
intracellular cystine concentration is remarkably high (Figs. 6C-6E). These data indicate a 
correlation between cystine accumulation and mTORC1 activity in PT epithelial cells.  
 
mTORC1 activation does not depend on alterations in MAPK/ERK signaling or changes in its 
regulatory subunits 
To rule out the possibility that alteration in MAPK/ERK signalling, involved in the upstream 
regulation of mTORC1, could contribute to mTORC1 phenotype in Ctns
-/- 
mPTCs, we blocked this 
path by using its inhibitor U0126 (18). Torin1 and Rapamycin inhibitors, which directly affect 
mTORC1 kinase activity, abolished the sustained phosphorylation of mTORC1 substrates in 
starved Ctns
-/- 
mPTCs, while U0126 treatment did not modify their state of activation (Figs.7A-7B). 
Of note, the phosphorylation status of Akt, a growth factor/MAPK-dependent upstream regulator of 
mTORC1, was unchanged in Ctns
-/- 
mice (Fig. 7D). These data demonstrate that in Ctns
-/- 
mPTCs 
the mTORC1 hyper-activation is independent on MAPK/ERK pathway. Of note, the protein levels 
of mTORC1 regulatory subunits Raptor and Rags were also unchanged in both presymptomatic and 
symptomatic Ctns
-/- 
mice (Figs. 7C-7D). These results suggest that abnormal mTORC1 activity in 
Ctns
-/- 
mPTCs occurs through a mechanism, which does not involve homeostatic changes of its 
regulatory complex neither aberrant activation of growth factors/MAPK cell signaling. 
 
mTORC1 inhibition in Ctns
-/- 
mPTCs rescues lyso-autophagy pathway and PT dysfunction 
Given (i) the temporal association between the appearance of abnormal mTORC1 signaling and the 
onset of impaired lyso-autophagy pathway in the kidney of Ctns
-/- 
mice (Figs. 1-2) and (ii) the 
correlation between rescued mTORC1 function and restored lyso-autophagy clearance upon 
cystinosin reintroduction in Ctns
-/- 
mPTCs (Fig. 5), we postulated a causative link between these 
two pathways. As active mTORC1 negatively regulates lysosomal biogenesis and autophagy, we 
reasoned that blocking its sustained activation might improve the functioning of the lyso-autophagy 
pathway in Ctns
-/- 
mPTCs and the downstream cellular aberrations related to it (18). In order to test 
this hypothesis we treated Ctns
-/- 
mPTCs with the mTORC1 inhibitors Torin1 (ATP-competitive 
mechanism) and Rapamycin (allosteric mechanism), previously shown to be effective in our cell 
system (Fig. 7B). mTORC1 inhibition reduced the abnormal size of LAMP1-positive vesicles, 
restored the peripheral lysosomal distribution (Fig. 8A) and restarted the stalled lysosomal function, 
as scored by the increased proteolytic generation of the 32 kDa mature CtsD and confirmed by the 
staining with PepA fluorescent probe (Figs. 8B-8C). These events were paralleled by an 
improvement of the autophagy flux, as shown by the decreased accumulation of LC3 II 
autophagosomal marker and reduced levels of EM-detected autophagic vacuoles (Fig. 8D and 
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Suppl. Fig. 4A). These data suggest that mTORC1 inhibition leads to the reactivation of the lyso-
autophagy degradative pathway, thus, establishing a clear pathologic connection between these two 
networks in cystinosis. Our previous studies show that impaired autophagy in cystinotic mice 
induced a defective clearance of damaged mitochondria-producing ROS, which in turn, disrupts the 
tight junction integrity. This event caused increased translocation of ZONAB transcription factor 
into the nucleus and activation of an abnormal transcriptional program leading to cell proliferation 
and dedifferentiation, with loss of reabsorptive capacity of PT cells (4). Interestingly, restoring the 
lyso-autophagy pathway by blocking mTORC1 signaling restored basal level of oxidative stress, as 
scored by decreased level of cellular ROS (Suppl. Fig. 4B). This event was associated with rescued 
integrity of tight junctions, as evidenced by increased ZO-1 abundance at cell boundaries and 
subsequent decrease of ZONAB nuclear localization (Fig. 8E and Suppl. Fig. 4C). Accordingly, we 
observed a decreased cell proliferation and increased apical uptake of albumin in Ctns
-/- 
mPTCs 
(Figs. 8F-8G). Thus, stimulating autophagy-lysosome systems, by shutting off mTORC1 in Ctns
-/- 
mPTCs, rescues the functional properties of PT cells. These results identify mTORC1 dysregulation 






In this work we unveil the mechanism bridging loss of CTNS function and impairment of lysosomal 
network in cystinosis. We showed that cystine accumulation induces an aberrant activation of 
mTORC1, which in turn, disrupts the identity of the lysosomal compartment and the related 
mechanism of autophagy clearance, leading to PT dysfunction. Hyperactivation of mTORC1 was 
confirmed in a novel Ctns
-/-
 rat model, demonstrating the conservation of these disease-pathways 
across mammals. Inhibition of mTORC1 pathway in murine Ctns
-/- 
PT cells rescues the lyso-
autophagy dysfunction, normalizes the level of oxidative stress, restores the TJ integrity and the 
abnormal ZO-1/ZONAB signalling axis resulting in an improvement of the transport activity of PT 
cells. Collectively these studies provide insights into the mechanism underlying the primary 
lysosome defect in cystinosis and offer new therapeutic perspectives for this, and potentially other, 
lysosome storage disorders. Most importantly, we found that: 
 
 Hyperactivation of mTORC1 was detected in kidneys from both Ctns-/- rat and mouse 
models and derived primary cultures of PT cells. These results are in contrast with the 
decreased mTORC1 signaling previously shown in immortalized PT cells isolated from the 
urine of cystinotic patients or from the kidney of CTNS-deficient mice (4, 19). The process 
of immortalization by infection with the Simian Virus 40 (SV40) used in the latter studies 
could per se decrease the phosphorylation of mTORC1 and its direct substrates, impairing 
the analysis of the pathway (10). 
 
 Abnormal activation of mTORC1 in Ctns-/- mPTCs is driven by cystine accumulation. Data 
supporting this hypothesis are: (i) the progressive activation of mTORC1 observed upon 
CDME overload in wild-type PT cells and (ii) the decreased mTORC1 activation observed 
after the treatment of Ctns
-/-
 PT cells with the cystine-depleting agent cysteamine. Future 
metabolomics studies on lysosomal fractions will help to understand whether cystine 
accumulation drives the dysregulation of mTORC1 alone or in cooperation with other 
metabolites and to decipher how metabolic changes within the lysosomal lumen contributes 
to the disruption of lysosomal identity in cystinosis (20). 
 
 Previous studies in kidney and fibroblast cell lines show that cystinosin interacts with many 
regulatory subunits of mTORC1. These interactions suggest a regulatory loop between the 
cystine transporter and the mTORC1 complex (4). However, as mTORC1 dysregulation is 
not detected in the early life of cystinotic mice, we exclude that the loss of cystinosin alone 
133 
 
is sufficient to drive mTORC1 aberration. Further work is needed to deepen the biological 
meaning of this protein-protein interaction. 
 
 mTORC1 could affect lysosomal function by blocking TFEB nuclear translocation, thus, 
impairing lysosomal biogenesis. This hypothesis is in line with the abnormal size and 
reduced number of lysosomes observed in cystinosis and it is supported by the studies of 
Rega et al. showing that activation of TFEB rescues lysosomal abnormalities in cystinotic 
kidney cells (7). Alternatively, mTORC1 alterations could affect lysosomal homeostasis by 
interfering with the process of autophagic lysosomal reformation (21). Additional work is 
needed to investigate these hypotheses. 
 
 mTORC1 is a new druggable target in cystinosis. Indeed, mTORC1 inhibition results in 
restored lyso-autophagy pathway and related pathogenic cascade in Ctns
-/-
 PT cells. These 
rescue events lead to a significant improvement of the transport activity of PT cells. This 
finding is significant as a wide range of mTORC1 inhibitors is commercially available and 
some already used in clinics (22). Further studies using mTORC1 inhibitors in vivo in Ctns
-/-
 
rat model, which presents an early and more prominent kidney phenotype compared to the 
mouse model and it is closer to human in the evolutionary scale (23), will allow us to 





MATERIAL AND METHODS 
Antibodies and reagents. The following Antibodies were used: rat anti-LAMP1 (sc-19992, Santa Cruz 
Biotechnology); rabbit anti-LC3 (PM036, MBL); rabbit anti-p62/SQSTM1 (PM045, MBL); rabbit anti-
AQP1(OASA00210; Aviva Systems Biology); rabbit anti-GAPDH (2118, Cell Signaling Technology), mouse anti-β-
actin (A5441, Sigma-Aldrich); goat anti-CtsD (sc-6486, Santa Cruz Biotechnology); mouse anti-α-tubulin (T5168, 
Sigma-Aldrich); rat anti-HA (11867423001, Roche); rabbit anti-ZO-1 (sc-10804, Santa Cruz Biotechnology); rabbit 
anti-ZONAB (A303-070A, Bethyl Laboratories); rabbit anti-human transferrin (A0061, Dako);  rabbit anti-human Gc-
globulin (also known as VDBP, A0021, Dako); sheep anti-Megalin (gift from P. Verroust and R. Kozyraki, INSERM); 
rabbit anti-phospho-S6 Ribosomal Protein (4858, Cell Signaling Technology); rabbit anti-S6 Ribosomal Protein (2217, 
Cell Signaling Technology); rabbit anti-phospho-p70 S6 kinase 1 (9234, Cell Signaling Technology); rabbit anti-p70 S6 
kinase 1 (2708, Cell Signaling Technology); rabbit anti-phospho-4EBP1 (9451, Cell Signaling Technology); rabbit anti-
4EBP1 (9644S, Cell Signaling Technology); rabbit anti-Raptor (2280, Cell Signaling Technology); rabbit anti-RagA 
(4357, Cell Signaling Technology); rabbit anti-RagC (5466, Cell Signaling Technology); rabbit anti-phospho-AKT 
(13038, Cell Signaling Technology); rabbit anti-mTOR (7C10, Cell Signaling Technology), WGA FITC Conjugate (L 
4895, Sigma-Aldrich), Torin1 (CAS 1222998-36-8, TOCRIS Bioscience), Cysteamine (M6500-25G, Sigma-Aldrich), 
Rapamycin (CAS 53123-88-9, Sigma-Aldrich); L-CDME(857327-5G, Sigma-Aldrich ), L-Cystine (C7602-
25G),UO126 (#9903, Cell Signaling Technology). Biotinylated Lotus Tetragonolobus Lectin (LTL; B-1325 Vector 
Laboratories).  
 




 littermates (C57BL/6 
background). Mice were maintained under temperature-and humidity-controlled conditions with 12 h light/12 h dark 
cycles with free access to appropriate standard diet in accordance with the institutional guidelines of National Institutes 
of Health Guide for the Care and Use of Laboratory Animals. Kidney tissues and/or urines were collected for analyses. 
The mouse study protocols (University of Zurich) were approved by the local legal authority (Veterinary Office, Canton 
of Zurich, Switzerland). 
 
Generation and maintenance of Ctns rat model. The Ctns
-/- 
rat model has been produced and obtained by PolyGene 
AG by using CRISPR/Cas9 technology. This system was used to introduce site-specific double strand breaks into the 
genome inducing insertions and deletions by the endogenous repair mechanism of non-homologous end joining. Two 
single guide RNAs (sgRNAs) targeting the same region in the exon 3 of the Ctns gene were selected: CRISPR1a: 
ACCAACGTCAGCATTACCCT(TGG),CRISPR1b:CCATTTACCAGCTTCACAGT(GGG). The sgRNAs sequences 
were blasted against the rat genome for off-targets. A total of 146 rat embryos was injected with the combination of 
CRISPRs 1a/b. From these embryos, 90 survived and could be transferred into foster rats. A total of 34 pups was born 
from these injections. These pups were analyzed for changes in the Ctns locus. PCR was used to amplify the Ctns 
region surrounding the CRISPR-target site using the following primer combination: CTNS_R:5'-
ACACCCGAAGTACATGCAGA-3', CTNS_L:5'ACAGAGATGGG AAGAGCACA-3'. The resulting PCR product 
was digested by T7 endonuclease. Five animals show a positive signal indicating insertion or deletion in the Ctns locus. 
These changes were analyzed via PCR and sequencing. The following primer combinations were used 5’– 
AGGCACGATGGAGCAGTAAAG–3’ and 5’–ATGCACGAATGAGACCAGACC–3’. Here we selected and used a 
Ctns rat line harboring a deletion of 12bp and insertion of 8bp resulting in a premature stop codon in the exon 3 of Ctns 





 littermates (Sprague-Dawley background). Rats were maintained under temperature-
and humidity-controlled conditions with 12 h light/12 h dark cycles with free access to appropriate standard diet in 
accordance with the institutional guidelines of National Institutes of Health Guide for the Care and Use of Laboratory 
Animals. Kidney tissues and/or urines were collected for analyses at the time of sacrifice. The protocols for the  rat 
study (University of Zurich) were approved by the local legal authority (Veterinary Office, Canton of Zurich, 
Switzerland). 
 
Renal function parameters. The mice were placed overnight in metabolic cages with ad libitum access to food and 
drinking water; urine was collected over ice. Urine from rats were collected at the moment of sacrifice. Urine and blood 
parameters were measured by using a UniCel DxC 800 pro Synchron (Beckman Coulter, Fullerton, CA, USA), whereas 
urinary Clara cell protein (CC16) concentration was measured in duplicate by enzyme-linked immunosorbent assay 




Cystine measurement. Kidney tissues from mice or rats, or primary cultured cells were homogenized and lysed with 
Nethylmaleimide (NEM) solution containing 5.2 mmol l
−1
 N-ethylmaleide in 10 mmol l
−1
 potassium phosphate buffer 
adjusted to pH 7.4. The lysates were collected and precipitated with sulfosalicylic acid (12% w/v) and centrifuged at 
10,000 r.p.m. for 10 min at 10 °C. The resulting supernatant was dissolved in citrate loading buffer (Biochrom Ltd, 
Cambridge, UK) and 50 μl of this solution was analyzed by Biochrom 30 Plus Amino Acid Analyzer (Biochrom Ltd). 
The protein pellet was dissolved in 0.1 mol l
−1
 NaOH solution and the protein concentration was determined by Biuret 
method. The concentration of amino acids was measured by using a lithium high performance physiological column 
(Biochrom) followed by postcolumn derivatization with ninhydrin. The amino acids were identified according to the 
retention time and the ratio of the area between the two wavelengths (570 nm and 440 nm) and quantified by using 
EZChrom Elite software (Agilent Technologies Inc., Pleasanton, California, USA). Cystine concentration was 
normalized to the protein concentration and reported in nmol per mg protein. 
 
Kidney isolation and primary cultures of mouse PT cells. The kidneys were collected from Ctns mice or rats: one 
kidney was split transversally and one half was fixed and processed for immunostaining, whereas the other half was 
flash frozen, homogenized by Dounce homogenizer in 1 ml of RIPA buffer that contains protease and phosphatase 
inhibitors, and processed for western blot analysis. The contralateral kidney of the rat was flash frozen and used for RT-
qPCR analysis. The contralateral kidney of the mice was taken to generate primary culture of proximal tubule cells 
(mPTCs). Freshly micro-dissected PT segments were seeded onto collagen-coated chamber slides (C7182, Sigma-
Aldrich) and/or collagen-coated 6- or 24-well plates (145380 or 142475, Thermo Fisher Scientific), and cultured at 37 
°C and 5% CO2 in Dulbecco’s modified Eagle’s medium/F12 (21041-025, Thermo Fisher Scientific) with 0.5% 
dialyzed fetal bovine serum (FBS), 15mM HEPES (H0887, Sigma-Aldrich), 0.55mM sodium pyruvate (P2256, Sigma-
Aldrich), 0.1 ml l
−1
 nonessential amino acids (M7145, Sigma-Aldrich), hydrocortisone, human epidermal growth factor, 
epinephrine, insulin, triiodothyronine, transferrin (TF), and gentamicin/ amphotericin (Single Quots kit, CC-4127, 
Lonza), pH 7.40, 325 mOsm kg
−1
. The medium was replaced every 48 h. Confluent monolayers of mPTCs were 
expanded from the tubular fragments after 6–7 days, characterized by a high endocytic uptake capacity. These cells 
were mycoplasma free. All experiments were performed on confluent monolayers grown on chamber slides or plates. 
 
Starvation and treatments in Ctns mPTCs. Ctns mPTCs were starved by incubation in amino acid-free RPMI 
medium 1640 (US Biological) for 120 minutes, and stimulated with a standard amino acid mixture composed of MEM 
nonessential amino acid solution, MEM essential amino acid solution, and L-glutamine (Invitrogen, Thermo Fisher 
Scientific) for 60 minutes. At the indicated time-points, starved mPTCs were stimulated with Cystine (0.15 mM) or 
Cystine Dimethyl Ester (CDME, 0.15 mM). After stimulation, the final concentration of amino acids in solution was the 
same as in the in growth cell medium. mTOR kinase activity in Ctns
-/-
 cells was inhibited by addition of either 
Rapamycin (1μM) or Torin1 (250 nM) or Cysteamine (100 μM) in starvation medium for 6h. U0126 inhibitor of 
MAPK /ERK pathway was used as control (50 μM 6h in starvation medium).  Rescue experiments were performed by 
treating mPTCs with either Rapamycin (1μM) or Torin1 (250 nM) for 6h in growth cell medium. 
 
Immunofluorescence and confocal microscopy. Fresh mouse or rat kidneys were fixed by perfusion with 50–60 ml of 
4% PFA in PBS (158127, Sigma-Aldrich) before being snap-frozen in cryogenic Tissue-Tek OCT compound (Electron 
Microscopy Sciences, Hatfield, USA). The embedded tissues were sectioned at 5 μm and processed for 
immunofluorescent staining as previously described. The slides were quenched with 50mM NH4Cl, blocked with 5% 
BSA in PBS Ca/Mg (D1283, Sigma-Aldrich) for 30 min and stained with the primary antibodies diluted in blocking 
buffer overnight at 4 °C. After two washes in 0.1% Tween 20 (v/v in PBS), the slides were incubated with the 
corresponding fluorophore-conjugated Alexa secondary antibodies (Invitrogen) diluted in blocking buffer at room 
temperature for 1 h and counterstained with 1 μg LTL when appropriate and 1 μM 4’,6-diamino-2-phenylindole 
dihydrochloride (DAPI; D1306, Thermo Fischer Scientific). The slides were mounted in Prolong Gold Anti-fade 
reagent (P36930, Thermo Fisher Scientific), acquired on Leica SP8 confocal laser scanning microscope (Center for 
Microscopy and Image Analysis, University of Zurich) equipped with a Leica APO × 63 NA 1.4 oil-immersion 
objective at a definition of 1,024 × 1,024 pixels (average of 8 or 16 scans), adjusting the pinhole diameter to 1 Airy unit 
for each emission channel to have all of the intensity values between 1 and 254 (linear range). The micrographs were 
processed with Adobe Photoshop (version CS5, Adobe System, Inc., San Jose, USA) software. Quantitative image 
analysis was performed by selecting randomly ∼ 5 visual fields per each slide that included at least three to five PTs 
(LTL positive), using the same setting parameters (i.e., pinhole, laser power, and offset gain and detector amplification 
below pixel saturation). ImageJ software was used for the analysis.The mPTCs were fixed in 4% PFA and processed for 
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immunofluorescent staining as previously described. Briefly, after incubation with blocking/permeabilization solution 
(0.1% Saponin,0.5% BSA and 50 mM NH4Cl in PBS), mPTCs were stained overnight with the appropriate primary 
antibodies and 45 min with the suitable fluorophore-conjugated Alexa secondary antibodies (Invitrogen). 
Immunostained mPTCs were analyzed by a Leica SP5 confocal laser scanning microscope using the settings described 
above. The quantitative cell image analyses were performed by using the open-source cell image analysis software 
CellProfiler™. In particular, the specific module “Measure-Object-Intensity-Distribution” was used to score the number 
of LAMP1+ and BSA+ structures and the diameter of LAMP1+ vesicles. The pipeline “Cell/particle counting and 
scoring the percentage of stained objects” was used to score either the numbers of LAMP1+ vesicles containing mTOR 
or Pepstatin A. The module “MeasureObjectIntensityDistribution” was used to score the  fluorescence intensity of 
LAMP1+ structures contained into perinuclear region (area defined by the first 10 bin) and peripheral region (area 
defined by the last 10 bin) of the cells. Briefly, the software generates 20 concentrically bin around the nucleus of each 
cell and 15 calculates the intensity distribution for each bin. The “Cytoplasm–Nucleus Translocation Assay” was used 
to score the numbers of Bromodeossiuridine (BrdU) - positive cells. The fluorescence intensity of cellular ROS was 
measured by using ImageJ. 
 
Endocytosis assay. The endocytic uptake was monitored in mPTCs cells following incubation for 60 min at 4 °C with 
50 μg ml−1 bovine serum albumin (BSA)–Alexa- Fluor-488 (A13100, Thermo Fisher Scientific) in complete HEPES-
buffered Dulbecco’s modified Eagle’s medium. The cells were given an acid wash and warmed to 37 °C in growth cell 
medium for 15 min before being fixed and processed for immunofluorescence analyses. 
 
Lysosomal activity. The detection of lysosomal activity was performed in live mPTCs using Bodipy-FL-PepA 
(P12271, Thermo Fischer Scientific) according to the manufacturer’s specifications. The cells were pulsed with 
1 μM Bodipy-FL-Pepstatin A in Live Cell Imaging (A14291DJ, Thermo Fischer Scientific) medium for 1 h at 37 °C 
followed by fixation and immunostaining with anti-LAMP1 and subsequently analyzed by confocal microscopy. 
 
ROS detection. The cells were pulsed with 5 μM CellROX Green Reagent (C10444, Thermo Fisher Scientific) for 10 
min in live-cell imaging at 37 ° C. After washing, the cells were subsequently analysed by confocal microscopy.  
 
Proliferation assay. mPTCs were incubated with BrdU (1.5 μg ml−1; Sigma-Aldrich) in accordance with the 
manufacturer’s protocol. BrdU-labeled cells were immunostained with rat anti-BrdU antibody (Oxford 
Biotechnology; 1:500), followed by the specific secondary biotinylated goat anti -rat antibody (1:300; Jackson 
Immunoresearch), mounted with the Prolong Gold Anti-fade reagent and subsequently analyzed by confocal 
microscopy. 
 
Electron microscopy. mPTCs were fixed in 2% PFA/2.5% glutaraldehyde (for zebrafish) and 4% PFA/0.1% 
glutaraldehyde (for cells) in 100 nM sodium cacodylate, at pH 7.43, dehydrated, and embedded in LR-White resin 
(LADD Research Industries). The grids were viewed on a Philips CM100 transmission electron microscope at 
80 kV. Autophagic vacuoles were identified and categorized as autophagosomes or autophagolysosomes according 
to standard criteria. The term autophagic vacuole was used when the differentiation between autophagosome and 
autophagolysosomes was not possible. The number of autophagic vacuoles was determined by using i -TEM 
software (Olympus, Germany).  
 
Quantitative real-time PCR.Total RNA was extracted from rat kidney tissues using Aurum Total RNA Fatty and 
Fibrous Tissue Kit (Bio-Rad, Hercules, CA). One microgram of RNA was used to perform the reverse transcriptase 
reaction with iScript cDNA Synthesis Kit (Bio-Rad). Changes in mRNA levels of the target genes were determined 
by relative reverse transcriptase-quantitative PCR with a CFX96 Real-Time PCR Detection System (Bio-Rad) using 
iQ SYBR Green Supermix (Bio-Rad). The analyses were performed in duplicate with 100 nM of both sense and 
anti-sense primers in a final volume of 20 μl using iQ SYBR Green Supermix (Bio -Rad). Specific primers were 
designed using Primer3. PCR conditions were 95 °C for 3 min followed by 40 cycles of 15 s at 95 °C, 30 s at 60 °C. 
The PCR products were sequenced with the BigDye terminator kit (Perkin Elmer Applied Biosystems) using 
ABI3100 capillary sequencer (Perkin Elmer Applied Biosystems). The efficiency of each set of primers was 
determined by dilution curves (Supplementary Table 1 and 2). The program geNorm version 3.4 was applied to 
characterize the expression stability of the candidate reference genes in kidneys and six reference genes were 
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selected to calculate the normalization factor. The relative changes in targeted genes over Gapdh mRNAs were 
calculated using the 2−ΔΔCt formula. 
 
Western blotting. Proteins were extracted from mouse or rat kidney tissues or mPTCs, lysed using a buffer, which 
contains protease (1836153001, Roche) and phosphatase inhibitors (04906845001, PhosSTOP Sigma), followed by 
sonication and centrifugation at 14,000 g for 10 min at 4 ° C. The samples were thawed on ice, normalized for 
protein (20 μg per lane), dissolved in Laemmli sample buffer, and separated by SDS -PAGE under reducing 
conditions. After blotting onto polyvinylidene difluoride and blocking with 5% non-fat milk (1706404, Bio-Rad 
Laboratories) diluted in PBS, the membranes were incubated overnight at 4 °C with primary antibody, washed, 
incubated with peroxidase-labeled secondary antibody, and visualized with enhanced chemiluminescence 
(WBKLS0050, Millipore, Life technologies). For re-probing, the membranes were rinsed, incubated for 30 min at 
55 °C in a stripping buffer (62.5 mmol l 
−1
 Tris-HCl, 2% SDS, 100mM mercaptoethanol, adjusted to pH 7.4), before 
incubation with primary antibodies. Quantitative analyses were performed by scanning the blots and measuring the 
relative density of each band normalized to β-actin, GAPDH, or α-tubulin with ImageJ software.  
 
Data analysis and statistics. The quantitative data were expressed as means ± standard error of the mean (s.e.m.). 
Differences between experimental groups were evaluated using analysis of variance followed by post hoc test, 
when appropriate. When only two groups were compared, unpaired or paired two tailed Student’s t-tests were used 
as appropriate. No statistical methods were used to predetermine the sample size. The sample size (n of biological 
replicates derived from distinct mice) of each experimental group is described in figure legends. GraphPad Prism 










1. Devuyst, O. and Luciani, A. (2015) Chloride transporters and receptor-mediated endocytosis in the renal proximal 
tubule. The Journal of physiology, 593, 4151-4164. 
 
2. Gahl, W.A., Thoene, J.G. and Schneider, J.A. (2002) Cystinosis. The New England journal of medicine, 347, 111-
121. 
 
3. Festa, B.P., Chen, Z., Berquez, M., Debaix, H., Tokonami, N., Prange, J.A., Hoek, G.V., Alessio, C., Raimondi, A., 
Nevo, N. et al. (2018) Impaired autophagy bridges lysosomal storage disease and epithelial dysfunction in the kidney. 
Nature communications, 9, 161. 
 
4. Andrzejewska, Z., Nevo, N., Thomas, L., Chhuon, C., Bailleux, A., Chauvet, V., Courtoy, P.J., Chol, M., Guerrera, 
I.C. and Antignac, C. (2016) Cystinosin is a Component of the Vacuolar H+-ATPase-Ragulator-Rag Complex 
Controlling Mammalian Target of Rapamycin Complex 1 Signaling. Journal of the American Society of Nephrology : 
JASN, 27, 1678-1688. 
 
5. Zoncu, R., Bar-Peled, L., Efeyan, A., Wang, S., Sancak, Y. and Sabatini, D.M. (2011) mTORC1 senses lysosomal 
amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science (New York, N.Y.), 334, 
678-683. 
 
6. Settembre, C., Fraldi, A., Medina, D.L. and Ballabio, A. (2013) Signals from the lysosome: a control centre for 
cellular clearance and energy metabolism. Nature reviews. Molecular cell biology, 14, 283-296. 
 
7. Rega, L.R., Polishchuk, E., Montefusco, S., Napolitano, G., Tozzi, G., Zhang, J., Bellomo, F., Taranta, A., Pastore, 
A., Polishchuk, R. et al. (2016) Activation of the transcription factor EB rescues lysosomal abnormalities in cystinotic 
kidney cells. Kidney international, 89, 862-873. 
 
8. Sardiello, M., Palmieri, M., di Ronza, A., Medina, D.L., Valenza, M., Gennarino, V.A., Di Malta, C., Donaudy, F., 
Embrione, V., Polishchuk, R.S. et al. (2009) A gene network regulating lysosomal biogenesis and function. Science 
(New York, N.Y.), 325, 473-477. 
 
9. Prange, J.A., Bieri, M., Segerer, S., Burger, C., Kaech, A., Moritz, W. and Devuyst, O. (2016) Human proximal 
tubule cells form functional microtissues. Pflugers Archiv : European journal of physiology, 468, 739-750. 
 
10. Yu, Y., Kudchodkar, S.B. and Alwine, J.C. (2005) Effects of simian virus 40 large and small tumor antigens on 
mammalian target of rapamycin signaling: small tumor antigen mediates hypophosphorylation of eIF4E-binding protein 
1 late in infection. Journal of virology, 79, 6882-6889. 
 
11. Xie, J., Wang, X. and Proud, C.G. (2016) mTOR inhibitors in cancer therapy. F1000Research, 5. 
 
12. Puertollano, R. (2014) mTOR and lysosome regulation. F1000prime reports, 6, 52. 
 
13. Bar-Peled, L. and Sabatini, D.M. (2014) Regulation of mTORC1 by amino acids. Trends in cell biology, 24, 400-
406. 
 
14.Wyant, G.A., Abu-Remaileh, M., Frenkel, E.M., Laqtom, N.N., Dharamdasani, V., Lewis, C.A., Chan, S.H., Heinze, 
I., Ori, A. and Sabatini, D.M. (2018) NUFIP1 is a ribosome receptor for starvation-induced ribophagy. Science (New 




15. Kalatzis, V., Nevo, N., Cherqui, S., Gasnier, B. and Antignac, C. (2004) Molecular pathogenesis of cystinosis: 
effect of CTNS mutations on the transport activity and subcellular localization of cystinosin. Human molecular 
genetics, 13, 1361-1371. 
 
16.Wilmer, M.J., Emma, F. and Levtchenko, E.N. (2010) The pathogenesis of cystinosis: mechanisms beyond cystine 
accumulation. American journal of physiology. Renal physiology, 299, F905-916. 
 
17. Pisoni, R.L., Acker, T.L., Lisowski, K.M., Lemons, R.M. and Thoene, J.G. (1990) A cysteine-specific lysosomal 
transport system provides a major route for the delivery of thiol to human fibroblast lysosomes: possible role in 
supporting lysosomal proteolysis. The Journal of cell biology, 110, 327-335. 
 
18. Settembre, C., Zoncu, R., Medina, D.L., Vetrini, F., Erdin, S., Erdin, S., Huynh, T., Ferron, M., Karsenty, G., 
Vellard, M.C. et al. (2012) A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR 
and TFEB. The EMBO journal, 31, 1095-1108. 
 
19. Ivanova, E.A., van den Heuvel, L.P., Elmonem, M.A., De Smedt, H., Missiaen, L., Pastore, A., Mekahli, D., 
Bultynck, G. and Levtchenko, E.N. (2016) Altered mTOR signalling in nephropathic cystinosis. Journal of inherited 
metabolic disease, 39, 457-464. 
 
20. Abu-Remaileh, M., Wyant, G.A., Kim, C., Laqtom, N.N., Abbasi, M., Chan, S.H., Freinkman, E. and Sabatini, 
D.M. (2017) Lysosomal metabolomics reveals V-ATPase- and mTOR-dependent regulation of amino acid efflux from 
lysosomes. Science (New York, N.Y.), 358, 807-813. 
 
21. Rong, Y., McPhee, C.K., Deng, S., Huang, L., Chen, L., Liu, M., Tracy, K., Baehrecke, E.H., Yu, L. and Lenardo, 
M.J. (2011) Spinster is required for autophagic lysosome reformation and mTOR reactivation following starvation. 
Proceedings of the National Academy of Sciences of the United States of America, 108, 7826-7831. 
 
22. Zheng, Y. and Jiang, Y. (2015) mTOR Inhibitors at a Glance. Molecular and cellular pharmacology, 7, 15- 
 
23. Nei, M., Xu, P. and Glazko, G. (2001) Estimation of divergence times from multiprotein sequences for a few 
mammalian species and several distantly related organisms. Proceedings of the National Academy of Sciences of the 









Figure 1. Abnormal lysosome dynamics and autophagy in proximal tubules of Ctns-/ - mice (A) Representative confocal micrographs of  LAMP1+ structures (red) and quantification of the diameter of LAMP1+ vesicles contained in 
LTL+ (green) proximal tubules from 6 and 16 weeks old Ctns mice.(two-tailed unpaired Student’s t-test, ***P < 0.001 relative to 6 weeks old Ctns+/+/ Ctns-/ - and 16 weeks old Ctns+/+ kidneys). (B) Western blotting and densitometry 
analyses of LAMP1and Cts-D protein levels in whole kidney lysates from Ctns mice (two-tailed unpaired Student’s t-test, *P < 0.05 (LAMP1) and **P < 0.01, ***P < 0.001 (Cts-D) relative to 6 or 16 weeks old Ctns+/ + kidneys, n=3-4 
mice per group). α-Tubulin and β-actin were used as a loading control. (C) Western blotting and densitometry analyses of LC3 protein levels in whole kidney lysates from Ctns mice (two-tailed unpaired Student’s t-test, ***P < 0.001 
relative to 16 weeks old Ctns+/+ kidneys, n=3-4 mice per group). β-actin was used as a loading control. (D) Representative confocal micrographs of LC3+ (red) structures and LTL+ (green) proximal tubule from 6 and 16 weeks old Ctns 








Figure 2. Cystine storage and abnormal mTORC1 signalling in Ctns-/ - kidneys. (A) Intracellular cystine levels were measured by HPLC in kidneys derived from 6 (n=4 mice per group) and 16 weeks old (two-tailed unpaired 
Student’s t-test, ***P<0.001 relative to 16 weeks old Ctns+/ + kidneys, n=6 mice per group) Ctns mice. (B) Western blotting and densitometry analysis of S6 and p-S6 protein levels in whole kidney lysates from 6 (n=3 mice per group) and 
16 weeks old (two-tailed unpaired Student’s t-test **P < 0.01 relative to 16 weeks old Ctns+/+ kidneys, n=4 mice per group) Ctns mice. β-actin was used as a loading control. (C) Representative confocal micrographs of p-S6+ structures 









Figure 3.  Cystine storage is associated with abnormal mTORC1 signaling and impaired lyso-autophagy in Ctns -/- rats. (A) Intracellular cystine levels were measured by HPLC in 20 weeks old Ctns rat kidneys. (n=5 rats per group, 
two-tailed unpaired Student’s t-test, **P < 0.01 relative to Ctns+/+ kidneys). (B) Western blotting and densitometry analysis of S6 and p-S6 protein levels in whole kidney lysates derived from 20 weeks old Ctns rat kidneys (two-tailed 
unpaired Student’s t-test, *P < 0.05 relative to Ctns+/+ kidneys; n=3 rats per group). (C) Representative confocal micrographs of p-S6+ structures (green) and Megalin+ (red) proximal tubules derived from Ctns rat kidneys. Nuclei 
counterstained with DAPI (blue). (D) Western blotting and densitometry analyses of Cts-D protein levels in whole kidney lysates from Ctns rats (two-tailed unpaired Student’s t-test, **P < 0.01 relative to Ctns+/+ kidneys, n = 3-4 rats per 
group). α-Tubulin was used as a loading control. (E) Western blotting and densitometry analyses of LC-3 protein levels in whole kidney lysates from Ctns rats (two-tailed unpaired Student’s t-test, *P < 0.05 relative to Ctns+/+ kidneys, 









Figure 4.  Altered mTORC1 sensing in mPTCs derived from Ctns-/- symptomatic mice. (A) Western blotting and densitometry analyses of phosphorylated and total form of S6 K1, S6 and 4EBP1 protein levels in starved (RPMI, 120 
minutes) and amino acids replenished (60 minutes) 16 weeks old Ctns mPTCs (n=3 mice per group). β-actin was used as loading control. (B) 16 weeks old Ctns mPTCs were immune-stained with anti-mTOR (green) and anti-LAMP1 
(red) antibodies. Quantification of mTOR/LAMP1+ vesicles (in percentage of total LAMP1; n = 5 randomly selected fields per condition, with each containing ~ 20–25 cells). Nuclei counterstained with DAPI (blue).(C) Western blotting 
and graphical representation of p-S6/S6 ratio at each time point analysed over 24 hours of starvation (RPMI) in 16 weeks old Ctns mPTCs. β-actin was used as loading control. Plotted data represent mean ± SEM; two tailed unpaired 







Figure 5.  Cystinosin transport activity is key for maintaining mTORC1 sensing and lyso-autophagy flux. (A) Schematic representation of the predicted cystinosin structure. Blue indicates the N-terminal uncleavable signal peptide, 
orange indicates the seven potential N-glycosylation sites, black indicates the third cytoplasmic loop, and red indicates the C-terminal GY-DQ-L lysosomal targeting signal. A green star in the sixth transmembrane domain associated with 
cystine transport indicated the position of the G339R missense mutation. (B-C) Ctns mPTCs were transduced with either Null (Ad-NULL) or hemagglutinin-tagged CTNS (Ad- HA-CTNS) or hemagglutinin-tagged CTNS G339R (Ad- 
HA-CTNS G339R) bearing adenoviral particles for 2 days. (B) Western blotting of Hemagglutinin tag (HA) and the phosphorylated and total form of S6 protein level in Ctns mPTCs in basal, starved (RPMI, 120 minutes) or amino acids 
replenished (60 minutes) condition. GAPDH was used as loading control. (C) Western blotting and densitometry analyses of Hemagglutinin tag (HA), SQSTM1 and LC3 protein level in Ctns mPTCs in basal, starved (RPMI, 120 minutes)  







Figure 6.  Cystine accumulation drives mTORC1 activation. (A) Cystine levels in Ctns mPTCs either starved (RPMI, 120 minutes) or starved and supplemented with Torin1 (250 nM) or cysteamine (100 μM) were assessed by HPLC 
(Ctns+/+ starved n=6 ; Ctns-/- starved n=6; Ctns-/- starved +Torin1 n=3; Ctns-/- starved +Cysteamine n=3; two tailed unpaired Student’s t test, *P < 0.05, relative to starved Ctns-/- mPTCs) (B) Western blotting and densitometry analyses of 
phosphorylated and total form of S6 K1 and S6 protein levels in starved (RPMI, 120 minutes), amino acids replenished (60 minutes) and starved Ctns mPTCs supplemented with either Torin1 (250 nM) or cysteamine (100 μM). β-actin 
was used as loading control (n=2 mice per group). (C) Cystine levels in Ctns+/+ mPTCs either starved (RPMI, 120 minutes) or starved and supplemented with Cystine (0.15 mM) or supplemented with CDME (0.15 mM), at the indicated 
time points, were assessed by HPLC (starved n=7 ; +Cystine 0.5h n=3; +Cystine 6h n=4; +CDME 0.5h n=3; +CDME 6h n=3; two tailed unpaired Student’s t test, ***P < 0.001, relative to Ctns+/+ mPTCs +Cystine 0.5h or +CDME 0.5h). 
(D) Western blotting and densitometry analyses of phosphorylated and total form of S6 K1 and S6 protein levels in starved (RPMI, 120 minutes), amino acids replenished (60 minutes) and starved Ctns+/+ mPTCs supplemented with either 
Cystine (0.15 mM) or CDME (0.15mM) at the indicated time point. β-actin was used as loading control (two tailed unpaired Student’s t test, *P < 0.05, **P<0.01, ***P<0.001 relative to starved or cystine or CDME replenished Ctns+/+ 
mPTCs at the indicated time points; n=3 mice per group). (E) Starved (RPMI, 120 minutes), amino acids replenished (60 minutes) and starved Ctns+/+ mPTCs supplemented with either Cystine (0.15 mM) or CDME (0.15mM) were 





Figure 7.  mTORC1 signaling is independent on MAPK/ERK pathway or homeostatic changes of its regulatory subunits in Ctns-/- mPTCs. (A) Graphical scheme showing the molecular pathways inhibited by UO126, Rapamycin 
and Torin1. (B) Western blotting and densitometry analyses of phosphorylated and total form of S6 K1 and S6 protein levels in starved (RPMI, 120 minutes), amino acids replenished (60 minutes) and starved mPTCs supplemented with 
either Torin (250 nM) or Rapamycin (1μM) or U0126 (50 μM) . β-actin was used as loading control ( two tailed unpaired Student’s t test, *P < 0.05;  relative to starved or amino acids replenished Ctns+/+or Ctns-/- mPTCs n=3 mice per 
group). (C-D) Western blotting and densitometry analyses of Raptor, RAG A, RAG C and p-AKT protein levels in starved (RPMI, 120 minutes) and amino acids replenished (60 minutes) mPTCs derived from 6 and 16 weeks Ctns mice. 






Figure 8.  mTORC1 Inhibition in Ctns-/- mPTCs rescues lyso-autophagy pathway & downstream PT dysfunction. (A-G) Ctns mPTCs were analysed in either baseline or in media supplemented with Torin1 (250 nM) or Rapamycin 
(1μM). (A) Ctns mPTCs were immune-stained with anti-PM marker (green) and anti-LAMP1 (red) antibodies. Quantification of the size and position of LAMP1+ vesicles (n =5 randomly selected fields per condition, with each containing 
~ 20–25 cells). (B and D) Western blotting and densitometry analysis of Cts-D and LC3 protein levels in Ctns mPTCs (C) Ctns mPTCs were loaded with Bodipy-FL-PepA (1 μM, for 1 h at 37 °C, green), immunostained with anti- 
LAMP1 antibody (red) and analysed by confocal microscopy. Quantification of numbers of PepA/LAMP1+ structures (in percentage of total lysosomes; n = 5 randomly selected fields per condition, with each containing ~ 20–25 cell). 
(E) Ctns mPTCs were immunostained with anti-ZO-1 (green) antibody and analysed by confocal microscopy. (F) Ctns mPTCs were loaded with bromodeoxyuridine, immunostained with anti-BrdU antibody and analysed by confocal 
microscopy. Quantification of numbers of BrdU+ cells (in percentage of total nuclei) obtained from five randomly selected fields per condition, with each containing ~ 20–25 cells. (G) Ctns mPTCs were loaded with Al647-BSA and 
imaged by confocal microscopy. Quantification of numbers of Al647-BSA+ structures (n = 49–85 cells pooled from three mouse kidneys per condition; each point representing the number of BSA+ structures in a cell). Plotted data 
represent mean ± SEM; two tailed unpaired Student’s t test, *P < 0.05, **P<0.01, ***P<0.001 relative to Ctns+/+or Ctns-/- mPTCs in basal condition. Nuclei counterstained with DAPI (blue)
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Supplementary Figure 1.  Proximal tubular dysfunction and impaired autophagy in  Ctns-/ - mouse kidneys. (A) CC16 was measured by Elisa in urine collected from 6 (n=4 mice per group) and 16 weeks old mice (two-tailed 
unpaired Student’s t-test, **P<0.01 relative to 16 weeks old Ctns+/+, n=8-11 mice per group). (B) Representative confocal micrographs of SQSTM1 structures (red) and LTL (green) proximal tubules from 6 and 16 weeks old Ctns 















Supplementary Figure 2.  Validation of the proximal tubule dysfunction in Ctns-/- rat model. (A) CRISPR/Cas9- induced deletion (blue)/insertion (green), generates a frame shift of the open reading frame, resulting in premature 
stop codon (TGA, red) in exon 3. (B) Genomic DNA analyses of Ctns and Gapdh by PCR and agarose gel electrophoresis isolated from kidney biopsies of Ctns rats. (C) Ctns and Gapdh expression in kidneys biopsies were analyzed 
by quantitative RT-PCR. (n=3 rats per group). (D) Dot plot representing the measurement of body weight (n= 6-9 rats per group), (E) urinary CC16 (n=6-8 rats per group) and (F) urinary albumin (n= 5-9 rats per group). (G) Western 
blotting and densitometry analyses of urinary Transferrin (TF) and Vitamin D Binding Protein (VDBP) (n= 3-4 rats per group). (H) Western blotting and densitometry quantification of Megalin in kidneys lysates (n= 3 rats per 
group). (I) Kidneys were immune-stained with anti- Megalin (red) antibody and stained afterwards with AQP1 (green, proximal tubule marker). Nuclei counterstained with DAPI (blue). Scale bars: 25 μm. (J) The mRNA kidney 
levels of Pcna, Ccnd1, Lrp2, Cubn, Vil1, Slc5a2 and Clcn5 were analyzed by real-time qPCR. Gene target expression normalized to NF and relative to Ctns+/+ rats (n = 5 rats per group). All the urine parameters were normalized to 









Supplementary Figure 3.  mTORC1 sensing in mPTCs derived from Ctns-/-asymptomatic mice. (A) Intracellular cystine levels were measured by HPLC in mPTCs  derived from 6 (two-tailed unpaired Student’s t-test,  ns, not 
significant, n=6 mice per group) and 16 week old (two-tailed unpaired Student’s t-test,  ***P<0.001, n=6 mice per group) Ctns mice. (B) Western blotting and densitometry analyses of phosphorylated and total form of S6 K1, S6 
and 4EBP1 protein levels in starved (RPMI, 120 minutes) and amino acids replenished (60 minutes) 6 weeks old Ctns mPTCs. β-actin was used as loading control (n=3 mice per group). Plotted data represent mean ± SEM; two tailed 













Supplementary Figure 4. mTORC1 Inhibition in Ctns-/- mPTCs rescues PT dysfunction and reduces intracellular accumulation of ROS (A-C) mPTCs were analysed in either baseline or in media supplemented with Torin1 
(250 nM) or Rapamycin (1μM). (A) Representative electron micrograph of autophagic vesicles in Ctns mPTCs (B) Ctns mPTCs were loaded with CellROX (cellular ROS probe; 5 μM for 10 min at 37 °C) and analysed by live 
confocal microscopy. Quantification of CellROX fluorescence intensity was obtained from five randomly selected fields per condition, with each containing ~ 20–25 cells (C) mPTCs were immunostained with anti-ZONAB (green) 






IV. DISCUSSION AND PERSPECTIVES  
The epithelial cells lining the PT of the kidney carry out the reabsorption of ~80% of ions and 
solutes, which are daily filtered through the glomerulus and that would otherwise be lost in the 
urine. The expression of multi-ligand endocytic receptors megalin and cubilin and the recycling-
degradative activity of the endolysosomal network sustain the terminal differentiation of the 
epithelial PT cells, hence their reabsorptive activity (107). Rare, congenital disorders involving the 
endocytic receptors (e.g. Donnai–Barrow and Imerslund-Gräsbeck syndrome) or the endolysosomal 
pathway (e.g. Dent disease 1 and 2, Lowe syndrome and cystinosis) cause PT dysfunctions, 
associated with RFS and severe metabolic complications including CKD (87). Although these 
disorders show marked clinical overlap, their genetic causes are heterogeneous and affect proteins 
with very different roles along the endolysosomal compartment. CLCN5, mutated in Dent disease 1, 




 exchange transporter 5 (ClC-5), which contributes to the 
acidification of EEs (86). OCRL, mutated in Dent disease 2/Lowe syndrome, encodes an inositol 
polyphosphate 5-phosphatase OCRL acting at the clathrin-coated vesicles, EEs and lysosomes 
where it controls the homeostasis of PI(4,5)P2 -essential modulators of membrane trafficking (34). 
Finally, CTNS, mutated in cystinosis, encodes a H
+
-coupled lysosomal transporter, allowing the 
export of cystine from the lysosomal lumen to the cytosol (96). Although the past two decades have 
witnessed tremendous progresses in understanding the role of ClC-5, OCRL and CTNS in 
maintaining the endolysosomal trafficking, further work is needed to understand the molecular 
mechanisms linking loss of function of these proteins with disorders of the kidney PT. The lack of 
adequate cellular models phenocopying critical aspects of epithelial transport and the absence of 
animal models mimicking the PT diseases hinder the progression of these investigations. In this 
thesis, in order to elucidate how loss of function of endolysosomal genes lead to PT dysfunction, we 
characterized faithful disease mouse models for Dent disease, Lowe Syndrome and nephropathic 
cystinosis and derived well differentiated primary culture of PT cells from the kidneys of these 
disease-mouse models. By using cutting-edge technologies and genetic and pharmacological 
manipulations in vitro and in vivo, we unveiled new pathogenic cascades linking defects in 
endocytosis, vesicular trafficking, lysosomal function and autophagy with the loss of differentiation 
and function of PT cells. These studies allowed us to validate new druggable targets for 





In the first part of this thesis, we characterized the first OCRL-deficient mouse model mimicking 
renal and extra-renal manifestations encountered in patients with Dent disease 2/Lowe syndrome. 
Our studies show that OCRL-deficient mice exhibit locomotor defects and a global impairment of 
the muscular apparatus. Furthermore, the absence of OCRL drives endolysosomal defects and 
epithelial dysfunction in the kidney PT resulting in LMW proteinuria. In this work, we also 
evidenced a partial convergence of disease-mechanisms and kidney tubular dysfunction between 
mouse models deficient in ClC-5 (Dent disease1) and OCRL (Lowe syndrome/ Dent disease 2). 
Altogether, these findings provide new insights into the mechanisms of endocytosis and the 
pathogenesis of Dent disease/Lowe syndrome. 
One of the major limitations to assess the role of OCRL in the pathogenesis of PT 
dysfunction is the lack of OCRL-deficient mouse models that faithfully reproduce the clinical 
phenotype described in patients. Indeed, Ocrl KO mice show no kidney, eye or brain defects. The 
absence of kidney phenotype in Ocrl KO mice is due to the compensatory role of INPP5B, the 
closest paralogue of OCRL in mice and humans (45% of sequence identity) (108). Indeed, the 
double kidney tubular deletion of OCRL and INPP5B in mice results in a remarkable PT endocytic 
dysfunction phenocopying the kidney defect observed in Dent disease 2/Lowe syndrome (109). 
Despite the clinical similarity with the human disorders, investigations of this mouse strain do not 
allow to discriminate the individual biological role of OCRL and INPP5B in the pathophysiology of 
the kidney disease. In our studies, we overcame this issue by using a mouse model where mouse 
Inpp5b was replaced by human INPP5B in a whole body Ocrl
Y/−
 mouse (92). The reinsertion of the 
human gene did not compensate for the PT endocytic defect caused by the loss of OCRL function 
and provided a genetic background, which allowed the identification of cellular dysfunctions due to 
the single loss of OCRL activity. How INPP5B compensates the PT endocytic defects caused by the 
loss of OCRL function in mice but not in human remains unclear. Although these two enzymes 
share many common interactors and present similar intracellular localization, OCRL is involved in 
the process of endocytosis in PT cells but not INPP5B (34). Thus, it is unlikely that differences in 
the expression or splicing of INPP5B between mice and human can fully account for the 
compensation of the endocytic defect observed in Ocrl KO mice. More studies are required to 
understand the mechanisms underlying the murine rescue operated by Inpp5b.  
The Ocrl
Y/-
 mice exhibited a specific defect in clathrin-receptor mediated endocytosis (110), 
which was mirrored by a selective LMW proteinuria occurring early and in absence of changes in 
other urine metabolites or signs of renal failure. These data indicate that Ocrl
Y/-
 transgenic mice 
faithfully mimics the partial Fanconi syndrome described in the majority of patients carrying 
mutations in OCRL (34), thus validate this in vivo system as a reliable tool for kidney therapeutic 
155 
 
interventions. The LMW proteins are reabsorbed by megalin (LRP2) and cubilin endocytic 
receptors expressed at the apical membrane of PT cells (107). Our analysis revealed a remarkable 
decrease of megalin receptor in the kidneys of OCRL-deficient mice. These data explain the 
massive LMW proteinuria observed in Ocrl
Y/-
 transgenic mice and are in line with previous results 
obtained from ocrl
-/-
 zebrafish model, demonstrating the evolutionary conservation of the role of 
OCRL in endocytosis (111).  
When we compared the renal phenotype of OCRL-deficient mice with those of ClC-5-
deficient mice, we observed an overlap of many pathological features. Also Clcn5
Y/-
 mice showed a 
defective megalin expression associated with an impaired RME and LMW proteinuria. However, 
this mouse model presented a PT dysfunction, which was more severe compared to the OCRL-
deficient mice with extended defects to the fluid-phase endocytosis and a complete Fanconi 
syndrome characterized by glycosuria, phosphaturia and calciuria. These differences could be 
explained by the broader function of ClC-5 compared to OCRL during the endocytic process. 
Despite both proteins have been described to be involved in the modulation of actin during the 
maturation steps of the clathrin-mediated endocytosis, ClC-5 plays an additional role in sustaining 
the acidification of apical early endosomes, which is key for the global trafficking of the 
endosomal-recycling compartment (90, 91). Accordingly, the loss of ClC-5 function would result in 
a wider dysfunction of the apical apparatus of PT cells. This could explain why the transport defects 
observed in the ClC-5-deficient mouse model were extended also to substances, which are not 
reabsorbed via receptor-mediated processes. On the contrary, OCRL function is specifically 
involved in clathrin-mediated endocytosis, which is needed for the receptor-mediated uptake of 
proteins (91). This would explain the selective LMW proteinuria observed in Lowe syndrome 
mouse model. Further studies are needed to better understand the cross-talk between these two 
proteins and their biological overlapping functions. 
The mechanism by which the loss of OCRL or ClC-5 might affect megalin protein levels 
remains to be clarified. A transcriptional effect seems unlikely, as we did not observe changes in 
Lrp2 mRNA levels between control and OCRL- or ClC-5 -deficient mice. The decrease of apical 
megalin may reflect an increased shedding of the receptor in the urine in response to the endolysosomal 
engorgement observed in our disease mouse models (17). Preliminary data (not shown in this thesis) 
indicating a higher abundance of megalin/LRP2 fragments in OcrlY/− urines compared to controls, 
support this hypothesis. By contrast, no megalin fragments were detected in the urines of Clcn5
Y/-
 
mice, suggesting that the absence of ClC-5 does not trigger the mechanism of shedding. These 
differences might be related to the specific roles of OCRL or ClC-5 in the homeostasis of PT cells. 
For instance, the lack of OCRL severely disrupts membrane trafficking and induces the misrouting 
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of lysosome enzymes to the plasma membrane (see below, 91). This event could result in an 
increased concentration of proteases at the apical surface and in the urine (112), which would 
facilitate the cleavage of the endocytic receptors and their release in the lumen. Although we 
observed a defective lysosomal function in ClC-5 deficient cells, this defect is not characterized by 
mis-trafficking of the lysosomal enzymes (data not shown) but rather due to defective acidification 
of the endolysosomal compartment (113), which impairs lysosomal proteolysis. The latter could 
drive an aberrant degradative response from the proteasome compartment, which in turn could 
increase the turnover of megalin. The rescue of megalin levels observed in ClC-5 deficient cells 
upon inhibition of proteasome activity supports this hypothesis (data not shown). Further studies 
have to address whether additional pathophysiological mechanisms contribute to the reduction of 
megalin in our models (eg. urinary excretion of LRP2-containing exosomes) (114). Because 
impaired homeostasis of megalin is a central event in the pathogenesis of Lowe syndrome and Dent 
disease, these insights could help to identify crucial targets for therapeutic approaches. 
Despite the marked decrease of megalin, a significant pool of this receptor was still detected 
in Ocrl
Y/-
 kidneys. Given the dramatic loss of LMW proteins in the urine, we reasoned that this pool 
was not active. To further explore the trafficking defects, which could impede the reabsorptive 
function of the residual megalin receptor, we investigated differentiated and polarized primary 
cultures of proximal tubular cell (mPTCs) derived from the kidneys of Ocrl
Y/-
 mice (115). These 
cells recapitulated critical aspects of the disease in vitro, including the ectopic accumulation of 
PI(4,5)P2 at the EEs (116, 117). The dynamic of these phosphoinositides is critical for actin 
assembly at the plasma membrane ruffles and early endosomes, hence, for the regulation of 
membrane trafficking during endocytosis (118). Accordingly, the endosomal accumulation of 
PI(4,5)P2 in Ocrl
Y/−
 mPTCs triggers an aberrant F-actin polymerization, which impairs the recycling 
of residual megalin, thus impeding the endocytic uptake. Further analysis evidencing an 
intracellular redistribution of CI-MPR and TfR (Transferrin Receptor) suggested that this actin-
trapping mechanism might affect the trafficking of other receptors crossing the EEs (91). Hence, 
this mechanism represents an appealing druggable target for rescuing the epithelial dysfunction 
associated with the disease. 
Previous studies have used pharmacological (Latrunculin B) approaches to sequester actin 
monomers or genetic approaches (silencing of N-WASP or SNX9) to inhibit the actin nucleating 
machinery. Both approaches led to alleviation of actin phenotypes and defective endocytic uptake in 
both kidney cells and fibroblasts derived from patients (91, 119). Since the actin defects depend on 
the aberrant accumulation of PI(4,5)P2, restoring the correct levels of these phosphoinositides 
represents an additional therapeutic strategy (91). In recent years multiple efforts have been directed 
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in the development of drugs targeting these molecular pathways and suitable for human use. Along 
these lines, recent studies from Daste et al., demonstrate that in addition to PI(4,5)P2, the presence 
of PI(3)P is  fundamental to catalyse actin assembly at the membranes of the endocytic pathway 
(120, 33). They demonstrated that PI(3)P is an important mediator in the actin comet phenotype in 
Ocrl knockout RPE cells using PI3-kinase inhibitors (120). The possible application of PI3-kinase 
inhibitors in Lowe syndrome is significant because PI 3-kinases are a major drug target in 
developing cancer therapeutics, and there are a range of drugs already approved and others, with 
isoform selectivity, in clinical trials (121). As Lowe syndrome is a rare disease, repurposing an 
existing therapeutic treatment is a time and cost effective option. 
It has been recently shown that upon cargo arrival in the lysosomal lumen OCRL 
translocates on the lysosomes to degrade PI(4,5)P2. This event is fundamental for enabling 
lysosomal activity under cargo overload conditions (122). Here, we demonstrated that the lack of 
OCRL induced an abnormal lysosome accumulation of PI(4,5)P2 , which resulted in perturbed 
lysosome dynamics and proteolytic function in vivo and in vitro. The impairment of lysosomal 
function could be due to the mis-trafficking of the receptors regulating the transport of lysosome 
enzymes from the Golgi to the endosomes to the lysosomal compartment. Our data showing a 
peripheral mis-localization of the CI-MPR (which is a carrier of cathepsin D), along with increased 
levels of cathepsin D in the plasma support this hypothesis. 
Defects in lysosomal proteolysis could trigger a block of the autophagy flux. Studies in 
human immortalized cells show that the lack of OCRL induces an accumulation of autophagosomes 
due to an impairment of lysosomal-autophagosomal fusion (122). On the contrary, in our 
preliminary data obtained from kidneys and cells from Ocrl
Y/- 
mice (data not shown), the amount of 
autophagosomes was reduced rather than increased. The same decrease was observed in presence of 
Bafylomycin, thus excluding the possibility of an accelerated lysosomal degradation of 
autophagosomes. Hence, we are tempted to speculate that the decreased autophagosomal levels 
detected in our system could be caused by a decrease autophagosomal biogenesis. This could be a 
plausible hypothesis if we take in account that the endocytic pathway is fundamental for the 
transport of ATG (autophagy related) proteins to the platforms for autophagosomal biogenesis and 
OCRL-deficient mice exhibit strong endocytic defects (123). Furthers studies are needed to clarify 
the molecular mechanisms, which operate in different species in absence of OCRL function. 
Despite the marked kidney PT dysfunction and mild muscular and locomotor defects, 
OCRL-deficient mice did not show any sign of neurological or behavioural abnormalities, 
classically associated with the human disease. This discrepancy between mice and humans could be 
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partly explained by interspecies differences in the brain-specific expression of enzymes with similar 
functions or in the role of OCRL in neurons. Indeed, previous studies suggest a partial overlapping 
function between OCRL and the 5-phosphatase Synaptojanin 1 in the brain (124). The lack of 
OCRL in patient-derived cells disrupts the homeostasis of PI(4,5)P2 and causes endocytic defects 
similar to those observed in absence of Synaptojanin 1 (125). However, while Synaptojanin 1 is the 
key player in clathrin-mediated endocytosis at synapses, OCRL may function at clathrin-coated pits 
that participate in a housekeeping form of endocytosis in neurons (119). This would explain why 
disruption of OCRL function leads to the cognitive deficiencies observed in Lowe syndrome 
patients. Based on these considerations, we could hypothesize that in the mouse brain Synaptojanin 
1 could compensate for OCRL, explaining the absence of neurological symptoms in OCRL-
deficient mice. Future investigations (e.g. double KO) using the mouse model that we describe in 
this thesis could help to substantiate these speculations. 
These enzymatic compensations (INPP5B, potentially Synaptojanin 1) are relevant for the 
design of therapeutic interventions. The cellular aberrations observed in absence of the 5-
phosphatase activity of OCRL are primarily due the disruption of PI(4,5)P2  homeostasis (91), which 
is a direct substrate of OCRL and a key regulator of the endolysosomal trafficking. One strategy to 
rebalance the PI(4,5)P2 pool, in the absence of OCRL, could be to harness the redundancy of the 
phospholipid enzymes by acting on other kinases and phosphatases involved in the metabolism of 
these lipids. As phosphoinositides are key for the function of many organs and their perturbation 
have been described in many diseases, the production of enzymatic inhibitors or activators 
controlling their metabolism has been a major target for the pharmaceutical companies in the last 
years and led to the generation of a range of drugs already approved and others in clinical trials 
(121). A current limitation is that the methodologies used to analyse the phosphoinositides profiles 
in tissue and cells rely heavily on imaging approaches, which are not rigorous enough for 
quantitative analyses and barely adaptable to drug-screening purposes. In recent years emerged a 
great interest to implement these technologies and new methods of quantifications, involving mass 
spectrometry, are developing (126, 127). Progresses in this direction would facilitate the 
investigations and validation of novel treatment in Lowe syndrome. 
Collectively, these studies validate the first mouse model of Lowe syndrome and provide 
new insights in the role of OCRL in cellular trafficking of multiligand receptors. Partial 





suggest shared pathological pathway in Dent disease 1 and 2. These insights open new scenario for 
successful therapeutic interventions in Lowe Syndrome and Dent disease. 
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In the second part of this thesis, we combined cutting-edge technologies in vitro and in vivo to 
decipher the link between lysosomal impairment and epithelial dysfunction in cystinosis. We 
demonstrated that lysosomal dysfunction results in defective autophagy-mediated clearance of 
damaged mitochondria, excessive oxidative stress, disruption of TJs integrity and activation of a 
signalling pathway causing epithelial cell proliferation and dedifferentiation, with loss of 
reabsorptive capacity of PT cells. This work uncovers the fundamental role of the lysosome-
mediated autophagic clearance in safeguarding epithelial differentiation and open new therapeutic 
options to restore epithelial transport downstream of the primary lysosomal defect. 
Since cystinosis is a typical lysosomal storage disorder, we first investigated the lysosomal 
phenotype of PT cells derived from Ctns
-/-
 mice. The loss of CTNS function in PT cells induced a 
major alteration of the lysosomal dynamics (101, 128), which was paralleled by an increased 
number of autophagosomes. Similar lysosomes and autophagosomes defects were detected in the 
pronephric tubules of Ctns-deficient zebrafish demonstrating the evolutionary conservation of these 
disease-pathways across vertebrates. These events along with the accumulation of the autophagy 
receptor SQSTM1, which is normally degraded within lysosomes, suggest an impairment of the 
autophagy flux. Further evidences demonstrating the inability of Ctns
-/-
 PT cells to degrade 
autophagy cargo include: (i) the aberrant number of autophagosomes observed under growth 
conditions, (ii) the failure to clear them under starvation-induced autophagy and (iii) the inability of 
Bafilomycin to further increase the autophagosomes level. These findings were akin to the block of 
the autophagy flux observed in other lysosomal storage diseases, indicating that this family of 
disorders could share similar pathological mechanisms (129). We exclude that these changes in 
autophagy were related to increased autophagosomes production or to delayed fusion between 
lysosomes and autophagosomes, as in cystinotic cells the upstream events regulating 
autophagosomes biogenesis were unaffected and LC3-marked autophagosomes were correctly 
delivered inside the LAMP1-marked lysosomes. In contrast with our observation, autophagy flux 
was found to be fully functional in fibroblasts derived from Ctns
-/-
 mice (130). The cause for this 
discrepancy could be related to tissue -specific effects of cystinosin depletion and further studies are 
required to examine this aspect.  
Because the autophagy flux relies on the degradative capacity of lysosomes (129), an 
impaired lysosomal function may explain the accumulation of autophagosomes in cystinotic cells. 
Confirming this hypothesis, our data showed that cystinosin deficiency affected lysosome function 
by inhibiting the processing/maturation of the cathepsins within the endolysosomal compartment. 
Indeed, the reinsertion of cystinosin in Ctns
-/-
 cells resulted in restored maturation of cathepsin D 
and a rescued autophagy-lysosome degradative activity. Defective processing/maturation of 
160 
 
cathepsins could be explained by alterations of the lysosomal acidification due to disrupted activity 
of the V-ATPase complex in absence of CTNS. This hypothesis is supported by recent studies 
showing that V-ATPase is part of CTNS interactome, thus the activity of these proteins could be 
interconnected (102). We exclude that the decreased cathepsin D activation was due to a defective 
delivery of the enzymes from the Golgi to the lysosomal compartment, as no changes in the 
trafficking of this protease were observed in cystinotic cells. Altogether these findings suggest a 
role of cystinosin -beyond its cystine transport activity- in maintaining the lysosomal function. 
Alternatively, defective lysosomal proteolysis can result from dysregulation of mTORC1-master 
regulator of lysosomal biogenesis and autophagy. As mTORC1 is activated by raised amino acids 
concentration inside lysosomes, we thought that cystine lysosomal storage might sustain mTORC1 
activity and negatively regulate lysosome function by suppressing TFEB/MiTF signaling (104). 
This hypothesis has been explored in the third part of this thesis.  
The association of impaired lysosomal dynamics and altered degradative capacity observed 
in cystinotic cells and mice is strikingly similar to the cellular changes caused by the endolysosomal 
accumulation of PI(4,5)P2 detected in patients and mice with Lowe syndrome (122). These data 
suggest that lysosomal accumulation of cystine or PI(4,5)P2 may have similar functional 
consequences on the epithelial phenotype, emphasizing the role of endolysosomes as crucial 
signaling hub to ensure cellular homeostasis.  
Regardless of the mechanisms, the block of the autophagy flux detected in Ctns
-/-
 PT cells 
leads to the accumulation of autophagy substrates, such as ubiquitinated proteins and dysfunctional, 
ROS-producing mitochondria. This is in line with previous studies reporting similar results in other 
lysosomal storage disorders with deficit in autophagy and substantiates the importance of autophagy 
as cellular quality control machinery preserving the integrity of subcellular compartments, 
especially mitochondria (131, 132). Similar to our findings in the cystinosis model, genetic or 
pharmacologic blockage of basal autophagy in PT cells resulted in disrupted mitochondria 
homeostasis leading to apical dedifferentiation and consequent decrease in the uptake capacity. 
These data highlight the importance of maintaining a healthy mitochondria pool to sustain the 
transport activity of PT cells.  
The next step was to identify the mechanisms bridging the excessive accumulation of 
damaged mitochondria-producing ROS and epithelial dysfunction. Recent advances have shown the 
role of TJs in safeguarding epithelial cell function. In particular, the TJ protein ZO-1 represses the 
nuclear translocation of ZONAB, a transcriptional factor that promotes cell proliferation and 
inhibits PT differentiation during kidney ontogeny (83).Of note; previous studies demonstrate that 
161 
 
TJs integrity is very sensitive to the level of oxidative stress. Accordingly, we found that increased 
levels of mitochondrial ROS in Ctns
-/-
 cells induced a G12-Src mediated phosphorylation of the 
ZO-1 and its consequent misrouting to enlarged, non-degradative endolysosomes (79, 133). In turn, 
the loss of TJs integrity promotes ZONAB signaling and the transcription of target genes increasing 
cell proliferation and decreasing cell differentiation resulting in defective endocytosis. Gain- and 
loss-of-function approaches targeting G12 or ZO-1/ZONAB axis and pharmacological 
interventions neutralizing oxidative stress or blocking the activation of G12/Src signaling (eg. Src-
inhibitors) restored epithelial function in Ctns
-/-
 PT cells, indicating the key role of these pathways 
in maintaining the PT transport activity. Aberrations of ZO-1-1/ZONAB axis were observed in 
other disorders characterized by epithelial dysfunction, such as cystic fibrosis and RFS caused by 
PT accumulation of  light chains (134, 135). These findings highlight the importance of TJs as 
essential regulators of epithelial cell differentiation.  
The identification of mitochondria oxidative stress as a central event in the pathogenesis of 
cystinosis allowed us to set up a mitochondrial-targeted therapeutic intervention with Mito-TEMPO 
anti-oxidant, which significantly rescued the integrity of TJs and the differentiation and endocytic 
uptake capacity of Ctns
-/- 
PT cells. These data extend the previous findings showing that swan-neck 
deformities of PT segments could be delayed in Ctns
-/- 
mice by administrating mitoquinone, an anti-
oxidant compound that acts on mitochondria (136).  
Altogether these studies decipher the pathogenic cascade bridging lyso-autophagy defects 
with impaired epithelial transport activity in cystinosis, thus offering new druggable targets for 
therapeutics. However, how the lack of CTNS compromises the identity of the lysosome and 
disrupts the autophagy pathway driving PT dysfunction remained unclear. We decided to examine 
this aspect in the last chapter of the thesis.  
In the third part of this thesis, we demonstrate that cystine accumulation in cystinosis triggers the 
hyper-activation of mTORC1, which in turn, drives the progression of the lysosomal disease 
leading to autophagy defects and consequent PT dysfunction. Alterations of mTORC1 were 
detected in Ctns
-/-
 mouse and rat models, demonstrating the evolutionary conservation of this 
disease-mechanism. In vitro treatment with specific and powerful mTORC1 inhibitors rescued the 
primary lysosomal defect and the downstream pathogenic cascade associated to it, thus improving 
the function of cystinotic PT cells. Collectively, these studies unveiled a novel link between 
defective mTORC1 activity, lysosome-autophagy degradation pathways and epithelial dysfunction 




By performing time-course analyses on the kidneys of Ctns
-/-
 mice, we noticed that signs of 
lysosome dysfunction were already shown in presymptomatic mice in absence of alterations related 
to cystine homeostasis, autophagy and PT function. The lysosome dysfunction became more 
prominent in the symptomatic stage, where it was accompanied by the simultaneous appearance of 
raised level of cystine, autophagy defects and LMW proteinuria. These data are in line with 
previous studies investigating the time course of the pathological events characterizing the 
progression of the kidney disease in Ctns
-/-
 mice. Indeed, Chevronnay et al. demonstrated that a 
mild impairment of lysosomal morphology in cystinotic mice precedes the formation of cystine 
crystals and appears when the PT dysfunction is barely detectable. They also showed that lysosomal 
disruption becomes more severe when cystine crystallizes inside the lysosomal lumen. This event 
was concomitant to the onset of Fanconi syndrome and PT dedifferentiation. Interestingly, the 
authors suggest a compensatory mechanism of lysosomal exocytosis in Ctns
-/-
 mice, which would 
help the cells in clearing their storage, as observed in other LSD (137). This hypothesis was 
supported by the later studies of Rega et al. showing that cells derived from cystinotic patients 
exhibit an abnormal translocation of the mediator of lysosomal exocytosis TFEB (transcription 
factor EB) into the nucleus (104). Based on these considerations, we speculate that the absence of 
cystine accumulation observed here in the kidneys derived from Ctns
-/-
 mice at early stages could be 
due to this excretion mechanism of lysosomes-containing cystine in the tubular lumen. This process 
might reach saturation over time and lead to the appearance of cystine crystals in the later stages of 
the disease. Further studies, including inhibition of possible compensation mechanisms, are needed 
to test this hypothesis.  
In order to identify the molecular players driving the progression of the lysosome disease 
and related deleterious effects on PT function, we investigated mTORC1. This kinase was an 
obvious candidate because: (i) mTORC1 is a master regulator of lysosomal function and autophagy, 
which are both disrupted in cystinosis (138); (ii) mTORC1 activity is modulated by the fluctuation 
of amino acids in the lysosomal lumen and cystinosis is a disorder characterized by the lysosome 
storage of amino acids (70); (iii) mTORC1 complex has been previously shown to be part of the 
cystinosin interactome (102). Our analysis showed that mTORC1 was aberrantly activated in the 
kidneys of Ctns
-/-
 mice and rats, suggesting the evolutionary conservation of this disease-phenotype. 
Further studies showed that mTORC1 sensing was impaired in Ctns
-/- 
mPTCs, as proved by its 
persistent status of activation during starvation. These data are in line with recent studies on human 
CTNS-iPSC, which suggest an upregulation of gene signatures involved in the regulation of 
mTORC1 and its downstream targets (139). On the contrary, our data contrast with prior work on 
immortalized PT cells derived from CTNS-deficient mice or human patients, showing a down-
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regulation of mTORC1 (102). The causes for these discrepancies remain unclear but may be related 
to metabolic differences between cell types or to the process of immortalization performed by 
infecting the cells with SV40 T antigen. Indeed, it has been previously shown that this virus 
significantly inhibits the phosphorylation of the signalling effectors directly downstream of 
mTORC1; therefore the use of this method is not appropriate for measuring the level of mTORC1 
activation (106).  
Next, we asked how the lack of CTNS might induce the aberrant activation of mTORC1. 
Given that in MDCK (Madin-Darby Canine Kidney cells) and 3T3 (3-day transfer, inoculum 
3×10
5
 cells- murine fibroblast) stably transfected with cystinosin, CTNS has been shown to interact 
with many regulatory subunits of mTORC1 complex (102), we could hypothesize a role of this 
transporter in negatively modulating mTORC1 activity by a protein-protein interaction mechanism, 
independent on cystine transport. In this scenario we would expect an activation of mTORC1 
already in Ctns
-/-
 mice at presymptomatic stage, in absence of increased cystine levels. Yet, our data 
show that mTORC1 activity was comparable to wild-type in pre-symptomatic Ctns 
-/-
 mice, 
suggesting that the absence of cystinosin alone is not sufficient to activate mTORC1. From these 
evidences we cannot exclude a role for cystinosin in regulating mTORC1 complex or vice versa, 
and therefore further studies are needed to clarify the biological relevance of these protein-protein 
interactions at the lysosomal membrane. More likely, the abnormal mTORC1 activity could be 
triggered by the storage of cystine characterizing cystinotic cells. Indeed, multiple studies showed a 
direct correlation between lysosomal amino acid concentrations and mTORC1 signaling (70). 
Evidences supporting the latter hypothesis are: (i) the appearance of mTORC1 activation 
concomitantly to the increase of cystine levels in the kidney of symptomatic Ctns 
-/-
 mice; (ii) the 
striking decrease of mTORC1 activation detected in Ctns
-/-
 mPTCs upon treatment with the cystine-
depleting agent cysteamine; (iii) the progressive mTORC1 activation observed upon CDME 
overload in wild-type PT cells. These experiments led us to conclude that cystine accumulation is a 
key event triggering mTORC1 dysfunction in cystinosis. However, whether the progressive 
lysosomal accumulation of other metabolites might contribute to mTORC1 activation remains to be 
clarified. Indeed, the lysosomal defects observed in Ctns
-/-
 mice might drive a progressive 
accumulation of undigested autophagy substrates in the lysosomal lumen, which could concur with 
cystine to sustain mTORC1 signal. Analyses of the metabolomics and proteomics profile of 
lysosome fractions isolated from cystinotic mice at different stages would help to elucidate these 
issues (140). 
Irrespective of the upstream mechanisms, mTORC1 hyper-activation could exert a negative 
feedback on the lysosomal function by limiting lysosome biogenesis through the inhibition of 
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MiTF/TFEB transcription factors (141). This is consistent with the decreased number of lysosomes 
in the cytosol of Ctns 
-/-
 mPTCs and in line with the enlarged and dysfunctional status of the 
remaining lysosomal pool. This hypothesis is further supported by a recent study showing that 
genetic and pharmacologic activation of the transcription factor TFEB rescued lysosome 
abnormalities in cystinotic kidney cells (104).  
Supporting the central role of mTORC1 dysregulation in the pathogenesis of cystinosis, we 
demonstrated that in vitro inhibition of mTORC1 pathway by Torin1 and Rapamycin successfully 
restored lysosomal function, normalized the abnormal level of autophagy markers and all the 
cellular aberrations downstream this cascade. The mechanism of rescue resulting from Torin1 and 
Rapamycin treatment could be due to their action (i) on the lysosomal function, through the 
activation of TFEB, which might increase the number of lysosomes and lysosomal enzymes, (ii) on 
autophagy pathway, by boosting the degradation of damaged cellular bulk, and therefore restoring 
the physiologic cellular homeostasis (141). Similarly, Hollywood et al. showed that Everolimus, a 
derivative of Rapamycin, was also able to repair the impaired lyso-autophagy path observed in 
CTNS-iPSC (139). These findings are important as they open realistic therapeutic opportunities for 
patients with cystinosis. Since mTOR inhibitors are clinically used with reasonable safety profile, 
their repurposing for cystinosis would be appealing (142). Furthermore, as aberrant activation of 
mTORC1 has been reported in other genetic disorders associated with lysosomal storage and 
autophagy defects, we believe that these families of diseases could share common pathological 
mechanisms (143, 144).  
Having demonstrated that cystine accumulation is responsible for mTORC1 dysregulation, 
which in turn plays a central role in driving the progression of the lyso-autophagy defect, one might 
ask why treatment with the cystine-depleting agent cysteamine is not effective in curing cystinosis 
(145). One explanation is provided by previous studies reporting that cysteamine has an inhibitory 
effect on the late stage of autophagy (146). Thus, it is likely that while cysteamine may restore 
lysosomal activity by depleting cystine and lowering mTORC1 levels, its inhibitory effect on 
autolysosome maturation induces a further block of the autophagy flux. 
In conclusion, we identified key pathogenic mechanisms linking lysosomal storage and 
defective lyso-autophagy pathway in cystinosis. These findings substantiate the role of mTORC1 in 
preserving lysosomal activity, which is crucial for properly functioning of specialized epithelial 
cells. mTORC1 inhibition offers a promising therapeutic strategy for rescuing the epithelial damage 
observed in this and potentially other lysosomal storage disorders. 
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The investigations performed during this thesis contribute in understanding how perturbation of 
phosphatidylinositol homeostasis, lysosomal function and autophagy impact on the endocytic 
pathway, with ensuing defects in differentiation and transport functions in PT cells. Since our 
investigations address the early stages of disease, before any structural, irreversible damage of the 
kidney, we will be able, in the following studies, to use genetic and pharmacologic tools to target 
the pathways (actin dynamics, autophagy, mTORC1, oxidative stress) and verify the consequences 
on the phenotype. Being able to correct some of the early defects could alleviate major clinical 
consequences of increased urinary losses of vitamins and solutes.  
More generally, these studies on the endolysosomal disorders improve our knowledge of 
fundamental processes (differentiation and morphogenesis, regulation of lysosomal function and 
autophagy) that maintain cell homeostasis and govern transport functions responsible for the 
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